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Introduction. Macrophages play a key role in atherosclerotic plaque instability, they 
engender plaque rupture, leading to thrombosis and myocardial infarction. Their detection 
in coronary artery plaques would enable stratification of patients for better treatment of 
“vulnerable” phenotypes. Intra-coronary Optical Coherence Tomography (OCT) enables 
visualisation of vulnerable plaque morphology and has the potential to detect the signal 
variance created by increased numbers of macrophages. 
Aims. Our aim was to enhance the detection of macrophages using OCT in combination with 
intracellular contrast agents; and to demonstrate it in-vitro, ex-vivo and in-vivo. This was first 
endeavoured using clinically approved ultra-small superparamagnetic particles of iron oxide 
(USPIOs): an MRI contrast agent which is readily uptaken by macrophages in coronary 
plaques. The second approach was to design a novel OCT contrast agent based on different 
lanthanide ions with either a carbonate or fluoride structure. 
Methods. A “phantom” artery model was designed and 3D printed for standardised in-vitro 
imaging with intra-coronary OCT. Particle-laden macrophages were tested in this system to 
determine OCT contrast enhancement. Cell viability assays were performed to determine 
toxicity of novel lanthanide particles. Aortic plaques of Apo-lipoprotein E knockout mice, 
treated with USPIO or saline were OCT imaged and sectioned for histological analysis. 
Patients presenting with acute coronary artery disease were randomised to receive USPIO or 
saline treatment, followed by OCT imaging of the culprit plaque and non-culprit control. The 
local pixel Standard Deviation (SD) of OCT images were processed in Matlab as a metric of 
contrast enhancement. A local SD hotspot visualisation tool was developed in Matlab for use 
with the phantom, murine and human OCT images. 
Results. In all 7 phantoms, USPIO-laden macrophages significantly increased the mean SD 
compared to untreated macrophages (p<0.001). USPIO treated mouse plaques (n=3) showed 
significantly higher mean SD than control plaques (n=3) (p<0.05). USPIO treated patients 
(n=8) demonstrated a significantly increased mean SD compared to control patients (n=10) 
in culprit and non-culprit plaques (p<0.05). Within patients the mean SD was significantly 
higher for culprit compared to non-culprit plaques in both USPIO and control groups. The 
initial OCT screening of 10 novel lanthanide particles revealed the carbonate structures to be 
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most efficacious for contrast enhancement compared to the fluoride ones. Phantoms made 
with particle-laden macrophages revealed the Gadolinium carbonate particle with Polyacrylic 
acid coating to have the highest mean SD increase compared to untreated macrophages. This 
particle also showed low levels of cell toxicity. 
Conclusions. USPIO administration was associated with a significant increase in OCT contrast 
in a novel in-vitro phantom model, an ex-vivo atherosclerotic mouse study and in a human 
clinical trial. USPIO enhances the detection of macrophages and may facilitate patient 
stratification. Additionally, novel OCT contrast agents have been made which show great 





















The heart muscle’s oxygen is carried by blood vessels called coronary arteries. Fat can build 
up inside the wall of these arteries, forming a dangerous package called a plaque. If the wall 
breaks and the content of the plaque meets the blood, a clot will quickly form and block the 
vessel, causing a heart attack. The muscle is no longer getting its oxygen supply from the 
coronary arteries and it starts to die. It won’t pump the blood properly and the rest of the 
body will not be getting the oxygen it needs - if not treated immediately, the patient could 
pass away. One of the main causes of the plaques breaking are immune cells called 
macrophages. These cells enter the plaque and start to break down the fibre which keeps it 
intact and separate from the blood. The following thesis focusses on finding a way to tag 
these macrophages so we can find the plaques which are more likely to cause a heart attack. 
This would help cardiologists find patients which are at higher risk of suffering a future heart 
attack so that they can treat them more appropriately to avoid it. That way, those fatty 
plaques can be reduced in size and the macrophages may be stopped from entering and 
breaking them open. The research was centred around Optical Coherence Tomography 
(OCT), an imaging technique which works in a similar way to ultrasound but using light waves 
instead of sound waves to create grayscale images of the layers of the artery wall. Different 
metal nanoparticles were used to tag macrophages and their detectability was tested in the 
lab, in mice and in human patients with a clinical OCT system. A few of the tested particles 
were found to be significantly better at detecting macrophages on OCT images compared to 
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a.u.: Arbitrary Units 
ACS: Acute Coronary Syndrome 
Apo: Apolipoprotein 
ApoE-/-: ApoE knockout mouse model 
CAD: Coronary Artery Disease 
DMSO: Dimethyl Sulfoxide 
DPBS: Dulbeco’s Phosphate Buffer Saline 
Dy: Dysprosium 
Er: Erbium 
FD-OCT: Fourier-Domain Optical Coherence Tomography 
Gd: Gadolinium 
HDL: High-Density Lipoprotein 
HMMs: Human Monocyte derived Macrophages 
IV-OCT: Intra-Vascular Optical Coherence Tomography 
IV-US: Intra-Vascular Ultrasound 
LDL: Low-Density Lipoprotein 
LDL-R: Low-Density Lipoprotein Receptor 
LDL-R -/-: Low-Density Lipoprotein Receptor knockout mouse model 
MI: Myocardial Infarction 
MMP: Matrix-Metalloproteinases 
MSD: Mean Standard Deviation 
Nd: Neodymium 
NSD: Normalised Standard Deviation 
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OCT: Optical Coherence Tomography 
PAA: polyacrylic acid  
PCI: Percutaneous Coronary Intervention 
PEG: polyethylene glycol 
PEI: polyethyleneimine 
RAW cells: RAW264.7 murine macrophage-like cell line 
ROI: Region of Interest 
SD: Standard Deviation 
SMC: Smooth Muscle Cell 
SS-OCT: Swept-Source Optical Coherence Tomography 
TCFA: Thin-Capped Fibroatheromas 
TD-OCT: Time-Domain Optical Coherence Tomography 
TEM: Transmission Electron Microscopy 
TF: Tissue Factor 
USPIO: Ultra-small Super-paramagnetic Particles of Iron Oxide 
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1.1 CORONARY ARTERY DISEASE AND ATHEROGENESIS 
1.1.1 Introduction and definitions 
Coronary Artery Disease (CAD), also named Coronary Heart Disease is the deadliest type of 
cardiovascular disease, and the leading cause of death worldwide1,2. As of 2020 CAD is 
responsible for the death of 14% of British men and 8% of British women2. Whereas the term 
“cardiovascular diseases” encompasses all diseases involving the heart and blood vessels, 
CAD more specifically designates a group of diseases caused by impaired blood flow 
(ischemia) from the coronary arteries to the heart muscle (myocardium) which can then 
become damaged due to the lack of oxygen (hypoxia)1–5. The coronary arteries descend from 
the aorta, wrap around the heart (Figure 1-1) and provide blood (and thus oxygen) to the 
myocardium. The coronary arteries are relatively narrow vessels which when restricted by 
atherosclerosis can cause the patient intense chest pain referred to as angina.  
 
Figure 1-1: Diagram showing the coronary arteries and a rupturing atheromatous plaque 
which has formed in the left anterior descending coronary artery. This artery has undergone 
eccentric outward remodelling to make space for the plaque which allows there to be minimal 
narrowing (i.e. stenosis) of the artery which can be seen on the longitudinal view. However 
not all plaques are non-stenotic, they can be more or less stenotic depending on many factors 
such as composition, age, history of rupture and repair. Adapted with permission from (5), 
Copyright Massachusetts Medical Society. 
 
It is useful to consider CAD in two forms: stable and unstable disease. Stable disease is 
characterised by fixed narrowing in the artery which prevents adequate blood flow reaching 
the heart muscle during exercise5–7. This causes stable angina which is defined as intense 
chest pain which occurs during physical activity or stress5–7. Unstable disease or Acute 
Coronary Syndromes (ACS) are caused by inflamed atherosclerotic lesions which can rupture 
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and then precipitate the formation of blood clots in the arteries5–7. These block off blood 
supply to the heart muscle, causing prolonged ischemia and eventually myocardial 
infarction5–8. The character of the pain (unstable angina) is different: frequently occurring at 
rest and being prolonged and associated with other features such as sweating, nausea and 
vomiting7,8. When the coronary arteries get blocked by a thrombus (blood clot) it causes 
ischemia to the myocardium which, if prolonged, results in heart muscle death and  
myocardial infarction (MI)5–7. It should also be noted that the difference between MI with 
and without ST-segment elevation has been overlooked here for the sake of simplicity. 
Underlying all of these CAD syndromes is the process of atherosclerosis: the formation of 
fibro-fatty plaques in the artery wall causing thickening, hardening and sometimes narrowing 
of the walls4,9,10. The formation of these atherosclerotic (or atheromatous) plaques, also 
known as atheromata or atherosclerotic lesions is a complex process with complex potential 
repercussions.4,9,10  
1.1.2 Atheromata: formation and progression 
The formation of plaques begins with a change in the permeability of the endothelial cells 
lining the arterial cavity, enabling LDL (low-density lipoprotein) from the blood to migrate 
into the tunica intima of the coronary artery wall4,11,12. Usually these endothelial cells, shown 
in green on Figure 1-2 (A), do not enable attachment of leukocytes (white blood cells), 
however, in response to certain stimuli (such as pro-inflammatory mediators), and because 
of the presence of LDL, they start expressing adhesion molecules which bind to monocytes 
and T cells, enabling their extravasation to the intima (Figure 1-2 (A)) 4,11–13. Once inside the 
arterial wall, monocytes differentiate into macrophages and then avidly phagocytose (ingest) 
free LDL to become foam cells (a term employed to describe their foamy appearance)4,12,13. 
Additionally, smooth muscle cells (SMCs) from the tunica media of the arterial wall migrate 
into the intima and start to produce extracellular matrix proteins such as collagen and elastin 
which together with the newly migrated SMCs produce a fibrous cap which covers the 
plaque, imparting stability and reducing the risk of plaque rupture and MI (Figure 1-2 
(B))4,12,13.  
Within the new plaque, macrophages and SMCs can die and their inefficient clearance leads 
to the accumulation of extracellular lipids which form the lipid or necrotic core of the plaque 
(Figure 1-2 (C))4,12–14. Moreover, plaque macrophages produce pro-coagulant factors such as 
tissue factor (TF) which render the necrotic core thrombogenic (i.e. prone to cause 
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coagulation of the blood)15,16. Many studies (17–20) have also shown that the inflammatory 
macrophages and foam cells of the plaque, which are activated by plaque T cells, produce 
matrix-metalloproteinases (MMP) which break down collagen in the fibrous cap4,12,13. This, 
along with the production of other factors which can induce the death of plaque SMCs or 
reduce their collagen production, leads to the thinning and weakening of the fibrous 
cap4,12,13. Eventually the cap may rupture and expose the thrombogenic necrotic core, 
resulting in  thrombosis and potentially MI4,12,13 (Figure 1-2 (C)). 
Atheromata (plaques) cause clinical syndromes in two ways. Firstly, stable plaques can cause 
stenosis of the vessels which limits the coronary arterial flow, leading to ischemia and 
symptoms of angina. Secondly, unstable inflamed plaques can rupture, triggering thrombus 
formation and vessel obstruction either at that site or in a downstream vessel via distal 
embolization12. Importantly not all plaque rupture events cause MI, with some simply 
resulting in subclinical plaque growth and healing. This depends in part on the 
thrombogenicity of the plaque contents and the stickiness of the blood. The latter is in turn 
dependent on multiple factors, for example plasminogen activator inhibitor-1 (PAI-1), which  
reduces the blood’s natural ability to combat persistent thrombi, the levels of which are 
increased in obese and diabetic patients13. Different patients therefore have different 






Figure 1-2: Diagram showing the different stages of atheroma formation starting from the 
top and progressing through to rupture of the plaque at the bottom. (A) Macrophages and T 
cells infiltrate the tunica intima of the artery wall, initiating plaque formation. (B) SMCs 
(smooth muscle cells) migrate from the tunica media to the tunica intima and produce 
collagen to form the fibrous cap which closes the plaque off from the blood flow. (C) The 
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fibrous cap ruptures and leads to thrombus formation. Adapted with permission (rightslink 
license number 4961350222324) from (12), Copyright Springer Nature. 
1.1.3 The lipoprotein metabolism and animal models of atherosclerosis 
Animal models have been and still are an extremely useful tool to our understanding of the 
chronic inflammatory disease that is atherosclerosis. The most commonly used animal 
models of atherosclerosis are mice, rabbits, pigs and a few different species of nonhuman 
primates21. As was touched on previously, atherosclerosis involves both the innate and 
adaptive immune systems which get activated in response to hyperlipidaemia: raised levels 
of lipids or lipoproteins in the blood12,21–23. The lipoprotein metabolism is vast, complex and 
differs between species, only a few key elements will be covered here.  
In short, lipoproteins are complexes formed between lipids (cholesterol, phospholipids, 
cholesterol esters and some triacylglycerols) and proteins called apolipoproteins22–24. These 
complexes travel through the blood and extracellular fluids and have different destinations 
depending on their type22–24. The four main types of lipoproteins are LDL (low density 
lipoprotein), HDL (high density lipoprotein), VLDL (very low density lipoprotein) and 
chylomicrons and each of these are made up of different types of apolipoproteins (apo) 22–24. 
HDL, often deemed “the good cholesterol” is part of the reverse transport pathway, it picks 
up excess cholesterol and delivers it to tissues in need22–24. Conversely, unless LDL is taken 
up by cells in the liver through the LDL receptor (LDL-R) it can accumulate in artery walls and 
increases the risk of coronary artery disease22–24. 
In humans, LDL is the primary lipoprotein while in wild type (WT) mice it is HDL21,25. This, as 
well as a few other differences in cholesterol metabolism is the reason why WT mice are 
naturally atheroresistant, even when fed a high fat diet21,25. However, mouse models of 
atherosclerosis are most easily made by knocking out apolipoprotein E (apoE) or the LDL 
receptor21,25. ApoE is the primary ligand for the LDL receptor on hepatic cells and is a key 
component of VLDL26,27. This means that when apoE or LDL-R is knocked out, there is a 
significant reduction in uptake of VLDL by the liver which results in its accumulation in the 
blood26,27. Because VLDL in the blood eventually gets cleaved into LDL, lower levels or 
dysfunction of either apoE or LDL-R leads to higher LDL levels in the blood which in turn 
increases the risk of atherosclerosis. Indeed, apoE-/- mice and LDL-R-/- mice develop 
hypercholesterolemia and atherosclerosis in the aorta when fed a high fat diet21,25. In humans 
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there is a genetic disease called familial hypercholesterolemia which is caused by the 
dysfunction of the LDL-R and significantly increases the risk of cardiovascular disease28. 
In contrast to the mouse, larger animals have more similar lipoprotein profiles to humans 
and therefore can have advantages for certain studies21,25. In particular, pigs develop 
spontaneous atherosclerosis in the coronary arteries which can be accelerated with a high 
cholesterol diet, making them an attractive model for many studies21,25. In rabbits, a natural 
strain exhibiting familial hypercholesterolemia was identified in 1980 and selectively bred by 
Dr Watanabe to produce rabbits with coronary thin capped fibroatheromas which 
spontaneously developed myocardial infarction29,30. This strain; the Watanabe heritable 
hyperlipidaemic (WHHL) rabbit has a defect in the LDL receptor and was instrumental in the 
discovery of the cause of human familial hypercholesterolemia 3 years later31. A number of 
non-human primates are also used for atherosclerosis studies thanks to the close similarities 
of their lipoprotein profile to that of humans21,25. However, all these large animals are more 
expensive in price and upkeep and atherosclerosis takes longer to develop than in mice21,25. 
For these reasons, as with many other disease models, mice have been the favoured species 
for the study of atherosclerosis21,25.  
1.1.4 Revascularisation procedures for treatment and prevention 
There are many different CAD treatments such as anti-platelet therapies to thin the blood, 
LDL-lowering medication to stabilise the plaque and importantly, lifestyle measures to 
modify risk factors such as high blood pressure, obesity and smoking12,13. These are often 
used in combination, depending on the specific syndrome and predisposition of patients12. 
Whilst these represent the most effective forms of treatment, due to length constraints they 
will not be expanded further upon here. Instead the focus will be on coronary artery 
revascularisation procedures that are required in some patients with advanced or unstable 
forms of coronary artery disease.  
Coronary angiography is an x-ray based technique developed in the 1950s which enables the 
visualisation of blood vessels thanks to the injection of radio-opaque contrasting agent 
(Figure 1-3). The advent of this technique lead to the development of coronary artery bypass 
surgery, a procedure whereby vessels from elsewhere in the body are grafted distal to sites 
of stenosis. Subsequently, coronary angioplasty was developed: a non-surgical procedure 
which involves the inflation of a balloon at the site of stenosis (to enlarge the vessel to its 
original size) and subsequent stent placement (Figure 1-3), implantation of a metallic scaffold 
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to keep the artery permanently open32. Angiography permits the visualisation of artery 
sections with the most severe stenosis, that can then be targeted with revascularisation 
therapies32. In unstable patients with MI, stent placement is a quick and effective method of 
opening up the artery and restoring blood flow. Moreover it can help stabilise the plaque and 
help prevent recurrent MI32,33. In patients with stable angina, stent implantation is an 
effective method of relieving severe symptoms and therefore improving quality of life.  
However, in major randomised trials, stent placement in severe stable stenoses has not 
proved successful in reducing the risk of subsequent MI32,33. Surprisingly, angiographic 
studies of patients before and after they suffered MI demonstrated that the culprit plaques 
which gave rise to the occluding thrombus were most commonly non-obstructive in nature 
(luminal stenoses <70%) and would not have warranted revascularisation procedures33–37. 
Culprit plaques do however have certain characteristics when analysed on histology or with 
imaging techniques. These include a large necrotic lipid core, a thin fibrous cap, 
inflammation, micro-calcifications and a very thin fibrous cap. Whilst they often have a large 
plaque volume they are frequently not stenotic because of outward (positive) remodelling of 
the artery (Figure 1-1)12,32,38,39. Improved techniques are therefore required, that assess both 
lesion severity and plaque type. The ability to identify plaques with a thin fibrous cap and 
extensive inflammation would be of particular clinical use for assessing the severity of patient 
disease and potentially in improving the prediction of future clinical events.  
 
Figure 1-3: Coronary angiogram of a 48 year old woman with unstable angina, showing 
severe stenosis in the mid-left anterior descending coronary artery marked by the arrow (left 
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picture), successfully stented in the right picture. Reused with permission (rightslink licence 
num 4961351450013) from (7), copyright BMJ publishing group Ltd. 
1.1.5 The Vulnerable Plaque and the Vulnerable Patient 
Each of the pathological features that characterise the culprit represents a potential imaging 
target that might be used to identify plaques at high risk of future rupture (the vulnerable 
plaque). In 1989, James E. Muller first described dangerous lesions as “vulnerable plaques”40 
which were soon after defined as having a large lipid core and a thin fibrous cap with high 
levels of macrophage infiltration41,42. This has since been a subject of intense research and 
whilst we now have an array of invasive and non-invasive imaging techniques capable of 
identifying all the individual components of the “vulnerable plaque”43 (see Figure 1-4), this 
strategy has to date failed to improve the clinical care of patients with atherosclerosis44,45. A 
detailed description of the vulnerable plaque literature is beyond the scope of this thesis but 
a summary figure is provided (Figure 1-4) and reference made to several excellent review 
articles on the subject42,44–46. 
  
Figure 1-4: Summary of the key vulnerable plaque characteristics and the imaging modalities 




Why then has vulnerable plaque imaging failed to impact clinical practice? In brief the 
positive predictive value of vulnerable plaque characteristics identified to date has been too 
low to be of clinical use45. In numerous prospective studies the vast majority of vulnerable 
plaques identified do not go on to cause myocardial infarction, but rather heal or rupture 
sub-clinically47–51. Plaque rupture and healing are in fact most often asymptomatic but lead 
to progressive stenosis52,53.The concept, however, works better at the patient level. Patients 
in whom vulnerable plaques are identified consistently appear at higher risk than patients 
with more stable patterns of disease54,55. The vulnerable plaque identified at the time of 
imaging may not itself cause an event, but the patient is prone to developing these unstable 
plaques, one of which may well cause an event in the future.  
On this background, attention is focusing upon methods to identify vulnerable plaques with 
improved positive predictive value, potentially by combining more than one high risk 
characteristic. Indeed, as is presented in Figure 1-4, no single imaging technique can identify 
the 3 most important vulnerable plaque characteristics at once. However, OCT has a high 
potential in this regard as it enables easy measurement of the fibrous cap, detection of a lipid 
pool and early data suggests it may also be able to identify the third key vulnerable plaque 
feature: inflammation56,57. This is of particular importance given the clear correlation 
between markers of inflammation and disease severity and risk of ACS58. Additionally, OCT, 
in contrast to PET-CT, MRI and NIRS is routinely used during coronary intervention to assess 
lumen size before stent placement. The precise detection of a high burden of “vulnerable 
plaques” could perhaps aid in the identification of “vulnerable patients” who would benefit 
from more expensive anti-inflammatory treatments. Numerous recent clinical studies have 
shown that targeted anti-inflammatory therapy yields significant reductions in future major 
cardiovascular events59–63. This idea of stratification of ACS patients is a big incentive for 
better detection of the “vulnerable plaque” profile in vivo, or more importantly, simply 
detecting high macrophage burden in plaque caps. Another benefit to the real-time 
visualisation of cap inflammation would be easier and faster identification of culprit plaques 
during coronary intervention. It is with these aims in mind that OCT is introduced in section 
1.2 and discussed in section 1.3 as a technique with high promise for the precise detection, 
quantification and visualisation of cap macrophages. 
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1.2 OPTICAL COHERENCE TOMOGRAPHY (OCT) 
1.2.1 Introduction and history  
Optical coherence tomography (OCT) is a medical imaging technique analogous to ultrasound 
imaging, using near-infrared light as opposed to sound to create an image of tissue64. 
Contrarily to OCT, ultrasound directly measures the time taken for an echo to reflect back 
from tissue structures to obtain depth information65. In OCT however, the velocity of light is 
too high for the electronic measurement of optical echoes. Instead, an interferometer is used 
to measure the back-scattered light from within the tissue by comparing it to light which has 
travelled along a known reference path66 (as will be explained in section 1.2.2). Although 
ultrasound can image structures deeper within the tissue than OCT can, OCT achieves a much 
higher resolution, as is demonstrated in Figure 1-5 and confirmed in quantitative 
measurements56,67,68. An additional advantage over ultrasound is that OCT does not require 
contact with the tissue, a property which has proved particularly advantageous when imaging 
the eye65.  
 
Figure 1-5: Comparison of Ultrasound and OCT imaging of the coronary artery with 
intravascular endoscope systems. Images reused with permission from (67) © [1999] IEEE. 
 
Because OCT functions in a similar way to ultrasound, most of the terminology has been 
borrowed from it. OCT produces depth profiles of the tissues, named A-scans (after 
ultrasound A-scans), a technique first developed in interferometry in 1986 to measure eye 
length66,69,70. These A-scans are then put together to form a 2D image of a tissue slice named 
a B-scan66,71 examples of which are shown in Figure 1-5 for ultrasound and OCT in a coronary 
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artery. In 1991 the first in vitro B-scan image of the eye acquired by OCT was published by 
Huang et al.64 and 2 years later the first in vivo images of the eye were published by Fercher 
et al.72 and Swanson et al.73.  Although OCT was initially conceived for retinal imaging, the 
first publication describing the system in 199164 already mentions the application of OCT to 
arterial imaging and this is later addressed more specifically in 199667,74,75. Intracoronary OCT 
has since made major developments with the shift from time-domain OCT (TD-OCT) to 
Fourier-domain OCT (FD-OCT) which enabled a great improvement of image resolution as 
well as acquisition time,75 to be described in the following section. 
1.2.2 Basic Theory 
Optical interferometry forms the basis of OCT and it is itself based on the interference 
between two light beams65. Interference refers to the phenomenon which occurs when two 
waves come together and merge to form a wave of greater amplitude (constructive 
interference) or lower amplitude (destructive interference). For instance, when two waves 
with the same frequency (or wavelength) are combined they undergo constructive 
interference if they are in phase or destructive interference if they are out of phase (Figure 
1-6)65. Two light beams which are in phase will have an amplified interference signal 
(constructive interference) only if they are still in phase when they recombine and this will 
only occur if they have both travelled the same “optical path” i.e., neither of them has 
encountered an obstacle which changed their distance travelled65. 
However, this only applies to monochromatic light beams (lasers), which are composed only 
of waves which each have the same wavelength and are in phase, this is named “coherent 
light”65 (Figure 1-6). Moreover, there exist many light sources (the sun, a light bulb) which, 
contrarily, are “incoherent”: they are composed of many waves of different frequencies65 
(Figure 1-6). Most light beams are “partially coherent”: they are coherent only periodically 
and the rest of the time they are incoherent. This means that for a given length of time (the 
coherence length) all the waves in the beam are identical but outside of this length the waves 
have different frequencies and phases. Additionally, when light is referred to as “low 
coherence” this infers that it is partially coherent and has a very short coherence length. 
Therefore, when two identical partially coherent light beams merge, signal amplification due 
to constructive interference solely occurs if the optical paths that each beam has travelled 
differ by a length inferior to the coherence length of the beam65. This is the principle by which 
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interferometers function to determine the distance travelled by backscattered light from a 
sample65.  
 
Figure 1-6: (A) Constructive interference: two waves in phase (red and blue) will combine to 
form a wave of greater amplitude (purple). (B) Destructive interference: two waves out of 
phase (blue and yellow) will combine to form a wave of lower amplitude (green). (C) Coherent 
light is composed of multiple waves that are in phase and have the same wavelength whereas 
incoherent light is made up of waves of different wavelengths and phases. 
An interferometer and specifically Michelson’s interferometer splits the beam of light which 
it receives from a source (Esrc) into two identical beams, the first one, the reference beam 
(Eref) is directed to a mirror and the other is directed towards the sample65 (Figure 1-7). The 
interferometer then receives the reference beam back from the mirror as well as the sample 
beam which has partially been back-scattered from the sample (Esam), these two are 
recombined and the interference is measured65 (Figure 1-7). In OCT, low coherence light is 
used as the source because interference will only be detected during short periods or 
“coherence lengths” which correspond to a very small section of tissue while the rest of the 
tissue above or below this section will be, so to speak, ignored, because the light is incoherent 
by the time it hits it (so no interference pattern will be detected). In this way, information 
about the depths of the tissue structures can be gained from the backscattered light. 
Conversely, if coherent light was used instead, amplified interference signals would be 





Figure 1-7: Diagram of the Time Domain (TD) and Fourier Domain (FD) OCT systems. In the 
TD-OCT system a simple detector is used to receive the recombined light beam and in the FD-
OCT system everything is the same except a spectrometer is used for detection and the 
reference mirror is fixed. 
 
There are two main different OCT system, the most simple to understand is time-domain OCT 
(TD-OCT) which is schematised along with Fourier-domain OCT (FD-OCT) in Figure 1-7. In TD-
OCT a standard detector is used to receive the light beam (Eout) composed of the combination 
of the beam back-scattered from the sample (Esam) and the beam back-scattered from the 
reference mirror (Eref)65. In this system, the reference mirror itself is mobile and it’s distance 
from the beam splitter (Lref) is adjusted initially to make it equal to the distance to the surface 
of the sample and then it is increased in the imaging depth range of interest to acquire an A-
scan profile of the depth of the sample65. However, in FD-OCT systems the reference mirror 
is kept fixed and the backscattered light from the whole depth range of the sample is 
processed at the same time. This can be achieved in two ways, the standard FD-OCT has a 
spectrometer instead of a simple detector as is pictured in Figure 1-765. The second FD-OCT 
system called Swept Source OCT (SS-OCT) has a simple detector (no spectrometer) but uses 
a tunable light source which sweeps the frequency range of interest65. Both FD-OCT systems 
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(FD and SS) exploit interference patterns in the spectral (or Fourier) domain rather than the 
time domain65. Since the arrival of FD-OCT systems in 1995 it was clear that the speed of 
acquisition was much faster than that of the TD-OCT system but in 2003 it was shown that 
the sensitivity of these systems is also far superior to that of the TD-OCT system76–78. 
1.3 INTRACORONARY OCT: VULNERABLE PLAQUES AND MACROPHAGE DETECTION 
Intracoronary OCT systems are composed of a single fibre optic wire (within a guide-wire) 
which emits light and simultaneously records the light back-scattered from the tissue. The 
wire also rotates (to get a 360 degree record of the artery wall) and gets pulled back along 
the artery, within the guide-wire (which itself stays fixed)68. This creates a series of circular 
2D cross-sectional images of the artery lumen and wall, they can be combined to create a 3D 
view of the vessel. Intracoronary OCT systems are SS systems (see section 1.2.2)57 which use 
a near-infrared light source with central wavelengths ranging from 1250 to 1350nm68. This is 
the case because light absorption by tissue is at its lowest between 700 and 1300nm in what 
is named the “window of transmission” which allows higher scattering and therefore more 
information about tissue contents66,67. Using light at this wavelength restricts the tissue 
penetration to 1-3 mm as opposed to 4-8mm with intravascular ultrasound (IVUS)68. 
Nonetheless, the axial resolution of intracoronary OCT (12-18µm for most recent and 
currently used clinical system by St. Jude) is far superior to that of IVUS (150-200µm)68. This 
is also true of the lateral resolution which is 20-90µm for OCT and  150-300µm for IVUS68 and 
these resolution differences are apparent in Figure 1-1. Due to blood being non-transparent 
and highly light scattering, OCT imaging of the artery wall requires a blood-free view68,75. 
Therefore, an intracoronary injection of x-ray contrast is administered during imaging in 
order to clear the blood pool68,75. The vessel size suitable for OCT imaging ranges from 2 to 
3.75mm in diameter, the upper limit being restricted by the actual depth imaging capacity of 
OCT68. 
1.3.1 Detecting vulnerable atherosclerotic plaques 
As was explained previously, the extent of stenosis caused by a plaque provides an 
incomplete indication of its vulnerability to rupture57. Indeed, angiography by itself cannot 
be used to predict plaque rupture. It is hoped that OCT may improve this ability via the 




Culprit plaque that have ruptured demonstrate several different pathological characteristics.  
It is suggested that around 80% of ruptures leading to clinical conditions originate from the 
thin-capped fribroatheroma68,79 (Figure 1-8 (C)). These are characterised by a large lipid core 
and a thin fibrous cap which has been infiltrated by inflammatory cells such as 
macrophages68. A further 10% of plaques associated with clinical events are suggested to be 
ones with calcium nodules (Figure 1-8 (B)) and approximately 20% are ones which cannot be 
classified as either68. OCT does not have the depth penetration necessary to visualise the 
whole lipid core of a plaque however it has the ability to accurately measure fibrous cap 
thickness as is demonstrated in Figure 1-8 (C), calcium nodules as demonstrated in Figure 1-8 
(A) and also has the potential to detect macrophages (20-30µm) which have infiltrated the 
fibrous cap (as will be discussed in the next section)57.  
 
Figure 1-8: OCT scans (top) of different plaque morphologies and their associated histology 
image (bottom). A is a mostly calcified plaque with the calcified regions marked with +, these 
have clearly defined borders with low signal and attenuation which permits deeper light 
penetration. B is a lipid-rich plaque with a thick fibrous cap (over 200µm) whereas C is a lipid-
rich plaque with a much thinner cap (40µm) as is demonstrated on the close up in the bottom 
panel. The lipid core in these lipid-rich plaque has a diffuse border as compared with calcified 
regions and high light attenuation which minimizes tissue penetration. * indicates the lipid 
core, x marks a guide wire artefact. Images reused with permission (license num 




1.3.2 Detecting macrophages in the fibrous cap 
Intra-vascular OCT (IV-OCT) systems have been used extensively in ex-vivo and in-vivo studies 
of atherosclerotic tissue structure both in animal models80–83 and humans56,74,84–88. This 
technique provides the gold standard assessment of coronary plaque cap thickness57.  
However, until relatively recently its ability to detect macrophages within the fibrous cap had 
not been confirmed57. The rationale for macrophage detection on OCT is based upon the 
large size of macrophages/foam cells (20-30µm) and their granularity (due to the presence 
of many lipid-rich phagolysosomes) which should in principle produce higher variability in 
OCT signal than the surrounding tissue57.  
A study in 2003 by Tearney et al. comparing histology and OCT data from ex-vivo coronary 
artery samples, showed not only that macrophages could be visualised on OCT images (Figure 
1-9) but that they could be quantified using the normalised standard deviation (NSD) of local 
pixel intensities of the images89. The standard deviation basically gives a measure of variation 
in brightness of pixels on an image; if there are very bright pixels and very dark pixels within 
a region of interest (ROI), the SD of that ROI will be high whereas if the pixels are relatively 
uniform in intensity (all a similar brightness) the SD will be much lower. The theory here is 
that when macrophages are present in plaque tissue, their scattering properties will produce 
a big variation in pixel intensities within a small area of an OCT image and will result in a high 
SD value for that ROI. Tearney et al. compared the NSD values of OCT images with percentage 
macrophage cover on histology images of the same plaque cap areas89. A cut-off value of 
CD68 stained macrophage cover was used to define caps with either “high macrophage 
infiltration” or “low macrophage infiltration” 89. Then, it was demonstrated that by using an 
appropriate threshold for NSD and a specific ROI, OCT could distinguish the high and low 
macrophage infiltration plaques with 100% specificity and sensitivity89. The areas of high 
macrophage burden can be clearly seen to co-localise on OCT and histological images taken 
(Figure 1-9) 89. However, a point to note is that this study was performed in atherosclerotic 
samples taken from randomly selected cadavers89 and therefore, no association between cap 
macrophage burden and clinical status could be made. Additionally, the authors used a 
bench-top OCT system with higher axial (10µm) and lateral (25µm)89 resolutions than clinical 
systems, and their analysis was performed on the raw OCT data rather than the images that 




Figure 1-9: OCT and associated histology images of human atherosclerotic plaques. A (OCT 
image) and B (histology image) show the same plaque, which has low macrophage infiltration 
in the fibrous cap whereas C (OCT image) and D (histology image) show a plaque with high 
macrophage infiltration in the cap. In the histology images the macrophages are apparent as 
dots because they have been stained with a CD68 specific marker. Images reused with 
permission (rightslink license num 4961361272178) from (89), copyright Wolters Kluwer 
Health, Inc. 
 
Since then, numerous studies have specifically investigated plaque macrophage detection 
with IV-OCT in-vivo and in excised tissue88,90–92. In particular, MacNeill et al., used the same 
macrophage quantification method on IV-OCT images to relate cap macrophage burden in 
patients presenting with different severities of coronary artery syndrome92. It was found that 
patients with unstable disease (MI and unstable angina) had significantly more macrophage 
cap infiltration (higher NSD) than those with stable angina92. Additionally, ruptured plaques 
had a greater macrophage density (higher NSD) compared to non-ruptured ones and in the 
case of culprit lesions (plaques responsible for disease) macrophage burden (NSD) in the 
surface of the fibrous cap was a stronger indicator of disease severity than macrophage 
presence deeper inside the cap. The same was not true for remote non-culprit lesions92. 
Moreover, an NSD colour map technique (shown in Figure 1-10) was presented in this study 





Figure 1-10: OCT image of a coronary artery with a lipid-rich plaque (LP) and site of rupture 
(arrow). The colours represent the normalised standard deviation (NSD) of the OCT signal, 
showing macrophage density from blue (low) to red (high). The * indicates a guide wire 
artefact and the colour bar shows the NSD scale, with percentage of macrophage cover. 
Reused with permission (rightslink license num 4961370273831) from (92), Copyright Elsevier. 
 
A limitation to the results of these studies is that although the NSD parameter is easy to 
understand, it is not the same as macrophage density, indeed in the absence of macrophages 
the NSD will not be zero, due to base-line scattering57. Moreover, different components, 
other than macrophages may also cause high NSD values such as cholesterol crystals and 
some calcifications, it cannot therefore be considered a specific marker of plaque 
inflammation57. It is clear from these limitations that a more specific way of detecting 
macrophages on IV-OCT would provide a major advance, potentially improving the accuracy 
of this technique and its widespread clinical adoption. Additionally, although comparisons 
with histology analyses were made in some studies, the association between OCT image SD 
values and macrophage burden has not been thoroughly interrogated in a controlled in-vitro 
setting. To date, only de Schellenberger et al. 93 attempted to image macrophages in-vitro 
with an IV-OCT system and although their results were positive, there were several 
limitations to the study which will be discussed in the following section. A robust proof of 
concept study would therefore be needed to confirm the validity of the OCT SD as a metric 
for macrophage burden. These are the incentives behind this thesis project as will be 
presented in the Aims & Hypotheses section. 
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Although the studies mentioned here have made big steps towards imaging and quantifying 
infiltrating macrophages in atherosclerotic plaques with OCT they are based solely on the 
concept that macrophages inherently have different light scattering properties to the tissue 
surrounding them. However, there are many variables in this system whereby other 
particulates could result in a signal similar to macrophage infiltration. To address this, 
Ultrasmall superparamagnetic iron oxides (USPIOs) are presented in the following section as 
an agent capable of tagging macrophages and enhancing their detectability on OCT. 
1.4 USPIOS FOR MACROPHAGE DETECTION 
Ultrasmall superparamagnetic iron oxides (USPIOs) are particles characterised by their iron 
oxide core (usually less than 10nm), their large magnetic moment in the presence of an 
external magnetic field and their small overall size of less than 50nm (including the coating)94. 
Due to their small size and hydrophilic coating, USPIOs avoid the initial rapid phagocytosis by 
macrophages of the reticuloendothelial system and therefore have a longer blood pool 
circulation time (between 24-36h) compared to the larger SPIOs (>50nm)94–97. This makes 
USPIOs particularly adept at accumulating in inflamed tissues thanks to transendothelial leak 
and uptake by macrophages95,97. They have indeed been found to accumulate in 
macrophages observed within atherosclerotic plaque of hyperlipidaemic rabbits98–101, ApoE-
/- mice102–104 and humans105–107. USPIO’s have now been used extensively in clinical in-vivo 
MRI studies as markers for inflammation in multiple diseases107–111. In-vitro, various USPIOs 
have been shown to be non-toxic to the murine RAW264.7 macrophage cell line and human 
monocytes after exposure for 24h112–114. 
Ferumoxytol is the USPIO solution exclusively used in this thesis. It is composed of a 5nm 
magnetite core (Fe3O4) in a thick carboxymethylated low molecular weight dextran coat, 
giving it a total hydrodynamic size of between 17-31nm115–117. This particle solution was FDA 
approved for clinical use in iron-deficient patients with chronic kidney disease in 2009117. 
Since then, it has been used extensively in the clinic as an MRI contrast agent thanks to its 
magnetic properties and low toxicity compared to gadolinium118. In-vitro, Ferumoxytol is 
readily taken-up by RAW cells and has not been found to be significantly cytotoxic93. Multiple 
studies have reported that the simple incubation of RAW cells with Ferumoxytol at Fe 
concentrations of 0.05 to 0.5 mg/ml for 24h led to significant particle uptake by the cells93,99. 
As with all iron oxide nanoparticles (IONPs), Ferumoxytol concentration can be accurately 
quantified by ICP-MS and ICP-OES, however the colorimetric “Ferrozine” assay developed by 
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Fish W.119 is often used as a faster and more cost effective alternative120. This assay has 
indeed become a popular method for in-vitro quantification of IONPs121–124 and has been 
used by Müller et al. for precise quantification of USPIOs taken up by RAW cells96. 
The mechanism by which Ferumoxytol is taken up by macrophages has not been extensively 
researched. However, studies of this kind have been conducted using its predecessor, 
Ferumoxtran-10, which has the same core composition and overall size but differs solely by 
the coating: dextran rather than carboxymethylated dextran96,125. Müller et al. found the 
uptake of Ferumoxtran-10 by human monocyte derived macrophages (HMMs) to be non-
saturable (with up to 10mg/ml incubation) and enhanced by incubation with transfection 
agent PLL but not by that with serum proteinases, suggesting non-specific fluid-phase 
transport as the mode of uptake96,97. This study also showed that incubation at 
concentrations of up to 1mg/ml for 72h was not toxic to HMMs nor did it cause them to 
activate, release pro-inflammatory cytokines or affect Fc-mediated phagocytosis96. 
The wealth of evidence showing USPIOs accumulate in atherosclerotic plaque macrophages 
and are non-toxic make them an excellent imaging target. Given their inherent metallic 
properties, it can be postulated that USPIOs may influence the backscattered OCT signal 
when imaged. To date, only one study has investigated the OCT properties of USPIOs; Ariza 
de Schellenberger et al.93 imaged pellets of RAW cells loaded with Ferumoxytol and found 
their OCT signal was significantly changed compared to that of untreated macrophages93. 
There were several limitations to this study: packed cell pellets do not closely reflect the 
distribution of macrophages in human coronary plaques, the phantom set-up introduced 
several unnecessary optical boundaries, and no repeats of the experiment were performed. 
However, the positive results of the study highlight the high potential of USPIO as an OCT 
contrast agent and the need for further investigation both in-vitro and in-vivo. 
1.5 OTHER OCT CONTRAST AGENTS 
The field of IV-OCT contrast agents is very small, so far only a handful of studies have been 
published presenting new agents capable of being detected at the operating wavelength of 
IV-OCT systems, 1300nm. In particular, gold nanoparticles in different forms have been 
shown to be detectable with IV-OCT. These include plasmon-resonant gold nanorods126, 
branched gold naonparticles127, gold nanocages128 and silica-coated gold nanoshells129. The 
reason there has been a focus on gold nanostructures is that their surface plasmon resonance 
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can be tuned by modifying their geometry to increase backscattering or absorption at the IV-
OCT wavelength: 1300nm129. The most successful of these thus far seems to be the silica-
coated gold nanoshells presented by Hu et al. 129,130. The only other contrast agents shown 
to be detectable on IV-OCT are quantum dots: a semiconducting nanoscale crystal 130. These 
quantum dots are capable of emitting light when excited which therefore makes them an 
ideal target for dual modality imaging130. 
Importantly, none of these studies investigated the biocompatibility or uptake of their 
contrast agents by cells. And although the experimental setups varied between the studies, 
with some imaging the particles injected into excised tissues, none actually investigated the 
IV-OCT properties of the contrast agents when loaded into cells. Additionally, the OCT 
“contrast enhancement” was evaluated either by eye or with image analysis metrics based 
on signal attenuation, both of which are significantly affected by many components of 
atherosclerotic plaques. These limitations and the small size of the field demonstrate a clear 
need for further investigation into the IV-OCT contrast properties of nanoparticles with an 
emphasis on real-world application. 
1.6 AIMS & HYPOTHESES 
The introduction to this thesis provides an overview of both coronary artery disease and OCT 
and how the latter can be used to help research, diagnose and treat the former. OCT is now 
a routine clinical care instrument for many diseases including coronary artery disease (CAD). 
Its ability to detect a thin fibrous cap, assess plaque integrity and accurately quantify the 
severity of luminal stenoses already makes it a useful clinical technique. If OCT could also 
reliably and accurately detect plaque macrophage infiltration then it might provide the gold 
standard technique for vulnerable plaque detection and thereby improve patient care and 
outcomes.  
In light of this, the aims of my research have been to establish methods for the enhanced 
detection and quantification of macrophages with the clinical IV-OCT system in-vitro, ex-vivo 
and in-vivo. The overarching hypothesis has been that macrophages can be detected and 
quantified on IV-OCT images using the standard deviation of pixel intensity metric and that 
this detection can be enhanced and made more specific by labelling with metallic particles, 
specifically USPIOs and novel lanthanide-based nanoparticles. This thesis aims to investigate 
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this model in vitro, in animal models and finally in humans presenting with symptomatic 
coronary artery disease. 
Chapter three of this thesis presents an in-vitro OCT study whose aim is the detection of 
macrophages labelled with USPIOs in a bespoke phantom artery model (described in Chapter 
two). The overarching hypothesis of Chapter three is that intra-cellular USPIOs will enhance 
the detection of macrophages on IV-OCT images in-vitro. 
In Chapter four, the same USPIO particles are used in an ApoE-/- mouse study with the aim 
of enhancing the OCT detection of macrophages in excised atherosclerotic tissue. The main 
hypothesis of chapter four is that the plaques of USPIO treated mice will have a higher signal 
on IV-OCT images compared to untreated mice. 
Chapter five presents an in-vivo human study with the aim of enhancing the OCT detection 
of inflammation (using USPIO) in the caps of culprit atherosclerotic plaques of patients 
presenting with acute coronary syndrome. The overarching hypothesis of chapter five is that 
culprit plaques of USPIO treated patients will yield higher OCT signal compared to saline 
treated patient culprit plaques and compared to non-culprit plaques. 
Finally, the main aims of Chapter six are to introduce a panel of novel lanthanide based 
nanoparticles designed to enhance OCT contrast. The main hypothesis of chapter six is that 




































2.1 CELL CULTURE  
The mouse macrophage-like cell line RAW264.7 was cultured in either T-75 or T-162 tissue 
culture flasks kept in the tissue culture incubator at 37°C. The RAW cell line was initially 
thawed from a stock kept in the -80°C freezer by Dr Marc Vendrell (originally bought from 
ATCC) and all the tissue culture was performed under sterile conditions using a laminar flow 
hood in the tissue culture room in the Centre for Inflammation Research (CIR) at the QMRI.  
The cells were cultured in RPMI media 1640 supplemented with 10% FBS (foetal bovine 
serum), 1% pen/strep (penicillin/streptomycin) and 1% L-glutamine, all supplied from 
Gibco®. 15 ml of media was used in T75 flasks and 30 ml in T162 flasks. The culture flask was 
checked every 2 to 3 days under the microscope and when the cells were fully confluent 
(approximately every 3 days) they were lifted by scraping with a plastic scraper and 10% of 
the culture was transferred to a new flask containing fresh warm media. Every so often, if 
many detached cells could be observed in the flask under the microscope, they were washed 
out with DPBS by Gibco® before the attached cells were lifted. 
2.2 OCT IMAGING 
All human coronary artery OCT images taken during the clinical trial presented in Chapter 5 
were acquired using the Terumo LunawaveTM system with the FastviewTM imaging catheter 
(Terumo international Systems). This system was on loan at the Royal Infirmary of Edinburgh 
Catheterisation Lab and unfortunately had to be returned during the course of this thesis 
project. The Ilumien OptisTM frequency domain OCT system (LightLab/St. Jude Medical, St. 
Paul, MN) was acquired to replace it and it was used in conjunction with the DragonflyTM 
imaging catheter (LightLab/St. Jude Medical, St. Paul, MN) to take the OCT images of 
phantoms (presented in Chapters 3) and murine aortas (presented in Chapter 4).  
Both OCT systems work in the same way: the 1mm catheter is introduced to the area of 
interest then the OCT controls are handled on the connected computer. First, the OCT image 
gets automatically calibrated, then a pullback scan is performed, whereby the OCT light 
source automatically gets pulled backwards through the transparent plastic tube of the 
catheter by the OCT machine mechanics. This enables the system to create multiple 
sequential circular cross-sectional OCT images throughout the entire length of the pullback 
scan. This results in a “stack” of logarithmic scale compressed images which are sequential 
slices through the tissue or phantom and are exported in .tiff format. The images from the 
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Terumo LunawaveTM system are 600x600 pixels in dimension and those from the Ilumien 
OptisTM system are 1024x1024 pixels. Both are grayscale images but the Ilumien OptisTM ones 
have an orange colour map filter on top which can be removed – it is mostly but not always 
present in the images shown in this thesis. The specifics of imaging methodology and image 
analysis for each system (phantom, mouse and human) are covered in the following chapters. 
2.3 PHANTOM MOULD DESIGN AND OPTIMISATION 
Initially, phantoms were made with agar in petri dishes, using tubing to create a cavity in 
which the OCT catheter could be placed (Figure 2-1 (A)). However, these were not useful for 
testing multiple conditions within one phantom, therefore segmented phantoms were 
developed. At first, they were made with readily available equipment (petri dishes, falcon 
tubes, blue tack, plastic sheets and plastic tubing) but these proved time consuming to make 
repeatedly and impractical to use.  
Consequently, a 3D printed mould was designed using Autodesk Inventor Professional, the 
design is shown on Figure 2-1 (B) and the printed mould with tube insert is pictured on Figure 
2-1 (C). This model was much more practical to use but nevertheless still had some flaws. 
Specifically, the differing sizes of the sections rendered gel making more complex, especially 
when these needed to be loaded with cells. For these reasons, new designs of segmented 
moulds were subsequently created (pictured in Figure 2-1 (D,E)) and 3D printed (pictured in 
Figure 2-1 (F,G)). These two models have 5 identical sections partitioned by plastic 
separations which are pierced by a hole measuring either 3 mm or 1 mm in diameter (panels 
(D) and (E) respectively) in which metal rods of those diameters can be placed to create an 
artery like cavity (panels (F) and (G) respectively). The phantom sections were designed to 
measure 0.5 cm3 when the rod is in place, and therefore hold exactly 0.5 ml of liquid or 
agarose gel. These moulds vastly improved ease and efficiency of creating agarose phantoms 





Figure 2-1: Development of a 3D printed phantom artery model. (A) Early prototype of an 
artery-like cavity moulded using agar in a petri dish with a plastic tube. (B) First 3D segmented 
phantom mould design on Autodesk Inventor Professional. C) 3D printed mould from design 
B with plastic tube insert. (D) and (E) two new 3D segmented phantom mould designs on 
Autodesk Inventor Professional differing by the size of the perforation: 3 mm (D) and 1 mm 
(E) in diameter. (F) and (G) 3D printed moulds from designs D and E respectively with metal 
rod inserts. 
 
Multiple phantom moulds were 3D printed at the School of Engineering in order to make 
several phantoms simultaneously. Optimisation with the previous phantom iterations 
identified agarose at 1.5 % as the best substrate for OCT imaging over agar. Phantoms in this 
thesis were therefore made with 50 ml of PBS and 0.75 g of agarose powder (Sigma-Aldrich) 
heated in the microwave for a few minutes (with regular stirring) until completely melted 
and no particulate matter could be seen by eye. 0.5 ml of the melted agarose was then 
pipetted into each phantom mould section and depending on the experiment, initially mixed 
with either particles or pellets of fixed RAW macrophages (detailed subsequently). Once the 
agarose gels are set, the metal rod is removed and the phantom is imaged using the 
commercially available Ilumien OptisTM frequency domain OCT system connected to the 
DragonflyTM imaging catheter (LightLab/St. Jude Medical, St. Paul, MN) which is inserted into 
the artery-like cavity. The OCT catheter is approximately 1 mm in diameter and therefore fits 
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snugly in the 1 mm diameter cavity phantom (Figure 2-1 (E,G)) enabling direct imaging of the 
gels without an air interface for the light to travel through. Conversely, the 3 mm cavity 
phantom (Figure 2-1 (D,F)) does not allow for the catheter to be fixed in place which means 
it’s position often changes along the length of the phantom.  
OCT slices of the 3 mm (large) and 1 mm (small) diameter cavity phantoms are shown side 
by side on Figure 2-2. The plain agarose gel images (A, B) are markedly different, with (B) 
showing much more homogeneity and better depth penetration of the signal compared to 
(A). Indeed, the air interface in the large cavity phantom induces a loss of signal at a depth of 
about 2 mm whereas the small cavity phantom shows no loss of signal, even at the maximal 
depth of 3.5 mm. Additionally, the position of the catheter in (A) affects which areas of the 
image are brightest whereas in (B), the catheter is in a fixed position in the phantom so the 
gel imaging appears much more even. These effects are also apparent when imaging agarose 
gels mixed with 20x106 fixed RAW cells (E, F). Indeed, the loss of OCT signal occurs at a depth 
of around 1.5 mm in the large cavity phantom (E) and at 2 mm in the small cavity phantom 
(F). Therefore in the large cavity phantom, the depth of imaging varies between 1 mm (where 
the catheter touches the gel) and 0.25 mm (where the catheter is furthest away from the 
gel). Conversely, the small cavity phantom enables even 1.5 mm depth imaging of the cell gel 
all the way around the catheter (as can be seen in (F)). Consequently the 1 mm diameter 
cavity phantom mould (Figure 2-1 (G)) was selected for use in all subsequent phantoms in 
this thesis to ensure best reproducibility as well as ease of ROI drawing. Panels (C) and (D) of 
Figure 2-2 show OCT images through the plastic separations in between the chambers of the 
phantom moulds – these look very different to agarose under OCT and enable clear 




Figure 2-2: Comparison of OCT images from 3 mm (left) and 1 mm (right) diameter cavity 
phantoms. (A) and (B): 1.5 % agarose gel only. (C) and (D): plastic separation between the gel 
compartments. (E) and (F): 1.5 % agarose mixed with 20x106 fixed RAW cells. 
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2.4 OCT IMAGE ANALYSIS AND PROCESSING  
2.4.1 Regions of interest 
The same method for OCT image analysis was applied across all the in vitro, mouse and 
clinical studies. Regions of interest (ROIs) were drawn on individual slices from the OCT stacks 
using a software called AnalyzeTM in order to avoid common artefacts such as dark bands, 
bright spots, stitching artefacts, signal drop off areas and guidewire artefacts as exemplified 
in Figure 2-3.  
For the in-vitro phantoms, between 1 and 4 ROIs of an average of 10000px were drawn on 
most slices of the imaging stacks (with 3 being most common), depending on the number of 
artefacts present (Figure 2-3 (A)). There are approximately 70 OCT image slices in every 
section of the phantom and therefore approximately 200 ROIs were drawn in each.  
For the mice, between 1 and 4 ROIs of an average of 700 pixels in size were drawn on each 
slice of the aorta imaging stacks (with 2 being most common), depending on the shape of the 
plaque and arterial wall as well as the artefacts present. There are approximately 88 OCT 
image slices in every aorta imaging stack. Approximately 175 ROIs were drawn for each 
mouse aorta, with an equal split drawn in the plaque containing images and the non-plaque 
control images. On the OCT slices of the plaque-containing section of aorta (in the aortic 
arch), the ROIs were drawn on the bright outer edge of the plaque (the cap) as exemplified 
in red on Figure 2-3 (B). ROIs were also drawn on each OCT slice of the descending aorta 
which did not contain plaque, to be used as a control – they were drawn on the outer edge 
of the tissue as exemplified in green on Figure 2-3 (B).  
For the patient images, ROI drawing was performed by cardiologist Dr Simon Wilson. For each 
plaque, 3 ROIs were drawn on 8 different OCT slices (equally distributed through the plaque). 
As shown in Figure 2-3 (C), one ROI was drawn in the middle of the plaque cap (green) and 
one ROI on each shoulder of the plaque (red). These ROIs were drawn small (average of 
530px) to avoid drawing over non-cap tissue, dark bands and guidewire artefacts.  
For both mouse and human images, ROI drawing was done blinded to the treatment 
information and clinical data. All ROIs were saved as .obj files for use in the Matlab processing 




Figure 2-3: OCT image artefacts and ROI drawing method for all three systems, phantoms (A), 
mice (B) and humans (C). Artefacts visible on these images include dark bands (DB), bright 
spots (BS), the air-liquid (AL) interface line, bright lines created by imperfections in the 
Silguard (SL) gel that the mouse aortas are pinned onto and the guidewire (GW) shadow on 
the human images. ROIs are shown here in green, yellow and red.  
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2.4.2 Automated quantification of ROI metrics 
Custom software was developed using Matlab (Mathworks, Inc) to process the pixel 
information within ROIs of OCT images. This software was used to calculate a number of 
different metrics (ROI size, ROI mean pixel intensity, min and max pixel intensity, standard 
deviation and variance of mean pixel intensity, etc…). The standard deviation of the mean 
pixel intensity (SD) is the most important of these metrics for the ensuing analysis, it 
represents the variation in the light scattering properties in the tissue. Indeed, if the tissue is 
very granular, with many cells, or reflective particles, the SD should be higher. This SD value 
has been used in other OCT studies, such as that of Tearney et al. 89, and formed the basis for 
our analysis approach to quantifying the burden of macrophages and/or nanoparticles in this 
thesis. Specifically the SD was calculated using the following formula where N is the number 
of pixels in the ROI, S(x,y) is the pixel intensity as a function of x and y locations within the 








(𝑆(𝑥, 𝑦) − 𝑆̅), 
In the study by Tearney et al. 89, they used the raw OCT images for their analysis and therefore 
performed a normalisation (to the images min and max) step, thus naming their metric the 
Normalised Standard Deviation (NSD). Subsequent to this, a background removal and median 
filtering step was also implemented. However, the image analysis for this whole thesis is 
based on pre-processed images from clinical IV-OCT systems. The images from these systems 
have already gone through normalisation, background removal and filtering steps in order to 
achieve clear images for clinicians to interpret. Therefore, in our image analysis software we 
did not implement normalisation, background removal and filtering steps as this would 
remove important information from the image and negatively impact the detection of 
macrophages with the SD metric. 
Two versions of the Matlab code for this ROI metric processing were written, one for OCT 
images from the Terumo LunawaveTM system (human clinical trial data) and the second for 
those from the Ilumien OptisTM system (in-vitro phantoms and ex-vivo mouse data). This is 
because the images from each machine have different sizes and different numbers of total 
pixels. In addition, the Terumo LunawaveTM images are saved with burnt-in tick marks (see 
Figure 2-4) which required removal from the image analysis for easier ROI drawing on the 
clinical images. This is implemented in the Terumo LunawaveTM version of the code using a 
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mask, as presented in Figure 2-4. Both versions of the Matlab code are shown in full in 
Appendix 1 and Appendix 2, they were written by Dr Calum Gray and edited/adapted by 
myself. 
 
Figure 2-4: Left – OCT image slice in the coronary artery of a patient taken with the Terumo 
LunawaveTM system. The images have burnt-in tick marks, some of which are barely visible 
against the tissue, and therefore time consuming to avoid when drawing ROIs. Right – mask 
created to enable the removal of tick marks and catheter at the image processing step. 
 
2.4.3 Automated production of SD hotspot maps 
In order to visualise the local differences in standard deviation of pixel intensity on the OCT 
images, another piece of Matlab code (Appendix 3) was developed to produce a SD hotspot 
map overlay. It was written by Dr Calum Gray and subsequently edited with help from Dr 
Pierre Bagnaninchi. The code processes the image in the following way: each individual pixel 
is assigned a colour based on the value of the SD of pixel intensity in a square kernel (of a 
predetermined size) surrounding the pixel. In this way, all pixels are assigned a colour which 
gives a scale of the SD in the local region – showing the extent of the variation in the OCT 
signal. The size of the square kernel affects the appearance of the resulting colour map 
greatly so detailed optimisation was performed to find the optimal kernel size. For the 
Ilumien OptisTM images (phantoms and mouse aortas) the kernel was selected to be 5x5 
pixels in size. The kernel size was scaled to 9x9 pixels for the Terumo LunawaveTM images 
based on the total pixel numbers in the images from each system (1024x1024 for OptisTM and 
600x600 for LunawaveTM). This colour mapping was restricted to ROIs drawn on select OCT 
49 
 
images for each condition, an example for a cell phantom and a human culprit plaque are 
shown at the top of Figure 2-5. 
 
Figure 2-5: Standard deviation (SD) hotspot map optimisation. Top: each individual pixel in 
the ROI is assigned a colour based on the value of the SD of pixel intensity in a square kernel 
(of a predetermined size) surrounding the pixel. The colour scale shows white/yellow to be 
low SD values and dark red high SDs. Middle: the lower half of the SD values are removed in 
order to leave cleaner, easier to see “hotspots”. Bottom: the number of colours on the scale 
are reduced so that variation in SD value is easier to see. 
 
For better visualisation of the SD “hotspots”, a threshold was set to half of the maximal SD 
value (second step in Figure 2-5). In this way, all pixels whose SD values are below half of the 
highest SD are not included in the colour map. This makes the image less overwhelming to 
look at and shows just the highest SD values overlaid on the original image. The colour 
scheme and scale also had to be optimised and integrated into the code in order to better 
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distinguish SD values. The third step in Figure 2-5 shows how setting the colour scale to have 
just 13 colours as opposed to the standard 64 makes the different values much easier to see 
on the images. A few OCT images from each condition for each of the 3 systems (in-vitro, ex-
vivo mouse and in-vivo human) were processed with this code and the resulting SD hotspot 
images were saved as .tif files. Representative examples of these are presented in Chapters 
3, 4 and 5. 
2.5 STATISTICAL ANALYSIS  
Statistical analysis was performed using the Graphpad Prism software, version 5. For all 
datasets with more than two columns to compare, significant difference was tested using a 
one-way ANOVA with the Tukey post-test to compare all pairs of treatments. For all datasets 
with only two columns to compare, significant difference was tested using a two-tailed 








































3.1 INTRODUCTION  
Chapter 1 demonstrated the need for a method of tagging vulnerable plaque macrophages 
on IV-OCT and presented USPIO as an agent which could fill that need. This chapter aims to 
test this hypothesis in an in-vitro setting. Indeed, in section 1.1.5 it was established that there 
has been a keen interest over the last 30 years in detecting “the vulnerable plaque” and that 
OCT has important potential in that respect. Intra-vascular OCT (IV-OCT) is used routinely in 
the clinic during coronary interventions, has the ability to detect important plaque 
components (fibrous cap, lipid pool and microcalcifications) with preliminary data suggesting 
it might also detect areas of increased plaque macrophage density. This last point is of 
particular interest given the key role played by plaque macrophages in driving atherosclerotic 
disease progression and plaque rupture but requires improvement to become of clinical 
utility.  
Previous attempts to quantify coronary macrophage density on OCT have used the local 
standard deviation (SD) of pixel intensity89,90,92, yielding positive results with some 
limitations, as is discussed in detail in section 1.1.3. Notably, this metric has not been shown 
to be unequivocally specific to macrophages and has never yet been tested in-vitro or in 
animal models. This calls not only for a robust in-vitro proof of concept study but perhaps 
also for an attempt to enhance the OCT detection of macrophages using a probe or 
nanoparticle. As introduced in section 1.4, USPIO particles are an ideal candidate for this, 
given that they are approved for clinical use and have been shown to accumulate in human 
coronary plaque macrophages105–107. Moreover, their scattering properties, should in theory, 
produce higher OCT contrast as has been demonstrated in one in vitro study93. Ariza de 
Schellenberger et al. showed that when packaged into RAW cells, USPIOs do significantly 
increase the OCT contrast93. However, the N numbers were low, the SD metric was not 
tested, and the experimental phantom created did not accurately reflect in-vivo conditions.  
There are therefore many incentives for further testing the OCT contrast properties of 
USPIOs and thus for the development of a new robust in vitro phantom model for coronary 
IV-OCT imaging. The following chapter is the in vitro stage of a 3-part translational study 
investigating the USPIO-enhanced detection of plaque macrophages on IV-OCT. The five aims 




AIM 1 (section 3.3.1): To determine how effectively murine macrophage cultures uptake 
USPIOs. 
Hypothesis 1: Murine macrophages will take up USPIOs from the media in a dose 
dependent manner during overnight incubation in normal cell culture conditions. 
AIM 2 (sections 3.3.2 and 3.3.3): To test whether USPIOs alone enhance the OCT signal in our 
novel phantom model. 
Hypothesis 2: USPIOs held homogenously in an agarose gel will yield higher OCT contrast 
compared to an agarose only gel. 
AIM 3 (sections 3.3.2 and 3.3.4): To test whether macrophages alone enhance the OCT signal 
in the phantom model (using the standard deviation of pixel intensity as a metric). 
Hypothesis 3: Macrophages held homogenously in an agarose gel will yield higher OCT 
contrast compared to agarose only. 
AIM 4 (sections 3.3.2 and 3.3.4): To determine if USPIOs loaded into macrophages can further 
enhance the OCT signal. 
Hypothesis 4: Macrophages loaded with USPIOs held homogenously in an agarose gel will 
yield higher OCT contrast compared to untreated macrophages in agarose. 
AIM 5 (section 3.3.5): To test whether the SD hotspot overlay tool accurately visually 
represents the SD analysis results in the macrophage phantom images. 
Hypothesis 5: There will be more, high intensity hotspots on the images of gels containing 
macrophages compared to the control gel. Additionally, there will be even more, high 
intensity hotspots on the images of gels with USPIO-loaded macrophages. 
 
If successful, this in vitro investigation and image analysis methodology will pave the way for 
the use of USPIOs as a new OCT contrast agent in atherosclerosis in murine models (Chapter 







3.2.1 Ferrozine assays 
The RAW264.7 murine macrophage-like cell line was cultured as described in section 2.1. The 
USPIO used throughout this thesis was the Ferumoxytol (or Ferahaeme) solution by Rienso® 
and the concentrations hereafter specified refer to the concentrations of iron present in the 
compound (30mg/ml in the stock solution). RAW cells were incubated with 0.3, 1.5 and 3 
mg/ml (equal to 5.37, 26.86 and 53.72 mM of Fe) of USPIO in media for 24 hours. Following 
washing in Dulbeco’s PBS (Gibco), lifting by scraping and counting with a haemocytometer, 
3x106 cells were taken from each treatment condition. These were pelleted and then lysed 
in 300µl of 1% triton for 10 mins. The cell lysates were diluted 100 times (1µl of lysate + 99µl 
of distilled water) and repeats were made for each tube. Each was treated with 100µl of iron 
releasing reagent (equal parts 1.4M HCl solution and 4.5% KMnO4 in H20 – combined and 
incubated at 60°C for 2 hours in a fume hood (chlorine gas is produced during the reaction).  
Iron standard solutions were made (300µL for each) using FeCl3 concentration between 0-
300µM. To each were added 300µl of 50mM NaOH, 300µl of iron releasing agent and 90µl of 
iron detection reagent (6.5mM ferrozine, 6.5mM neocuproine, 2.5M ammonium acetate, 
and 1M ascorbic acid in water). These were incubated for 30mins before being transferred 
to a 96 well plate.  
After their 2-hour heated incubation with the iron releasing reagent, the cell lysate samples 
were cooled to room temperature. 30µl of the iron detection reagent was then added to 
each and incubated for 30mins before transferring to the 96 well plate with the iron standard 
solutions. The full plate was run in a plate reader, measuring the absorbance at 550nm with 
700nm for the background. The background values were subtracted from the 550nm 
absorbance values. An iron standard curve was plotted using the measured absorbance 
values of the iron-standard solutions against their known Fe concentrations. The equation of 
this curve was then used to convert the cell lysate absorbance values to Fe concentrations 
and plot these against the initial Fe treatment concentrations (Figure 3-1). This assay was 
repeated 4 times, on separate days with a different passage of RAW264.7 cells. 
3.2.2 Phantoms 
A bespoke phantom artery mould was designed and 3D printed, as described in detail in 
methods section 2.3, in order to easily and reproducibly image multiple agents of interest 
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(macrophages and/or particles) in one scan, using a clinical IV-OCT system. In brief, this 
mould has five identical square chambers of a volume of 0.5ml and each plastic partition has 
a central 1 mm diameter opening through which the IV-OCT catheter is introduced for 
imaging. Using this 3D printed mould two simple phantoms were made with 1.5% agarose in 
PBS and different amounts of USPIO solution (Ferumoxytol by Rienso® 30mg/ml) to obtain 
different concentrations of particles in each of the 5 phantom sections in the following way: 
•  No USPIO control: 0.5ml melted agarose alone 
• 0.05 mg/ml USPIO: 1.7μl USPIO in 1ml melted agarose (0.5ml discarded) 
• 0.25 mg/ml USPIO: 4.25μl USPIO in 0.5ml melted agarose 
• 2.5 mg/ml USPIO: 42.5μl USPIO in 0.46ml melted agarose 
• 5mg/ml USPIO: 85μl USPIO in 0.42ml melted agarose 
These were mixed well to ensure homogenous distribution of the particles in the gel and they 
were each transferred to a section of the phantom mould described in section 2.3 to form 
the phantoms pictured in section 3.3.2. 
Additionally, 7 macrophage laden phantoms were made. For this, the RAW264.7 murine 
macrophage cell line was cultured as described in section 2.1 in T162 flasks and incubated 
with 33μl, 167μl and 1.7ml USPIO solution in a total of 20ml of media (corresponding to 0.05, 
0.25 and 2.5 mg/ml concentrations respectively) for 24 hours. Following washing in Dulbeco’s 
PBS (Gibco), lifting by scraping and counting with a haemocytometer, 20x106 cells were taken 
from each treatment condition. These were washed, pelleted and fixed in 1ml of 4% PFA for 
15 minutes (to ensure the cell membrane remains intact and retains the intra-cellular 
particles) then pelleted again and the supernatant removed. These pellets were warmed up 
in a water bath then thoroughly mixed with 0.5ml of warm 1.5% agarose using a warmed 
pipette tip (to avoid setting prematurely) before transferring to the phantom mould.  
All these phantoms were made with the 1mm rod insert in place to create a “lumen” through 
the agarose gel phantom. This rod was removed in order to insert the DragonflyTM OPTISTM 
OCT catheter and image the phantom using the St. Jude Medical OTPIS integrated system. 
Image analysis was performed using the custom methods and software described in section 
2.4.  Finally, the bespoke OCT SD hotspot tool described in section 2.4.3 was tested on sample 





3.3.1 Iron uptake quantification 
To be certain that any OCT signal changes between untreated cells and USPIO treated cells 
are due to the presence of USPIOs inside the cells, a number of experiments were performed. 
Loading of mouse macrophage cultures with USPIOs was done by 24h incubation with varying 
concentrations of particles. These cultures retained iron colourations post-washing as can be 
seen in Figure 3-1 (A) suggesting the particles were effectively taken up by the cells during 
incubations. Microscopy observations of these cultures further confirmed this with very dark 
endosomes being visible in the cytoplasm of cells incubated with USPIOs at concentrations 
above 0.3mg/ml. The highest concentration tested (3mg/ml) yielded very clear differences 
with the untreated control as shown in Figure 3-1 (B). 
To further confirm USPIO uptake by the murine macrophages and test its efficacy, Ferrozine 
assays were performed in order to quantify intra-cellular iron as described in methods 
section 3.2.  In this assay, the acidic KMnO4 solution is used on cell lysates to separate iron 
complexed with cellular proteins. Following this, a Ferrozine (C20H13N4NaO6S2) solution is 
used to bind ferrous iron into a complex which absorbs light in the 550nm wavelength, 
enabling colorimetric quantitation of intracellular iron. These assays were completed 
following a 24h incubation of murine macrophages with 3 different concentrations of USPIOs 
(0.03, 0.3 and 3mg/ml), a media only control and using iron standard solutions as a reference. 
The results are presented as a plot of incubated iron concentrations against measured intra-
cellular iron concentrations in Figure 3-1 (C). As expected, increasing the incubation 
concentrations of USPIOs leads to higher intra-cellular concentrations measured with the 
Ferrozine assay and these results were reproducible over 4 repeats (tight error bars). This 
increase however is not proportional - the curve’s slope becomes less acute as the incubated 
concentrations increase and shows signs that it might plateau past the highest concentration 
tested (3mg/ml USPIO = 53.72 mM of Fe). This is again to be expected given that 





Figure 3-1: Iron uptake quantification assays. (A) Mouse macrophage suspensions after 24h 
incubation with varying concentrations of USPIOs and multiple washes – the iron colour is 
retained, indicating the remaining USPIOs are inside the cells. (B) Microscopy photos of these 
cells, the USPIOs are clearly visible in cellular endosomes when comparing to the control. (C) 
Ferrozine assay results plot showing the measured iron concentrations within the cells after 
incubation with USPIOs against the initial concentrations those cells were incubated with 
(n=4, error bars=SD). 
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3.3.2 Phantom OCT imaging 
The 3D-printed phantom artery moulds described in methods section 2.3 were used to make 
two 1.5% agarose phantoms for IV-OCT imaging. 5 different agarose gels were made, one for 
each section of the segmented phantom mould. These are pictured in Figure 3-2 (A) and the 
sections contain the following: 1- agarose only control, 2- USPIO 0.05 mg/ml, 3- USPIO 0.25 
mg/ml, 4- USPIO 2.5 mg/ml and 5- USPIO 5 mg/ml. The dilution of USPIOs in each gel is easily 
inferable by the intensity of the iron colouration visible in the photo. The phantoms were 
subsequently imaged by IV-OCT with the catheter placed through the lumen in the middle of 
the phantom (where the needle is visible in the Figure 3-2 (A)). The numbered panels in 
Figure 3-2 show a representative cross-sectional OCT slice from each phantom section (from 
approximately 70 slices per section), the circle in the centre of each image is the imaging 
catheter and the rest of the image is the agarose gel. The 4 dark bands radiating from the 
catheter are imaging artefacts that were avoided when drawing ROIs for the image analysis 
steps. There does not seem to be any strong differences visible between the images of the 5 
different sections suggesting USPIO alone doesn’t affect the OCT signal. 
The same bespoke phantom moulds were used to create a different set of 1.5% agarose gels 
for IV-OCT imaging. The 5 sections contained the following: 1) agarose only control, 2) 20 
million untreated murine macrophages, 3, 4 and 5) 20 million murine macrophages loaded 
with 3 different concentrations of USPIOs - incubations at 0.05, 0.25 and 2.5 mg/ml 
respectively. 7 repeats of these phantoms were made, one of which is pictured in Figure 3-3 
(A). Despite the particles being contained inside the cells, themselves embedded in agarose, 
the iron colouring of the different dilutions is visible. Figure 3-3 (B) is a transversal OCT image 
through the middle of the phantom and along the whole length, showing the 5 square gels 
each separated by the plastic walls (bright bands) and the catheter running through the 
centre of each. The numbered panels show a representative cross-sectional OCT slice from 
each phantom section (from approximately 70 slices per section). Contrarily to those in 
Figure 3-3, the OCT images from the different sections do have visual differences. In 
particular sections 2 to 5, which all contain cells, look distinct from the agarose only control: 
the depth penetration of the OCT signal is much reduced and there are many more, brighter 
spots. Although 2 and 3 look quite similar, image 4 shows a slight decrease in the signal depth 
penetration: the bright section has a smaller diameter around the catheter and the area past 
this is darker. The same again can be said for image 5 compared to image 4 – the OCT signal 
seems to drop off as it goes through the gel. These observations show that the presence of 
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macrophages has a big effect on the OCT signal and suggests that the presence of USPIOs 
inside the cells at a high enough concentration increases this effect. 
 
Figure 3-2: OCT imaging of a phantom model with different dilutions of USPIOs. (A) Photo of 
the two phantoms made with 1.5% agarose and varying dilutions of USPIOs in each section. 




Figure 3-3: OCT imaging of a phantom artery model. (A) Photo of one of the 7 phantoms made 
with 1.5% agarose and 20x106 macrophages having been incubated with varying 
concentrations of USPIOs. (B) OCT image through the middle of this phantom showing each 
section, the plastic separations between them (bright vertical bands) and the OCT catheter 




3.3.3 Image analysis – USPIO alone 
As explained in section 2.4, the standard deviation (SD) of the mean pixel intensity within 
certain regions of the OCT images was used as a metric of the “granularity” to measure the 
effects of the different phantom compositions. In order to avoid imaging artefacts, ROIs were 
drawn on each of the OCT slices and the SD values for each ROI were processed in Matlab as 
described in section 2.4. Figure 3-4 presents the mean of these SD values for each section of 
the two “USPIO alone” phantoms introduced in Figure 3-2. Figure 3-5 shows the image 
analysis results processed in the same way but using the mean pixel intensity within the ROIs 
rather than the SDs.  
 
Figure 3-4: Top: standard deviation of pixel intensity analysis of OCT images from 2 phantoms 
made with 1.5% agarose and varying dilutions of USPIOs. Bottom: the mean intensities for 
each condition from both phantoms pooled. All values normalised to the agarose only control. 
Letters show results of statistical test, when two bars share the same letter they are not 
significantly different whereas different letters indicate significant difference (p<0.05). 
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For each phantom and for the pooled results, the mean SD (MSD) of the USPIO 0.25mg/ml 
gel shows no significant difference with the control. Aside from this, the presence of USPIOs 
in the other gels significantly lowered the MSD in a concentration dependant manner: with 
each increase in concentration the MSD becomes significantly lower. This shows that USPIOs 
alone reduce the “granularity” of the OCT image, contrary to what had been hypothesised. 
This is potentially due to the homogeneous nature of the USPIO spread within the gels – the 
particles are making the gels more opaque (visible in Figure 3-2 (A)), letting less light through 
and therefore dampening the overall OCT signal. This is corroborated by the fact that the 
mean intensity analysis (Figure 3-5) shows very similar results to the MSD ones: not only are 
the USPIO images less granular, they are also less bright as a whole. 
 
Figure 3-5: Top: mean pixel intensity analysis of OCT images from 2 phantoms made with 
1.5% agarose and varying dilutions of USPIOs. Bottom: the mean intensities for each condition 
from both phantoms pooled. Values normalised to the agarose only control.  Letters show 
results of statistical test, when two bars share the same letter they are not significantly 
different whereas different letters indicate significant difference (p<0.05).  
63 
 
3.3.4  Image analysis – USPIO laden macrophages 
The macrophage loaded phantoms introduced in Figure 3-3 were analysed in the same way 
as the USPIO only ones presented above. The results of the MSD analysis of the 7 individual 
macrophage phantoms are presented in Figure 3-6 (phantoms 1 to 3) and Figure 3-7 
(phantoms 4 to 7). The agarose only control gel made in each phantom had a significantly 
lower MSD compared to all other gels in each phantom (p<0.001) but the results are only 
shown for phantom 1 as a representative example (Figure 3-6, (1) Controls). This signifies 
that untreated macrophages reproducibly increase the OCT signal. In addition, the gel 
containing USPIO 0.25mg/ml treated macrophages showed a significant increase in MSD 
compared to untreated macrophages in every phantom made (see Figure 3-6 and Figure 3-7). 
This finding shows that USPIOs loaded into macrophages at this concentration do increase 
their contrast on OCT. Furthermore, 5 of the 7 phantoms also show the USPIO 0.05mg/ml gel 
having a significantly higher MSD compared to untreated, showing promise for this 
concentration also having an enhancement effect on the OCT images. However, the 
remaining two phantoms (2 and 7) show no significant difference between the USPIO 
0.05mg/ml treated and untreated, suggesting this concentration does not produce 
consistent OCT contrast enhancement. Moreover, the macrophage gels treated with the 
highest USPIO dose (2.5mg/ml) showed much more variable MSD values between phantoms: 
• Phantoms 1, 3 and 5 show USPIO 2.5mg/ml treatment significantly increases the 
MSD compared to untreated 
• Phantoms 4 and 6 show USPIO 2.5mg/ml treatment to have no significant effect on 
the MSD compared to untreated 
• Phantoms 2 and 7 show USPIO 2.5mg/ml treatment significantly decreases the MSD 
compared to untreated 
When packaged into cells, USPIOs increase the MSD on OCT images but only at certain 
concentrations. When used at 2.5mg/ml they create a much more variable signal which could 
be traced back to behaviour when they are placed alone in agarose gels (not inside cells). In 
this case the presence of USPIOs renders the gels more opaque and less penetrable for the 
OCT light, reducing the overall intensity (Figure 3-5) of OCT images and also the MSD (Figure 
3-4). At 2.5mg/ml, even when loaded into cells, USPIOs seem to cause the gels to be too 
opaque and reduce the overall OCT signal instead of increasing the variances in the pixel 




Figure 3-6: Standard deviation of pixel intensity analysis of OCT images from 3 phantom 
artery models made with 1.5% agarose and mouse macrophages loaded with varying 
concentrations of USPIOs. Top left: the agarose only control of phantom 1 shows significantly 
lower SD compared to the cell control group as well as all other groups. All values normalised 




Figure 3-7: Standard deviation of pixel intensity analysis of OCT images from 4 phantom 
artery models made with 1.5% agarose and RAW cells loaded with varying concentrations of 
USPIOs. Agarose only gels were also included in each of these phantoms and showed 
significantly lower mean SDs compared to all other gels. All values normalised to cells control, 
ns= not significant, * p<0.05, ** p<0.01, *** p<0.001. Error bars = SEM. 
 
Figure 3-8 shows the results of all 7 macrophage phantoms pooled together (»1400 values 
per bar). From this figure, it is apparent that OCT images from USPIO treated macrophages 
(at all 3 concentrations) have significantly higher SD values than the untreated control. There 
is no significant difference between the USPIO 0.05 and 0.25 concentrations. However, the 
2.5mg/ml concentration shows significantly lower mean SD compared to the other two, 





Figure 3-8: Standard deviation of pixel intensity analysis of OCT images of all 7 macrophage 
phantom models pooled. Agarose only gels were also included in each of the phantoms and 
was found to have a significantly lower MSD than all other conditions. Values normalised to 
cells control, ns= not significant, * p<0.05, ** p<0.01, *** p<0.001. Error bars = SEM.  
 
3.3.5 SD hotspot visualisation tool 
The MSD results presented above showed that USPIO can at certain concentrations 
significantly increase the local SD of OCT images when loaded into macrophages compared 
to untreated macrophages. It would however be useful to be able to visualise these increased 
SD regions in order to detect where specifically the macrophages are located. An SD hotspot 
visualisation tool was therefore developed in Matlab as described in section 2.4.3. OCT 
images from each treatment section of macrophage phantom 5 were selected for processing 
through this SD hotspot code to produce the colour map images presented in Figure 3-9 and 
Figure 3-10.  
These hotspots seem to effectively convey the MSD results shown previously, with “cells only 
control” showing more spots than “no cells control” and “USPIO 0.05mg/ml” showing more 
spots still. The “USPIO 0.05mg/ml” and “USPIO 0.25mg/ml” images look relatively similar but 
the latter does show more darker spots indicating higher SD values which is concurrent with 
the findings in Figure 3-7 (5) when comparing the MSDs of the two treatments. Additionally, 
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the “USPIO 2.5mg/ml” image shows fewer spots than the previous dilution which 
corroborates the fact that it’s MSD is significantly lower. These images show an effective way 
of visualising areas of higher SD produced by the presence of macrophages. They also 
demonstrate the advantage USPIO loading can bring to this visualisation. 
 
Figure 3-9: Standard deviation hotspots visualisation tool. Left shows OCT slices through the 
two control sections of phantom 5. Right are the same slices with a colour map overlay of 





Figure 3-10: Standard deviation hotspots visualisation tool. Left shows OCT slices through the 
3 USPIO-laden cells sections of phantom 5. Right are the same slices with a colour map overlay 





To summarize, in this chapter the IV-OCT imaging properties of USPIO particles were 
investigated in vitro and there were four main outcomes. The first is that USPIOs were 
confirmed to be readily taken up by RAW cells in a dose dependent manner. Secondly, a 
robust phantom model and image analysis methodology was developed and lead to the 
successful IV-OCT imaging and quantification of cells and particles in vitro. Using this model, 
it was established that USPIO particles homogenously distributed in the gels by themselves 
do not increase the OCT signal in the way we expected: they dampen it instead. However, it 
was subsequently established that when loaded into cells, USPIOs actually enhance their OCT 
detectability. Each of these four outcomes will be discussed in more detail subsequently. 
Firstly, section 3.3.1 investigated the uptake of USPIO particles by RAW cells to ensure 
appropriate loading of the cells before performing OCT experiments. It was determined, both 
visually (on microscopy imaging) and quantitatively that RAW cells reproducibly internalised 
USPIOs in a dose dependent manner after incubation with them for 24 hours, confirming 
hypothesis 1. Indeed, the Ferrozine iron quantification assays showed an incremental 
increase in intra-cellular iron when USPIO incubation concentration was increased between 
0.03 and 3mg/ml. Particle uptake experiments with this particular USPIO (Ferumoxytol) have 
only been published in two papers which encouragingly found similar results, albeit by 
different means7. In fact, there have been very few in vitro studies involving the use of 
Ferumoxytol, perhaps because it is so similar to its predecessor, Ferumoxtran-10, differing 
only by its carboxymethylated dextran coat compared to plain dextran for Ferumoxtran-10. 
Although Ferumoxtran-10 has been found to be non-toxic to HMMs nor cause them to 
activate, release pro-inflammatory cytokines or affect Fc-mediated phagocytosis96, these are 
important factors worth re-investigating specifically with Ferumoxytol. Similarly, only one 
study has investigated the uptake mechanism of Fermoxtran-10 by HMMs and suggested it 
to be fluid-filled transport96 but this bears repeating with Ferumoxytol. 
Section 3.3.2 presented IV-OCT images of our bespoke phantom model. The creation of this 
model involved designing and 3D-printing a mould and developing and optimising a brand 
new methodology for casting cell-laden agarose gels for IV-OCT imaging (section 2.3). This 
novel phantom model was very successful: it enabled easy and reproducible IV-OCT imaging 
of different experimental cell and particle combinations in one scan. On these IV-OCT images, 
cell presence was easy to visually discern compared to control agarose gel and the presence 
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of USPIO particles within the cells was also detectable by eye. Ariza de Schellenberger et al.93 
found similar results imaging RAW cells loaded with Ferumoxytol with the same OCT system 
but their phantom setup was not optimal; they held two Eppendorf tubes each with a cell 
pellet (with and without USPIO loading) next to the catheter for imaging. The first issue with 
this method, which they themselves mention, is that cell pellets are very dense and so will 
most likely produce much higher OCT contrast than macrophages normally distributed in 
plaque tissue. Our model, although not nearly a perfect recreation of plaque structure, at 
least holds macrophages more sparsely with approximately 40 000 cells in 1mm3. The second 
limitation of the Ariza de Schellenberger phantom setup is that the OCT light has to penetrate 
3 optical boundaries (catheter/air/plastic tube) before hitting the cell pellet93 whereas our 
system only has one optical boundary (catheter) before hitting the gel/cell sample. 
Additionally, they did not do any repeat experiments and had a different, more manual, 
image analysis method based on the backscatter coefficient. Although the image analysis 
methodology and software we created had a manual ROI drawing step, it enabled the rapid 
processing of hundreds of images for a more robust OCT signal analysis. 
Section 3.3.3 presents the image analysis results of phantoms gels containing different 
concentrations of USPIO particles. We found that when USPIOs are alone and 
homogeneously distributed in the phantoms (not loaded into cells) they do not enhance the 
signal and instead actually dampened it. This effect was more severe with increased USPIO 
concentrations and this was reproducible over two phantom repeats. This means that 
hypothesis 2 of this chapter “USPIOs held homogenously in an agarose gel will yield higher 
OCT contrast compared to an agarose only gel” is rejected. We theorize that this OCT signal 
dampening effect of USPIOs is due to the fact that when light travels through a homogenous 
medium the penetration depth decreases exponentially with the scattering and absorption 
properties. Meaning that when they are distributed homogenously in a gel USPIOs actually 
serve to make it more opaque – less light can travel through so the OCT image is less bright 
and less detailed. This theory makes sense given that the more USPIOs are present in 
solution, the more opaque the gel is to the naked eye and the lower the OCT image intensity 
is. Encouragingly, Ariza de Schellenberger et al. also encountered a similar effect when 
imaging USPIOs alone in suspension and made similar assumptions as us about the light 
scattering properties of USPIOs in homogeneous suspension93. 
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Section 3.3.4 presented the image analysis results of phantom gels containing RAW cells and 
showed that they yield significantly higher OCT contrast compared to agarose only, 
confirming hypothesis 3 of this chapter. This is the first time that the SD metric, first 
suggested to reflect macrophage presence by Tearney et al. in 200389, has been tested on 
macrophages in a controlled in vitro setting. Although the SD is understandably not zero on 
plain agarose images, it is significantly higher when cells are present in the gel, confirming 
their detectability on IV-OCT. Additionally, when USPIOs are loaded into these cells, the SD 
of OCT images is significantly increased compared to untreated cells, confirming hypothesis 
4 of this chapter. Again, similar results were found by Ariza de Schellenberger et al.93 using a 
different image analysis method. Like us they theorise that this effect is due to the increased 
size of USPIOs when they are aggregated into the phagolysosomes of cells which makes them 
better at scattering light and therefore increasing the SD on OCT images. We found that this 
increase in OCT contrast of macrophages loaded with USPIOs was mostly reproducible for 
two of the USPIO concentrations tested (0.05 and 0.25 mg/ml). However, the third and 
highest incubation concentration (2.5mg/ml) tested produced much more variable results 
across the individual phantoms made, with a couple showing that this concentration 
significantly decreased the OCT signal compared to untreated cells. This shows that USPIOs 
at too high a concentration in cells can revert back to an OCT signal dampening effect, 
perhaps due to rendering the whole gel more opaque as they do when imaged alone in 
suspension. We were therefore able to establish 0.05mg/ml as an appropriate concentration 
for USPIO use in OCT imaging that we used as the basis for designing our subsequent mouse 
and human studies.  
Finally, section 3.3.5 presented a bespoke OCT SD hotspot visualisation tool which accurately 
represented the quantitative results obtained previously. This is the first time that a tool such 
as this has been shown to pick out and visually represent macrophages on OCT images in a 
controlled in vitro setting (where only macrophages are present). Indeed, we observed many 
more hotspots on OCT images from gels containing cells compared to agarose alone and 
many more still when the cells were pre-loaded with USPIOs, confirming hypothesis 5 of this 
chapter. 
There are however a few limitations to the work of this chapter. Firstly, due to the presence 
of artefacts on the OCT images it was necessary to manually draw ROIs on all images. It would 
of course be better to develop an automated whole image analysis method but this is difficult 
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to do without forfeiting a lot of image information and altering results (due to background 
removal and filtering steps for example). Looking forward to in vivo plaque OCT imaging, 
whole image analysis is not currently possible due to the complexity and variability of plaque 
structure and appearance. So our method of ROI drawing stays closely translatable to what 
is possible in clinical image analysis. Another limitation of this study is the lack of co-
registration of macrophages in the gel (on histology) to the SD hotspots uncovered in the 
image analysis. This would have been a nice addition to further confirm the association of 
high SD with individual macrophage accumulations but was beyond the scope of this 
translational study. Finally, although the SD hotspot tool mostly produced very convincing 
images, there was some variability to these results when processing different images from 
the same gel. Although these are not presented here (due to length constraints), it bears 
mentioning that this method was the first iteration with improvement possible with further 
research. 
In conclusion, this novel in vitro study has served as a robust proof of concept for the use of 
USPIOs (Ferumoxytol) to enhance the IV-OCT detectability of macrophages. USPIOs were 
shown to be readily taken up by macrophages. A bespoke phantom model and image analysis 
method were developed and used to show that USPIOs enhance the detectability of 
macrophages with IV-OCT. And this OCT signal enhancement was effectively visualised using 
a novel standard deviation of pixel intensity hotspot tool. Chapter 4 will follow on from this 
with the next step in the translational USPIO-OCT study: investigating USPIO uptake by 






































In Chapter 3 it was established that in an in-vitro phantom setting USPIOs are readily taken 
up by mouse macrophages (RAW cells) and that this enhances macrophage detectability with 
IV-OCT. This chapter aims to validate these in-vitro results in an animal model of 
atherosclerosis and is therefore the second stage of our 3-part translational study 
investigating the USPIO-enhanced detection of plaque macrophages on IV-OCT. 
As established in section 1.1.3 the ApoE knockout (ApoE-/-) mouse is a widely used animal 
model which spontaneously develops atherosclerotic plaques sharing many of the features 
of human coronary plaque progression including plaque rupture27,131–135. The atherosclerotic 
process can be accelerated to produce larger plaque when ApoE-/- mice are fed a high fat 
diet27,131–135. As described previously (sections 1.1.5 and 3.1) there are many incentives for 
refining the detection of macrophages on IV-OCT, yet to date only two studies have 
attempted OCT imaging of atherosclerosis in mice80,83. The first aimed to identify the key 
components of vulnerable plaques in ApoE-/- mouse, investigating their brachiocephalic 
arteries both in vivo and ex-vivo80. Although this study found excellent correlation between 
the OCT and histology measurements for lipid core size and fibrous cap thickness they used 
a bench top OCT system with an operating light source of 830nm wavelength80. This is 
therefore not closely comparable to the IV-OCT currently used in the clinic which operates at 
1300nm. Additionally, with this OCT system, plaques could only be imaged from outside the 
vessel and they did not investigate the presence of macrophages in the plaques and whether 
these created a detectable change in the OCT images. 
The second study on OCT imaging of ApoE-/- mouse plaques used a clinical IV-OCT system and 
attempted to detect and quantify the presence of macrophages within the imaged aortic 
plaques8. Excitingly, the IV-OCT system they used had a small enough imaging catheter 
(0.48mm) for in-situ intra-aortic imaging, albeit after euthanizing the mice8. In this study, 
Tahara et al. were able to successfully correlate macrophage presence on histological and 
OCT images with their bespoke semi-automated macrophage quantification tool8. However 
this software required a training procedure in which someone manually marked out 
“macrophages” on OCT images based on their location in the corresponding histology slide8 
– a process which is obviously not feasible to implement in humans. Additionally, this study 
used an older generation Time-Domain OCT (TD-OCT) system which produces lower quality 
images and is no longer clinically relevant compared to its replacement, the Frequency 
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Domain (FD-OCT) system136–138 which has a catheter that is almost double the diameter 
(0.9mm). 
Other studies have used MRI to demonstrate USPIO enhanced detectability of plaque 
macrophages in ApoE-/- mice102–104. Indeed these studies showed accumulation of USPIO 
particles within the macrophages of mouse atherosclerotic plaques on histology slides which 
were easily detectable with MRI102–104. However, until now, no one has attempted to image 
the plaques of USPIO treated ApoE-/- mice with IV-OCT. This was the intention of this chapter, 
with the help of the image analysis tools developed and optimised in the previous chapter. 
We raised ApoE-/- mice, treated them with or without USPIOs (at the concentration optimised 
in the previous chapter) and imaged their aortic plaques with IV-OCT. Initially, one of our 
main aims was to perform a histological analysis of the aorta tissues after OCT imaging to 
confirm the presence of USPIO-laden macrophages in the plaques and co-localise areas of 
high macrophage burden on histology with areas of high OCT signal. However, this histology 
study, performed by external collaborators at the University of British Columbia was severely 
delayed by the advent of the COVID-19 pandemic and could not be finalised in time for 
inclusion in this thesis. The remaining four aims and four associated hypotheses of this 
chapter are outlined below: 
AIM 1 (section 4.3.1): To successfully induce the formation of atherosclerotic plaques in the 
aortas of ApoE -/- mice and to successfully identify their morphology on OCT images. 
Hypothesis 1: Aortic plaques of ApoE-/- mice will be visible and identifiable in the excised 
and dissected tissue and their morphology on OCT will closely resemble that of lipid-rich 
human atherosclerotic plaques: with a bright outer cap and a dark blurry lipid core. 
AIM 2 (section 4.3.2): To determine whether ApoE-/- mouse plaque caps produce a higher OCT 
signal compared to healthy aortic wall tissue within the same vessel. 
Hypothesis 2: The caps of the aortic plaques will yield higher OCT signal (using the standard 
deviation of pixel intensity metric) than healthy aortic wall tissue regardless of treatment. 
 AIM 3 (section 4.3.2): To determine whether USPIO treatment of ApoE-/- mice enhances the 
OCT signal in the plaque caps compared to saline placebo treatment. 
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Hypothesis 3: The caps of the aortic plaques of USPIO treated mice will yield higher OCT 
signal (using the standard deviation of pixel intensity metric) than those of saline treated 
mice. 
AIM 4 (section 4.3.3): To test whether the SD hotspot overlay tool accurately visually 
represents the SD analysis results in the mouse aorta images. 
Hypothesis 4: There will be more, high intensity hotspots on the caps of the plaques 
compared to healthy aortic wall tissue and this difference will be more marked in USPIO 
treated mice compared to saline control. 
 
If successful, this ex vivo murine investigation and image analysis methodology will develop 
our in-vitro work and pave the way for the use of USPIOs as a new OCT contrast agent to 

















The ApoE-/- mouse was selected as the best model for the needs of this project due to the 
similarity of its atherosclerotic plaque structure to those of humans131–135. The mouse 
facilities and expertise in ApoE-/-  mouse models in our research centre were also contributing 
factors to this decision. All experiments were performed according to the Animals (Scientific 
Procedures) Act 1986 (UK Home Office). Adult male ApoE-/- mice (N = 10) were purchased 
from Charles River (Margate, UK) aged 8-9 weeks (20-25g) and received a high fat ‘Western 
Diet’ (21% fat; Research Diets, New Brunswick, USA) to induce lipid-rich plaque formation in 
the aortic arch. Three mice were sacrificed due to injuries from in-fighting in the first few 
weeks and an additional mouse had to be culled due to disease after 24 weeks. On week 25, 
1.9µl of USPIO (Ferumoxytol by Rienso®) or saline placebo per ml of blood was administered 
by tail-vain injection (by Dr Rodger Duffin) 12 hours prior to cull by CO2 overdose. This USPIO 
dose (1.9μl per ml) equates to the 0.05mg/ml of Fe demonstrated to give optimal OCT 
contrast in the in vitro Chapter 3. Three mice received a USPIO injection and three a saline 
placebo in order to compare the OCT signal in the plaques with and without USPIO.  
Pre-study optimisation involved testing whether mouse aortas can be imaged intact using 
the DragonflyTM OPTISTM OCT catheter.  As can be seen on Figure 4-1 (C) an intact mouse 
aorta has approximately the same outer diameter as the catheter (1mm). This made 
introduction of the catheter into the vessel very technical and resulted in a compressed view 
of the arterial wall on the OCT images (shown in Figure 4-1(A)). It was therefore determined 
that mouse aortas are too narrow to be imaged by intra-coronary OCT systems without 
damaging the plaque or impairing the OCT image detail. To overcome this issue, the aortas 
were harvested and carefully cut open from the descending aorta up to the aortic root along 
the outside of the aortic arch (so as not to disrupt the plaque on the inner curve of the arch) 
as is demonstrated in Figure 4-1 (D). For OCT imaging, the aortas were then pinned onto 
Sylguard® (The Dow Chemical Company) coated petri dishes, plaque side up, immersed in 
saline and the catheter was laid and held in place on top as is demonstrated in Figure 4-1 (E). 
This dissection and imaging method results in clearer OCT images of mouse aortas as 
exemplified in Figure 4-1 (B) and in the figures of section 4.3.1. Following OCT imaging, the 
murine aortic tissues were fixed in 4% PFA for 18h and embedded in paraffin wax for tissue 
sectioning and histological validation of the USPIO signal. The histological study performed 
by external collaborators (Dr Stephanie Sellers’ group at the University of British Columbia) 




Figure 4-1: Imaging and dissection protocol. (A) OCT image through an intact WT mouse 
aorta. (B) OCT image of the same aorta after cutting and pinning it open. (C) Photo showing 
the size of an intact WT mouse heart and aorta, the OCT catheter and another WT mouse 
aorta after being cut and pinned open. (D) Images showing how the aorta incisions are made 
to avoid disturbing the aortic plaque. (E) Photo of the mouse vessel OCT imaging setup. 
Similarly to the in-vitro work in the previous chapter, the aortas were imaged using the St 
Jude system and image analysis was performed using the custom methods and software 
described in section 2.4. The standard deviation of the mean pixel intensity within specific 
regions of the OCT images was used in this analysis to determine differences in OCT contrast 
enhancement between the two treatments: USPIO and saline. And the bespoke OCT SD 





4.3.1 Mouse vessels OCT imaging  
The six ApoE-/- mouse aortas are pictured down the dissecting microscope on the numbered 
panels of Figure 4-2  (saline treated mice) and Figure 4-3 (USPIO treated mice) after being cut 
open along the outside of the aortic arch and pinned onto a Sylgard® gel. On these photos 
the normal aortic wall tissue appears slightly transparent and is easily distinguishable from 
the opaque white mass that is plaque tissue. Each of the six aortas have a large plaque in the 
centre of the tissue, starting from the top (the aortic root) and ending three quarters of the 
way down the tissue. In the intact aorta this location corresponds to the curve of the 
ascending aorta in which atherosclerotic plaques commonly form in western diet fed ApoE-/- 
mice131. Aside from aorta 4 (which unfortunately is not clearly visible due to the white 
background) each vessel also has small plaque portions on the left and right edges of the 
tissue, which correspond to the openings of the brachiocephalic, left carotid and left 
subclavian arteries. These artery branching points are also common areas for plaque 
formation in ApoE-/- mice131. 
As outlined in the methods, each mouse vessel was imaged by OCT pullback scan to produce 
a stack of approximately 40 cross sectional images along the whole length of the pinned aorta 
tissue. One representational OCT image of the aortic plaque as well a non-plaque section of 
aorta from each mouse are shown in the lettered panels of Figure 4-2  (saline treated mice) 
and Figure 4-3 (USPIO treated mice). The plaques on images A, C and E of both figures are 
easily distinguishable as protrusion with a bright outer edge and a blurry darkened interior. 
This is similar to human plaques on OCT, the bright outer edge corresponds to the cap of the 
plaque, below which there is a blurry region and the OCT signal drops off. This dark signal 
drop off area corresponds to the lipid pool of the plaque, below which nothing more can be 
observed. Conversely, the non-plaque control sections (B, D and F) show a much more 
homogenous, mostly flat tissue with no signal drop off. Below the aortic wall tissue in these 
images, imperfections in the Sylgard® gel (SL) can be seen as diagonal lines. These SL 
imperfections can be seen in some of the “plaque section” images (Figure 4-2 C and E) below 
the normal aorta tissue (left of the plaque on both C and E) but never below the plaque tissue 




Figure 4-2: Aorta images of three ApoE-/- mice treated with saline placebo. Panels 1-3 are 
photos through the dissecting microscope of each aorta (from mice 1-3), cut open and pinned 
out onto a Sylgard® gel. The lettered panels show representative OCT slices through the 
corresponding aortas. A, C and E are OCT images of the plaque containing sections of aortas 
1, 2 and 3 respectively. B, D and F are representative OCT images of the normal “control” 
tissue of aortas 1, 2 and 3 respectively. AL: air-liquid interface artefact. SL: Sylgard® gel 
artefacts. 
 
When qualitatively comparing the OCT images of control mice aortas (Figure 4-2) and USPIO 
treated mice aortas (Figure 4-3) not many conclusions can be drawn.  Visually, the control 
sections of aortas from mice 1-6 are near identical, with none standing out as brighter or 
more punctuate than the rest. When it comes to the plaque section images, there is more 
variation, for instance, the images from mice 1, 4, 5 and 6 show a much more extensive 
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plaque (width-wise) than the images from mice 2 and 3. Additionally, the images from mice 
2, 5 and 6 show a few spots in the cap of the plaque that are significantly brighter than the 
rest of the tissue whereas the caps of mice 1, 3 and 4 appear to have much less variation in 
pixel intensity. However, these differences are most likely due simply to natural variation in 
plaque structure and size between mice. In order to discern any real differences in OCT signal 
between the two different treatments, a quantitative investigation was performed and the 
results are presented in the following section. 
 
Figure 4-3: Aorta images of three ApoE-/- mice treated with USPIO. Panels 4-6 are photos 
through the dissecting microscope of each aorta (from mice 4-6), cut open and pinned out 
onto a Sylgard® gel. The lettered panels show representative OCT slices through the 
corresponding aortas. A, C and E are OCT images of the plaque containing sections of aortas 
4, 5 and 6 respectively. B, D and F are representative OCT images of the normal “control” 
tissue of aortas 4, 5 and 6 respectively. 
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4.3.2 Mouse vessels OCT image analysis 
For each mouse aorta, regions of interest (ROIs) were drawn on every OCT image of the 
pullback scan (88 images per aorta), amounting to approximately 175 ROIs per mouse. The 
final number of ROIs drawn depends on the length of each plaque, the size and position of 
the tissue and the number of artefacts present on the areas of interest. One set of these ROIs 
were drawn in the cap of the plaques and another in the healthy aortic wall of the non-plaque 
control section described previously. See section 2.4.1 for detail on ROI drawing 
methodology. The pixel information within these ROIs was then processed using a custom 
Matlab code (see section 2.4.2). As with the phantom OCT data, the metric of interest is the 
standard deviation (SD) of the mean pixel intensity within the ROIs. For each of the 6 mouse 
aortas, the SDs of the ROIs drawn in the plaque caps were averaged, and are presented as 
non-patterned plain white and plain orange bars in Figure 4-4. The SDs of ROIs drawn in the 
healthy “control” aortic wall tissue were also averaged and are presented as the striped white 
and striped orange bars in Figure 4-4. The colours of the bar charts represent the treatment, 
with white charts 1, 2 and 3 showing results from each of the 3 saline treated mice. And 
orange charts 4, 5 and 6 showing results from each of the 3 USPIO treated mice. The datasets 
for each mouse are normalised to the control so each control value is 1 and the plaque SD 
values range from 1.107 to 1.182. The standard error of the mean (error bars) are small due 
to the high N numbers (ranging from 26 to 136 for individual bars) which correspond to the 
number of ROIs drawn over many images. For each individual mouse, the plaque mean SD is 
significantly higher than the control mean SD (p<0.001). This confirms the hypothesis that 
ApoE-/- mouse plaque cap components (most likely macrophages) significantly change the 
OCT signal compared to normal artery wall tissue.  
When looking at the plaque mean SD values of saline versus USPIO treated mice in Figure 
4-4, not many conclusions can be drawn. Saline treated mouse 2 has the highest plaque mean 
SD value at 1.182 ± 0.01404 (N=75), followed by USPIO treated mice 6 and 4 with 1.172 ± 
0.01703 (N=87) and 1.168 ± 0.01216 (N=136) respectively. Then comes saline treated mouse 
1 with 1.135 ± 0.01220 (N=127) and lastly USPIO treated mouse 5 at 1.107 ± 0.01193 (N=116). 
From these results, neither of the treatments stand out as superior for OCT plaque contrast 
enhancement. In order to properly compare the two treatments, the data from mice 1,2 and 
3 (saline treated) need to be pooled together and analysed against that of mice 4, 5 and 6 




Figure 4-4: Standard deviation of pixel intensity analysis of OCT images from 6 excised aortas 
of ApoE -/- mice. Mice 1-3 were injected with a saline placebo and mice 4-6 were injected with 
USPIO. Mean SD values from the plaque section and non-plaque control section are shown 
for each mouse. All values normalised to control, ns= not significant, * p<0.05, ** p<0.01, *** 
p<0.001. For each bar N>26. Error bars = SEM.  
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When the data is pooled together in this way and normalised to the saline control (Figure 
4-5), there is no significant difference between the control sections in the two treatment 
groups but there is a significant difference between the plaque sections in the two treatment 
groups. As expected from the previous results, both treatment groups showed that plaque 
tissue had a significantly higher mean SD than control healthy tissue with p<0.001. Although 
the mean SD of the control tissue from the USPIO treated mice (1.016 ± 0.005296 N=299) is 
higher than the control tissue from the saline treated mice (1 ± 0.009583 N=115), this 
difference is not significant, with p=0.1225. However, the mean SD of the plaque cap tissue 
from USPIO treated mice (1.166 ± 0.007977 N=339) is significantly higher than that of saline 
treated mice (1.144 ± 0.007110 N=301) with p<0.05. This means overall, USPIO treatment 
increases the OCT signal in ApoE-/- mouse aortic plaques but does not affect the OCT signal 
in their healthy aortic tissue. This last point is of particular importance because it shows that 
USPIO treatment does not raise the OCT signal non-specifically. Instead, it enhances the high 
signal associated with plaque inflammation without affecting that of aortic wall tissue with 
little inflammation.  
 
Figure 4-5: Standard deviation of pixel intensity analysis of OCT images from 3 USPIO treated 
ApoE -/- mice pooled and 3 saline treated control ApoE -/- mice pooled. Mean SD values from 
the plaque section and non-plaque control section are shown for USPIO and saline mouse 
groups. All values normalised to “saline non-plaque”, ns= not significant, * p<0.05, ** p<0.01, 




4.3.3 SD hotspot visualisation  
The SD results presented above showed that USPIO treatment of ApoE-/- mice can 
significantly increase the local SD of plaque OCT images  compared to placebo treated ApoE-
/- mice. It would however be useful to be able to visualise these increased SD regions in order 
to detect their specific locations within the plaque tissue and whether these co-localise with 
macrophage accumulations in the histological analysis. An SD hotspot visualisation tool was 
therefore developed in Matlab as described in section 2.4 and a selection of mouse aorta 
OCT images were processed. Figure 4-6 shows two OCT images from a plaque section (A and 
B) and one image from a control non-plaque section (C) of saline treated mouse 1’s aorta 
with (right) and without (left) the SD hotspot overlay. Similarly, Figure 4-7 shows two OCT 
images from a plaque section (A and B) and one image from a control non-plaque section (C) 
of USPIO treated mouse 4’s aorta with (right) and without (left) the SD hotspot overlay.  
The raw OCT images (left of Figure 4-6 and Figure 4-7) are difficult to distinguish from each 
other, however after application of the SD hotspot tool (right panels) it is clear that the 
plaques from the USPIO treated mouse (Figure 4-7 A and B) have more hotspots than the 
saline plaques (Figure 4-6 A and B). These visual differences between USPIO and saline 
plaques are concurrent with the quantitative results obtained in the previous section. In 
particular Figure 4-6 (B) (saline plaque image) shows a few barely visible, small hotspots 
whereas all the other images have much larger hotspots. On Figure 4-7, in the USPIO mouse, 
it is clear that the control section (C) has fewer hotspots than the plaque sections (A) and (B), 
which again is concurrent with the quantitative results. However, in the saline mouse (Figure 
4-6), the control section (C) actually appears to have more hotspots, although lower in value 
(yellow rather than red), than plaque sections (A) and (B). The results of this hotspot map 
image processing are mixed. Some individual OCT cross-sections reflect the overall 
quantitative results observed in the previous section while others do not. In these mouse 
aorta images, the hotspot processing is very variable between sections of the same plaque 
and there is often not a clear distinction in hotspot cover between plaque and non-plaque 
areas. This signifies more work is needed to optimise this visual tool specifically for the mouse 







Figure 4-6: Standard deviation hotspots visualisation tool on saline treated mouse images. 
Left shows raw OCT slices through the aortic tissue with plaque (A, B) and without (C). Right 
are the same slices with a colour map overlay of areas of high standard deviation in pixel 








Figure 4-7: Standard deviation hotspots visualisation tool on USPIO treated mouse images. 
Left shows raw OCT slices through the aortic tissue with plaque (A, B) and without (C). Right 
are the same slices with a colour map overlay of areas of high standard deviation in pixel 






To summarize, in this chapter the IV-OCT imaging properties of USPIO particles were 
investigated in ApoE-/- mouse aortic plaques and there were four main outcomes. The first is 
that we successfully imaged ApoE-/- mouse aortic plaques with the St Jude IV-OCT system and 
their morphologies were clearly distinguishable on the OCT images. Secondly, using the novel 
image analysis method developed in section 2.4 and first presented in Chapter 3, we 
determined that the caps of murine plaques significantly enhanced the OCT signal compared 
to healthy aortic wall regardless of treatment. Using the same image analysis methods it was 
found that treatment with USPIO significantly increases the OCT contrast in plaque caps but 
does not affect that of healthy tissue. And finally, the SD hotspot tool presented in the last 
Chapter was implemented in the mouse images and found to support most of the 
quantitative results obtained. Each of these four outcomes will be discussed in more detail 
subsequently. 
Firstly, section 4.3.1 presented, for the first time, IV-OCT images of ApoE-/- mouse aortic 
plaques taken with the current, routinely used Ilumien OptisTM (St. Jude) OCT system. In order 
to achieve this, we developed a protocol whereby the aortas were cut open and the catheter 
was placed on top of the open aorta (on the inside). This had to be done because the clinical 
catheter (made for human coronary arteries) is approximately the same diameter (0.9mm) if 
not larger than mouse aortas. The six mice we raised on a high fat diet all successfully 
developed large aortic plaques whose lipid pool and fibrous cap were clearly visible on the 
OCT images, confirming hypothesis 1 of this chapter. Indeed, in the OCT imaging of each of 
the 6 mice, the plaques appeared as protrusions from the aortic wall which had a bright outer 
edge (the fibrous cap) below which the OCT signal dropped off, indicating the presence of a 
lipid rich pool. Encouragingly, the aortic plaque OCT images obtained by Tahara et al. in their 
study showed very similar morphology and theirs correlated well with the plaque structure 
observed on histology slides8. 
Section 4.3.2 presented the image analysis results of the murine vessels and showed that 
plaque caps produced significantly higher OCT signal compared to the healthy aortic wall 
control tissue regardless of treatment, confirming hypothesis 2 of this chapter. This is the 
first time that the SD metric, first suggested to reflect macrophage presence by Tearney et 
al. in 200389, has been tested on murine atherosclerotic plaque images. Although the SD is 
understandably not zero in the healthy aortic wall tissue, it was significantly lower than the 
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plaque tissue SD in every individual mouse (Figure 4-4). Ideally we would have been able to 
correlate the increased MSD in plaque caps with macrophage presence on histology slides 
but unfortunately this was not ready in time. It would also have been interesting to see 
whether this OCT SD metric was able to accurately grade the density of macrophages 
present. 
The third main outcome of this chapter is that USPIO treatment significantly increased the 
OCT signal of murine plaque caps compared to saline control treatment, confirming 
hypothesis 3. As is presented in Figure 4-5, when the data from all mice are pooled together 
in order to compare the treatment groups with each other, it was found that the overall MSD 
of the plaque caps of USPIO treated mice were significantly higher than that of saline treated 
mice. Importantly, USPIO treatment did not significantly enhance the OCT signal of the 
control healthy aortic wall tissue, confirming that the particles do not end up non-specifically 
in the vessel walls. However, an important point to note is that not every USPIO treated 
mouse had higher plaque cap SD values than every saline mouse – it is only when the data 
from the different mice are pooled together that we can observe a difference between the 
treatments. This is likely simply due to the natural variation in plaque macrophage burden 
between mice; it could be the case that the saline treated mouse with the highest SD value 
(mouse 2) happened to have developed more severe disease with a much higher macrophage 
burden in its plaques. It could also be the case that the USPIO treated mouse with the lowest 
SD value (mouse 5) had less severe disease and lower plaque macrophage burden. Again, 
variability in plaque macrophage burden between mice is something that could have been 
confirmed with the histology analysis which was intended to be included here. 
Finally, section 4.3.3 presented a bespoke OCT SD hotspot visualisation tool which appears 
to accurately represent most of the quantitative results obtained previously. This is the first 
time that a tool such as this has been shown to pick out and visually represent macrophages 
on OCT images in mouse atherosclerosis. Indeed, we observed many more hotspots on the 
plaques of USPIO treated mice compared to the healthy aortic wall, partly confirming 
hypothesis 4. However, in saline treated mice the difference in number of hotspots between 
plaque and control tissue was not as clear cut, which was not expected based on the 
quantitative results presented previously (all mice had higher SDs in the plaques compared 




There are a few limitations to the work of this chapter. Firstly, the study population was quite 
small due to the loss of 4 mice and therefore it could be worthwhile re-investigating with a 
higher power study. Secondly, we unfortunately could not include the histological analysis of 
the mouse aortas in this chapter due to COVID-related delays. This means we could not 
directly confirm that USPIO particles have made it into plaque macrophages. This has 
however been demonstrated in detail in multiple previous studies using USPIOs at 
comparable concentrations as an MRI contrast agent in ApoE-/- mice102–104. Because of the 
lack of histology data we also cannot confirm that the raised SD values in plaque caps 
compared to healthy aortic wall is specifically due to macrophage presence. However, the 
fact that USPIO treatment does not raise the MSD in healthy control tissue (Figure 4-5) is a 
good indicator that USPIOs are actually transported by macrophages to the inflammation site 
(plaque caps) and cause a significant raise in SD. The final limitation is with regards to the SD 
hotspot map tool: although promising in vitro, it seems a little less accurate in this mouse 
system. Indeed, non-plaque areas look like they have a lot of hotspots, almost as many as 
some of the plaque areas and this was also the case for other images analysed and not shown 
here. This effect could be due to the micro-structure in the mouse healthy arterial wall 
causing a lot of variation and therefore more optimisation could be done to improve the 
technique in mice specifically. 
In conclusion, following on from the previous chapter, this novel mouse imaging study has 
served as a second robust proof of concept for the use of USPIOs to enhance the IV-OCT 
detectability of macrophages in vivo. In this chapter, protocols were established for the 
successful ex-vivo imaging of ApoE-/- mouse plaques with a clinical IV-OCT system. The OCT 
scans revealed clear lipid-rich plaques with fibrous caps resembling those of humans in each 
of the six mice. The bespoke image analysis software and methods presented in the previous 
chapter were used here to find that USPIO treatment (informed by optimal concentration 
determined in Chapter 3) significantly enhances plaque OCT signal compared to saline 
treatment but does not affect the signal of control tissue. And this OCT signal enhancement 
was effectively visualised using a novel standard deviation of pixel intensity hotspot tool. 
Chapter 5 will follow on from this with the final step in the translational USPIO-OCT study: 















5 CHAPTER FIVE: IN VIVO HUMAN USPIO-















In the previous two chapters, it was established that USPIOs enhance the detection of 
macrophages with IV-OCT in vitro and in a mouse model. Building on this, as the last stage of 
these translational studies, in this chapter we investigate whether USPIOs can enhance IV-
OCT detection of macrophages in vivo in human atheroma. 
As presented in section 1.3.2, Tearney et al. first demonstrated a linear correlation between 
macrophage accumulations in the caps of lipid rich atherosclerotic plaques (on histology) and 
the local normalised standard deviation (NSD) on OCT images89. By taking the standard 
deviation of pixel intensity within a specific region of an OCT image, the variability of the OCT 
signal in that ROI can be quantified with the presence of macrophages in theory increasing 
this value. This pioneering study involved ex-vivo, enface imaging of arterial segments (aortas 
and carotid bulbs) from randomly selected cadavers with a bench-top OCT system89. 
Therefore no association between cap macrophage burden and clinical status could be made, 
although this was later addressed in a study by MacNeill et al.92. This study related NSD values 
in the caps of coronary plaques to disease severity in patients presenting with coronary artery 
syndrome imaged with IV-OCT92. It was found that patients with acute coronary syndromes 
(MI and unstable angina) had significantly higher NSD than those with stable angina92. 
Additionally, culprit plaques had higher NSD compared to non-culprit ones within the same 
patient but this difference was not significant92. One limitation of this study was that the 
authors only analysed 3 OCT images per plaque. A few years later, another study by Raffel et 
al. successfully determined that thin-capped fibroatheromas (TCFA) had significantly higher 
NSD than non TCFA in patients suffering from ACS139. 
One key limitation of all three of the mentioned studies is that the NSD parameter by its 
nature, cannot be specific to macrophages only. Indeed different components such as 
cholesterol crystals and some calcifications have been found to cause high NSD values57. 
Whilst ROIs can be restricted to the caps of plaques (as these studies have done) to reduce 
the risk of false positives, this ignores macrophages and inflammation deeper within the 
plaque and brings considerable challenges in the accurate and reproducible delineation of 
drawing ROIs over such small structures. One interesting recent study tried to overcome 
these issues by developing a new IV-OCT macrophage detection method which automatically 
identified plaque areas with high NSD which had areas of signal attenuation (with low NSD 
values) directly below them140. This technique was based on a previous report that 
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macrophages produce signal-rich regions with punctuate bright spots and cause signal 
attenuation below, presenting as a shadow in the underlying tissue141. Although this study 
reports their new technique to identify macrophages with 88% sensitivity and specificity 
when correlated with histology sections, this was done using only one OCT image for each 
human coronary artery plaque collected post-mortem140. This was therefore quite a small 
preliminary analysis which did not attempt to make any connections between in vivo 
macrophage burden and clinical status. 
Although a few studies have tried variations on the NSD analysis method in an attempt to 
more sensitively detect macrophages, as of yet no one has attempted to enhance the OCT 
detectability of macrophages in vivo using a tagging agent. In this thesis we propose that 
nanoparticles loaded into macrophages can increase the local SD on IV-OCT images and thus 
enhance their detectability in fibrous caps of vulnerable plaques. This would hopefully 
address the issue of non-specificity of the SD metric as well as increasing sensitivity. As 
demonstrated previously, USPIOs look to be the perfect nanoparticle to fill this need because 
their accumulation in plaque macrophages has been extensively demonstrated105–107. Our 
preliminary investigations of the IV-OCT contrast potential of USPIOs in vitro (Chapter 3) and 
in ApoE-/- mice (Chapter 4) have yielded very positive results. We have brought the optimised 
image analysis methods and USPIO concentrations forward into this chapter investigating the 
USPIO enhanced detection of macrophages in vivo in patients presenting with ACS.  The three 
aims and three associated hypotheses of this chapter are outlined below: 
AIM 1 (section 5.3.1): To determine whether the caps of ruptured plaques produce a higher 
OCT signal compared to those of stable atherosclerotic lesions from the same patients. 
Hypothesis 1: The caps of the culprit plaques will yield higher OCT signal (using the standard 
deviation of pixel intensity metric) than those of non culprit plaques regardless of 
treatment. 
 AIM 2 (section 5.3.1): To determine whether USPIO treatment of ACS patients enhances the 
OCT signal in the culprit plaque caps compared to saline placebo treatment. 
Hypothesis 2: The caps of the culprit plaques of USPIO treated patients will yield higher 




AIM 3 (section 5.3.2): To test whether the SD hotspot overlay tool accurately visually 
represents the SD analysis results in the patient plaque images. 
Hypothesis 3: There will be more, high intensity hotspots in the caps of the culprit plaques 
compared to those of non-culprit plaques and this difference will be more marked in USPIO 
treated patients compared to saline control. 
If successful, this technique would permit a detailed examination of the role of macrophages 
in the pathophysiology of atherosclerosis in vivo in man and may lead to early identification 
of vulnerable patients with a high vulnerable coronary plaque burden at high risk of suffering 



















This clinical trial was conducted by Dr Nick Cruden with the aim to enhance plaque 
macrophage detection with OCT. This trial was approved by the South East Scotland Research 
Ethics Committee 01 on 22/07/2014. Twenty patients presenting to the Royal Infirmary of 
Edinburgh with acute Type 1 myocardial infarction and scheduled to undergo diagnostic 
coronary angiography were recruited prospectively. Myocardial infarction was defined as a 
rise in cardiac troponin associated with new ischaemic electrocardiographic changes and / or 
a history of cardiac chest pain according to the third Universal definition6. Patients were 
randomised to receive 4 mg/kg UPSIO (Ferumoxytol by Rienso®) or saline injection 12-24h 
prior to invasive coronary angiography. This USPIO dose equates to 0.05mg/ml which was 
the concentration demonstrated to give optimal OCT contrast in the in vitro Chapter 3 and 
in the mouse Chapter 4. Culprit and non-culprit plaque were identified by the interventional 
cardiologist (Dr Nick Cruden, Dr Simon Wilson or Dr Andrew Mitchell) based on the clinical 
presentation, electrocardiographic changes, echocardiography and angiographic findings.  
OCT imaging was performed using the commercially available Lunawave OFDI system 
(Terumo, Tokyo, Japan). Briefly, a 2.6F imaging Fastview OFDI catheter (Terumo, Tokyo, 
Japan) was advanced into the coronary artery over a standard 0.014” coronary guide wire 
and an automated pullback performed at 20 mm/s across the lesions of interest: both culprit 
and non-culprit coronary plaques. A simultaneous intracoronary injection of undiluted X ray 
contrast (omnipaque 300) at 4 ml/s was used to achieve a blood-free field of view. In patients 
presenting with a recent myocardial infarction both the culprit lesion and a remote epicardial 
vessel (control) was assessed using OCT. Following OCT imaging, percutaneous coronary 
intervention was performed according to routine clinical practice. Due to randomisation 
issues and one exclusion based on image quality, the final study population consists of 8 
USPIO treated patients and 11 saline treated patients. Additionally, one of the USPIO treated 
patients did not undergo imaging of a remote non-culprit plaque, however the data from 
their culprit plaque imaging was still included in the pooled analysis. Image analysis was 
performed blinded to the treatment information using the custom methods and software 
described in section 2.4. The standard deviation of the mean pixel intensity within specific 
regions of the OCT images was used in this analysis to determine differences in OCT contrast 
enhancement between different plaques (culprit and non-culprit) and between different 
patient treatment groups (USPIO and saline). In addition, the bespoke OCT SD hotspot tool 
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(developed in section 2.4.3) was tested on sample images to render a visual representation 
of these OCT contrast differences. 
For each patient plaque, regions of interest (ROIs) were drawn in the caps of the plaques 
(shoulders and centre of the cap) on each of 8 OCT images equally distributed along the 
length of the plaque, amounting to approximately 20 ROIs per plaque. The final number of 
ROIs drawn depends on the size and position of the tissue and the number of artefacts 
present on the areas of interest. See section 2.4.1 for detail on ROI drawing methodology. 
The pixel information within these ROIs was then processed using a custom Matlab code (see 
section 2.4.2). As with the previous two chapters, the metric of interest is the standard 
deviation (SD) of the mean pixel intensity within the ROIs. For each patient plaque, the SDs 
of the ROIs drawn in the caps were averaged and are presented in Figure 5-1 and Figure 5-2. 
Culprit plaques are represented by non-patterned plain bars and non-culprit plaques are 
represented by striped bars. The colours of the bar charts represent the treatment, with 
white charts on Figure 5-1 showing results from each of the 11 saline treated patients. And 
orange charts on Figure 5-2 showing results from each of the 8 USPIO treated patients. The 
datasets for each patient are normalised to the mean of all non-culprit plaques from saline 
treated patients.  
5.3 RESULTS 
5.3.1 Patient plaques OCT image analysis 
For each individual patient (both saline and USPIO treated), the culprit plaque mean SD is 
higher than the control non-culprit plaque mean SD but this difference is not always 
significant. Saline treated patients 1, 2, 3, 6, 7, 9, 10 and 11 (Figure 5-1 ) all have a significantly 
higher (p<0.05) OCT signal in their culprit plaques compared to their non-culprits whereas 
patients 4, 5 and 8 (Figure 5-1 ) do not have a significant difference. USPIO treated patients 
1, 2 and 3 (Figure 5-2) all have a significantly higher (p<0.05) OCT signal in their culprit plaques 
compared to their non-culprits whereas patients 4, 5, 6 and 7 (Figure 5-2) do not have a 
significant difference. USPIO treated patient 8 unfortunately could not have a non-culprit 
plaque imaged for comparison. Therefore, 61% of patients in this study (11 out of 18) had a 
significant increase in OCT signal in the caps of ruptured culprit plaques compared to stable 
non-culprit plaques. This indicates that the standard deviation metric, although not perfect, 
is somewhat predictive of plaque severity. A number of factors could be affecting these 
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results, namely, small N numbers, systemic inflammation and variability in non-culprit plaque 
types. These factors will be explored further in the discussion section. 
 
Figure 5-1: Standard deviation of pixel intensity analysis of OCT images from saline treated 
control patients. Each plot shows the mean SD from ROIs of culprit versus non-culprit plaques 
of each patient. All values are normalised to mean of non-culprit plaques, ns= not significant, 




Figure 5-2: Standard deviation of pixel intensity analysis of OCT images from USPIO treated 
patients. Each plot shows the mean SD from ROIs of culprit versus non-culprit plaques of each 
patient. All values are normalised to the mean of saline non-culprit plaques, ns= not 
significant, * p<0.05, ** p<0.01, *** p<0.001. Error bars = SEM. 
 
In order to compare the OCT signal enhancement efficacy of the two treatments (saline and 
USPIO) the data from the saline treated patients need to be pooled together and analysed 
against that of the USPIO treated patients, as is presented in Figure 5-3. This figure shows 
that the SD of the OCT images is greater in the culprit plaques of patients treated with USPIO 
compared to culprit plaques in patients treated with saline (1.132 vs 1.102 respectively, 
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p<0.05). Similarly, the SD was higher in non-culprit plaques of patients treated with USPIO 
compared to those administered saline (1.053 vs 1, p<0.001). In patients treated with USPIO, 
the SD was higher in the culprit plaque when compared to their non-culprit plaques (1.132 
vs 1.053 respectively, p<0.001).  Although lower than UPSIO patients, a difference in the SD 
signal in the culprit versus non-culprit plaques was observed for patients treated with saline 
(1.102 vs 1 respectively, p<0.001). These results indicate that when pooled together in this 
way, culprit plaques overall have significantly higher OCT signal in their caps compared to 
non-culprit plaques, regardless of treatment. Additionally, USPIO treatment significantly 
enhances the OCT signal in both culprit and non-culprit plaque caps. 
 
Figure 5-3: Standard deviation of pixel intensity analysis of OCT images from all patients 
pooled together. All values are normalised to saline non-culprit mean, ns= not significant, * 
p<0.05, ** p<0.01, *** p<0.001. Error bars = SEM. 
 
5.3.2 SD hotspot visualisation tool 
The SD results presented above showed that USPIO treatment of ACS patients can 
significantly increase the local SD of plaque OCT images compared to placebo treated 
patients. It would however be useful to be able to visualise these increased SD regions in 
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order to detect differences in plaque inflammation in real time in vivo. An SD hotspot 
visualisation tool was therefore developed in Matlab as described in section 2.4.3 and a 
selection of OCT images from the two treatment groups were processed.  
Figure 5-4 shows an OCT image from each of the non-culprit plaques of saline treated 
patients 8, 9 and 11 with (right) and without (left) the SD hotspot overlay.  Figure 5-5 shows 
an OCT image from each of the culprit plaques of saline treated patients 8, 9 and 11 with 
(right) and without (left) the SD hotspot overlay. Similarly, OCT images from non-culprit and 
culprit plaques of USPIO treated patients 1, 3 and 6 are presented in Figure 5-6 and Figure 
5-7 respectively with (right) and without (left) the SD hotspot overlay. As with the murine 
study from the previous chapter, the raw OCT images of coronary plaques from ACS patients 
treated with USPIO or saline were not visually distinguishable from each other (left panels). 
Application of the SD hotspot mapping technique (right panels) yielded clear visual 
distinctions between the treatment groups and culprit versus non-culprit plaques.  In 
particular, there were visually more high-intensity hotspots in the culprit plaques of patients 
treated with USPIOs (Figure 5-7) compared to their non-culprit plaques (Figure 5-6) and to 
both the culprit (Figure 5-5) and non-culprit plaques (Figure 5-4) of patients pre-treated with 
saline.   
When looking at saline patients alone, both patients 9 and 11 have more hotspots in their 
culprit plaque (Figure 5-5) compared to their non-culprit (Figure 5-4) with patient 9 having a 
much starker difference. In contrast, saline patient 8 counter-intuitively has more hotspots 
in the non-culprit (Figure 5-4) compared to the culprit (Figure 5-5). However, in USPIO treated 
patients, the difference between culprit and non-culprit plaques is much clearer; each 
individual patient (1,3 and 6) has a much higher density of higher intensity (more orange/red) 
hotspots in the culprit plaques (Figure 5-7) than the non-culprit plaques (Figure 5-6). These 
visual differences are concurrent with the quantitative results obtained in the previous 





Figure 5-4: OCT slices through non-culprit plaques of saline treated patients 8, 9 and 11 with 




Figure 5-5: OCT slices through culprit plaques of saline treated patients 8, 9 and 11 with a 




Figure 5-6: OCT slices through non-culprit plaques of USPIO treated patients 1, 3 and 6 with 




Figure 5-7: OCT slices through culprit plaques of USPIO treated patients 1, 3 and 6 with a 




To summarize, in this chapter IV-OCT imaging of ACS patient culprit and non-culprit plaques 
was performed with and without pre-treatment with USPIO particles. Image analysis 
methodologies presented in the previous chapters were employed here and there were 
three main outcomes. The first is that the caps of culprit plaques yielded significantly higher 
OCT contrast compared to non-culprit plaques regardless of treatment. Secondly, USPIO 
treatment was found to significantly increase the OCT signal in plaque caps compared to the 
plaque caps of saline treated patients. And finally, the SD hotspot tool presented in the 
previous chapters was implemented in the images of human plaques and found to support 
the quantitative results obtained. These three outcomes will be discussed in more detail 
subsequently. 
Firstly, section 5.3.1 presented the SD image analysis results from the IV-OCT imaging of 19 
ACS patients. When the data from all patients was pooled together (Figure 5-3) culprit 
plaques were found to have significantly higher OCT signal compared to non-culprits in both 
treatment groups, confirming hypothesis 1 of this chapter. Some overlap in these values in 
individual patients were observed, in part this is because non-culprit plaques in ACS patients 
are an imperfect control. Indeed, atherosclerosis is a systemic disease process so the 
inflammation that can trigger an event is frequently observed in numerous plaques across 
the coronary and systemic vasculature. Additionally, although the non-culprit plaques were 
in a remote vessel and were selected for their relatively stable appearance, there could be 
any number of plaque subtypes in this “non-culprit” cohort. This variability in plaque 
type/structure/composition will affect the macrophage burden and therefore the SD value 
in the caps. Indeed, MacNeill et al. found no significant difference between the NSDs of 
culprit and non-culprit plaques of ACS patients92. It would be interesting to clinically grade 
the non-culprit plaques based on their OCT appearance and then investigate plaque type 
correlation with SD values but this was beyond the scope of this translational study. 
The second main message emerging from the image analysis results (section 5.3.1) relates to 
the effect of USPIO treatment on OCT signal. From the results of Figure 5-3 it was shown that 
the caps of the culprit plaques of USPIO treated patients had significantly higher OCT signal 
than those of saline treated patients, confirming hypothesis 2 of this chapter. The non-culprit 
plaques of USPIO patients also showed significantly higher OCT signal compared to the non-
culprits of saline patients, again showing that USPIO serves to enhance the detection of 
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systemic inflammation and macrophage infiltration observed throughout the coronary 
vasculature at the time of ACS. This is the first time that any OCT contrast agent has been 
tested in humans, making this a truly novel translational study. Although histological 
validation in human coronary atheroma is not feasible, thanks to the proof-of-concept 
studies in the previous chapters showing that USPIOs enhance the SD associated with 
macrophages in vitro and in ApoE-/- mouse plaques we can be reasonably confident that 
these increased SD values in the USPIO treated patients are due to their accumulation in 
plaque macrophages. This is the very first time that USPIOs have been used in vivo as an OCT 
contrast agent to enhance the detection of plaque inflammation. 
Finally, section 5.3.2 presented a bespoke OCT SD hotspot visualisation tool which accurately 
represented the quantitative results obtained previously. Indeed, there were more high 
intensity hotspots in the caps of the culprit plaques compared to those of non-culprit plaques 
and this difference was more marked in USPIO treated patients compared to saline control, 
confirming hypothesis 3 of this chapter. Although the appearance of these hotspot maps 
varied a lot between different OCT slices, the technique is an appealing intuitive tool which 
could be implemented in real-time IV-OCT imaging to aid cardiologist in assessing plaque 
inflammation and using this information to guide their intervention.  
There are several limitations to the work of this chapter. Firstly, due to errors in blinded 
treatment assignment the study ended up with two more patients in the saline treated group 
(11) than the USPIO treated group (8). Additionally, for one of the 8 USPIO treated patients 
the non-culprit plaque imaged had to be removed from analysis due to poor image quality. 
These factors make for a relatively small group of experimental treatment patients which 
does reduce the power of the study and shows that larger confirmatory studies are required. 
Additionally, the required manual ROI drawing step involved in the image analysis is a 
significant limitation. Because of the time-consuming nature of drawing ROIs in the fibrous 
caps of plaques, this was only done on 8 images for each plaque (equally distributed along 
the full length of the plaque). It would of course be better to include all the images of the 
plaques in the analysis (as was done for the in vitro phantoms and the mouse plaques in 
previous chapters) but this would involve too high of a time commitment for a cardiology 
expert to commit to. All of the OCT macrophage quantification studies to date also involved 
an ROI drawing step in order to restrict the image analysis to the fibrous cap and all in fact 
analysed fewer images per plaque (maximum 3)89,92,139,140 than we did here. ROI drawing was 
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also a necessary step in the SD hotspot tool implementation, demonstrating that this tool is 
not quite ready for real-time assessment of plaque inflammation. 
In conclusion, this novel in vivo human study has further confirmed previous findings that 
the local OCT standard deviation of pixel intensity in plaque caps accurately detects 
macrophage burden. For the first time, using this metric, it was shown that the caps of culprit 
plaques of ACS patients have significantly higher OCT signal than non-culprit plaques of the 
same patients. Additionally for the first time, USPIO particles were used as an IV-OCT contrast 
agent to enhance the detectability of plaque macrophages in vivo. This OCT signal 
enhancement was effectively visualised using a novel standard deviation of pixel intensity 
hotspot tool which presented an attractive view to the future of real-time inflammation 
visualisation with OCT in vivo. This was the final chapter of the 3 part translational USPIO-
OCT study demonstrating USPIO as an effective OCT contrast agent for macrophage 
detection. The following chapter is a perspective study looking even further into the future, 
making first steps towards developing brand new OCT and macrophage specific imaging 


























6 CHAPTER SIX: NOVEL OCT CONTRAST 














The previous three chapters investigated USPIO (an already clinically approved particle) as a 
new IV-OCT contrast agent in vitro, in a murine model and in man. In so doing we have 
established a robust framework for the screening of potential new IV-OCT contrast agents. 
In this chapter we utilise this framework to test and optimise a panel of novel lanthanide-
doped upconversion nanoparticles for their ability to enhance macrophage detectability with 
IV-OCT in vitro. 
As presented in section 1.5 there have been very few studies investigating the IV-OCT signal 
enhancement properties of new agents, with most of the focus being on different forms of 
gold nanoparticles126–129 and just one study investigating quantum dots130. Although most of 
these studies have shown the particles to significantly enhance IV-OCT contrast, there is a lot 
of room for discovery of new, more specific particles. Importantly, none of the studies 
mentioned investigated the toxicity of their particles or their IV-OCT properties when actually 
loaded into cells. Additionally, their assessments of OCT contrast enhancement were varied 
but none used techniques that can be implemented on human atherosclerotic plaque 
imaging in vivo. The work in chapter 3 showed that we have developed a robust phantom 
model and image analysis methodology which is highly translatable and allows easy, 
standardised and reproducible screening of imaging agents with IV-OCT. This makes us 
perfectly placed to test new contrast agents. 
Although USPIOs are very attractive potential OCT contrast agent, given their clinical 
approval and their proven accumulation in atherosclerotic plaques, there were some 
limitations to this choice of nanoparticle. Firstly, they are not entirely specific to 
macrophages, it is possible that they could be taken up by other cells in atheromatous 
plaques. Additionally, although their scattering properties were shown to be high enough for 
detection by IV-OCT (when packaged into cells), this is not what they were designed and 
optimised for, it should be possible to design bespoke contrast agents with even higher, more 
specific IV-OCT signal enhancement. In this chapter we propose to start anew, with particles 
that are tuneable in all aspects: OCT detectability, macrophage specificity and dual modality 
imaging potential. 
With this in mind, we partnered with the world leaders in the field of upconversion 
nanoparticles: Prof Xiaogang Liu’s lab group at the National University of Singapore. They 
design and produce lanthanide doped nanocrystals for many applications, as described in the 
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review by Lui et al.142. This process involves incorporating lanthanide ions into host lattices in 
order to fine tune many of their defining characteristics: electric properties, magnetism and 
light absorption and emission properties142–144. In this way, nanoparticles can be designed 
which absorb light at one wavelength and emit it at a different wavelength; an extremely 
attractive quality for fluorescence imaging142–144. The magnetism of the particles can also be 
modulated for use with MRI and their optical scattering properties can be tuned by changing 
the nanocrystal structure142–144, making them interesting potential OCT contrast agents. 
For the purposes of this IV-OCT study, Zhigao Yi from Prof Xiaogang Liu's group, designed and 
produced a panel of different lanthanide doped upconversion nanoparticles which can 
absorb a small percentage of the light emitted by the IV-OCT laser and re-emit it at different 
wavelengths. This makes them ideal candidates for dual OCT and fluorescence imaging 
studies, similar to that published with quantum dots130. This upconversion property would 
also be an extremely useful tool when it comes to functionalising the particles for use in 
actually tagging specific sub-types of macrophages such as highly pro-inflammatory plaque 
macrophage profiles. Indeed, the fluorescent properties would be essential to in-vitro flow 
cytometry and confocal microscopy assays necessary for investigating macrophage tagging. 
The purposes of this chapter however were to perform preliminary IV-OCT screens to start 
to assess and fine tune the OCT contrast enhancement properties of the particles before 
moving onto functionalising them at a later date. 
Initially, 9 lanthanide particles of either fluoride or carbonate structure were screened 
(section 6.3.1) in order to select the one with the highest OCT contrast: Gd-carbonate. This 
particle was subsequently coated in 3 different ways and these new coated particles were 
further tested for biocompatibility as well as their OCT and MRI contrast properties (section 
6.3.2). The three aims and three associated hypotheses of this chapter are outlined below. 
AIM 1 (section 6.3.1): To successfully screen a panel of new IV-OCT contrast agents with the 
previously established phantom methods in order to identify particles with high OCT 
detectability. 
Hypothesis 1: The phantom mould and methodologies developed previously will enable us 




AIM 2 (section 6.3.2.1 and 6.3.2.2): To determine the OCT contrast capabilities and the 
cytotoxicity of the selected particle (Gd) after it has been coated for biocompatibility. 
Hypothesis 2: The particle selected (Gd) to take into cell experiments will still produce high 
OCT contrast when coated for biocompatibility and will not be significantly cytotoxic to the 
cell line used here. 
AIM 3 (sections 6.3.2.3 and 6.3.2.4): To determine if the coated Gd particles loaded into 
macrophages can enhance their OCT signal and retain MRI contrast capabilities. 
Hypothesis 3: When loaded into cells, the coated Gd based particles significantly increased 



















6.2.1 Particle design and production 
All the nano-particles used in this chapter were designed and produced by Zhigao Yi from 
Prof Xiaogang Liu's group at the National University of Singapore.  These upconversion 
lanthanide doped nanoparticles were designed with an absorption band in the excitation 
range of the clinical OCT system (1300 nm). This means that they can absorb a percentage of 
the light emitted by the OCT system and they can then re-emit this light at a different 
wavelength (e.g. visible), making them agents capable of dual modality imaging. They were 
made with either a carbonate or fluoride structure doped with different lanthanide ions: 
Ytterbium (Yb), Erbium (Er), Neodymium (Nd), Dysprosium (Dy) and Gadolinium (Gd). 
Initially, the 9 nanoparticles received were the following: Yb(OH)CO3, Er(OH)CO3, Nd(OH)CO3, 
Dy(OH)CO3, Gd(OH)CO3, NaYbF4, NaErF4, NaNdF4, NaDyF4. The average sizes of the carbonate 
particles, based on TEM imaging, were respectively: 67 nm, 80 nm, 640 nm (rod-shaped), 313 
nm, 188 nm. The fluoride particles were all an average of 15-25nm in size. Following 
preliminary testing, solely the Gd(OH)CO3 particle was selected and coated by Yi Zhigao to 
improve bio-compatibility, this is referred to subsequently as the Gd particle. Three new 
batches of this particle were produced, each coated with either polyacrylic acid (PAA), 
polyethylene glycol (PEG) or polyethyleneimine (PEI).  
6.2.2 Cell viability assays  
To measure the biocompatibility of the differently coated Gd particles described above, MTT 
assays were performed using the TACS® MTT cell proliferation kit from Trevigen. This 
colorimetric assay is NADPH dependent and is widely used for the measurement of cell 
metabolic activity. The RAW264.7 murine macrophage cell line was cultured as described in 
section 2.1. In a 96-well plate, approximately 20 million RAW cells per well were incubated 
with each of the 3 differently coated particles (Gd-PAA, Gd-PEG and Gd-PEI) at 1mM 
concentration in media. 4 well repeats were plated for each condition, including positive 
controls with media only and negative controls with 30% dimethyl sulfoxide (DMSO) in 
media. The incubations were performed for 2 and 20 hours in a 37˚C incubator. Following 
incubation, the wells were washed twice with DPBS and then incubated with 110 μl of a 10% 
solution of MTT reagent 1 in media. This incubation was performed for 4 hours in a 37˚C 
incubator, after which a dark purple precipitate could be observed inside the cells under a 
compound microscope. 100 μl of MTT reagent 2 was subsequently added to each well and 
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incubated in the dark at room temperature overnight. Finally the absorbances were read on 
a Bioteck Synergy spectrophotometer at 570 nm and 650 nm (for background absorbance) 
after shaking for 2mins. The background absorbance readings (at 650 nm) were subtracted 
from the sample readings (at 570 nm), the 4 repeat wells were averaged for each condition 
and this was normalised to the positive control mean. This experiment was repeated 4 times 
for both the 2 and 20 hour particle incubation time points, and the cell viability results are 
presented in section 6.3.2.2. 
6.2.3 Preliminary OCT screenings in water 
The 9 uncoated lanthanide particles described in section 6.2.1 (5 carbonates and 4 fluorides) 
were initially OCT screened in order to determine which ones had the best signal 
enhancement potential. This was done using the 3-D printed phantom mould described in 
section 2.3. The sections of the phantom mould were filled with 250 μl of the different 
particle solutions diluted to 100 mM in distilled water. These were imaged (as well as a water 
only control) using the DragonflyTM OPTISTM OCT catheter and St. Jude Medical OTPIS 
integrated system.  
6.2.4 Agarose phantoms 
A simple phantom was made using 1.5% agarose in PBS and each of the 4 different carbonate-
lanthanide particles (Dy, Nd, Y and Gd) at final concentrations of 100 mM in different sections 
of the phantom. The gels were made by combining 300 μl of particle stock solutions (200 
mM) with 300 μl of melted agarose. A control gel was also made by combining 300 μl of PBS 
with 300 μl of melted agarose. Each was thoroughly mixed (while kept warm) to ensure 
homogenous distribution of the particles in the gel and they were transferred to separate 
sections of the phantom mould. A second simple phantom was made with the same particles 
at final concentrations of 10 mM by combining 60 μl of the particle stock solutions (200 mM) 
with 540 μl of melted agarose. The control gel was made by combining 60μl of PBS with 540 
μl of melted agarose. Each was thoroughly mixed (while kept warm) to ensure homogenous 
distribution of the particles in the gel and they were transferred to separate sections of the 
phantom mould.  
A third simple phantom was made with the 3 differently coated Gd-carbonate particles at 
1mM final concentrations in the following way: 
• No particle control: 500 μl melted agarose 
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• 1 mM Gd-PAA: 1.7 μl of Gd-PAA stock (300 mM) and 500 μl melted agarose 
• 1 mM Gd-PEG: 1.7 μl of Gd-PEG stock (300 mM) and 500 μl melted agarose 
• 1 mM Gd-PEI: 2.5 μl of Gd-PEI stock (200 mM) and 500 μl melted agarose 
Each was thoroughly mixed (while kept warm) to ensure homogenous distribution of the 
particles in the gel and they were transferred to separate sections of the phantom mould. 
Additionally, 3 identical macrophage laden phantoms were made. For this, the RAW264.7 
murine macrophage cell line was cultured as described in section 2.1 in three separate T162 
flasks and each incubated with 67 μl of one of the 3 coated Gd-carbonate particles (Gd-PAA, 
Gd-PEG and Gd-PEI from 300 mM stock solutions) in a total of 20 ml of media (final 
concentration of 1mM) for 24 hours. Following washing in Dulbeco’s PBS (Gibco), lifting by 
scraping and counting with a haemocytometer, 20x106 cells were taken from each treatment 
condition. These were washed, pelleted and fixed in 1ml of 4% PFA for 15 minutes then 
pelleted again and the supernatant removed. These pellets were warmed up in a water bath 
then thoroughly mixed with 0.5ml of warm 1.5% agarose using a warmed pipette tip (to avoid 
setting prematurely) before transferring to the phantom mould.  
All these phantoms were made with the 1mm rod insert in place to create a “lumen” through 
the agarose gel phantom. This rod was removed in order to insert the DragonflyTM OPTISTM 
OCT catheter and image using the St. Jude Medical OTPIS integrated system. Image analysis 
was performed using the custom methods and software described in section 2.4. 
6.2.5 MRI imaging 
The third “simple phantom” made with the coated Gd-carbonate particles, as well as one of 
the “macrophage phantoms” were imaged by Dr. M.A. Jansen at Edinburgh Preclinical 
Imaging (BHF Centre for Cardiovascular Science). The individual agarose gel cubes were taken 
out of the phantom mould sections and each placed in wells of a 24-well plate. 
MRI of these phantom cubes was performed on a 7 T horizontal bore Biospec AVANCE neo 
preclinical imaging system equipped with a 116 mm bore gradient insert (Bruker BioSpin 
GmbH, Germany, maximum gradient strength 660 mT/m). A 86 mm quadrature volume coil 
(Bruker BioSpin GmbH, Germany) was used for signal transmission and reception. Scout 
images were taken to confirm correct positioning and the magnetic field was optimised using 
an automated shimming routine. For all subsequent sequences, the field of view was 80 × 60 
mm, matrix size 200 × 150 and slice thickness 2.0 mm. For T2 mapping, 1 horizontal slice 
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through the centre of the phantoms was acquired using a Multi-Slice-Multi-Echo sequence 
with the following parameters: TR 2200 ms, 14 images with echo time varying from 14 – 98 
ms, number of signal averages 4. The scan time was 22 min. T1 maps were acquired of the 
same slice as for T2 mapping using a Rapid Acquisition with Relaxation Enhancement (RARE) 
sequence with the following parameters: TR 200, 500, 1200, 2500, 5000, and 10000 ms, TE 6 
ms, RARE factor 2, number of signal averages 3. The scan time was 35 min. T1 and T2 maps 





















6.3.1 Preliminary OCT screening of nine lanthanide particles 
To determine the potential of the lanthanide particles for OCT contrast enhancement a 
screening was done with each of the particles diluted to 100 mM in distilled water, using 
water alone as a control. These solutions were imaged in the chambers of the 3D printed 
phantom mould described in section 2.3 in order to use the IV-OCT imaging catheter. Figure 
6-1 shows representative OCT images of each sample particle and one of the water only 
control. The chambers of the phantom mould were half filled with the particle solutions 
which results in the images being roughly half dark (representing the air half of the chamber) 
and half bright and speckled (representing the sample half of the chamber) with an air-liquid 
(AL) interface which appears as a bright line draped over the catheter artefact. However, in 
the water only control image, the sample and air halves of the image look almost identical 
and the AL interface is barely visible, since water is transparent at this wavelength. The 
fluoride Er, Nd and Dy particles have in comparison, a much brighter AL interface but their 
sample portion of the image is only slightly brighter than that of the air and water control.  
However, the fluoride Yb particle as well as each of the carbonates (Yb, Er, Nd, Dy and Gd) 
have very bright OCT images, suggesting that they are potential good contrast agents for OCT 
imaging. When comparing these 6 brighter particles, the Nd carbonate image stands out as 
containing many more bright dots which could be a sign of being a stronger contrast agent 
but could also suggest that it is less soluble in water and more prone to aggregation. The Gd 
and Dy carbonates stand out as having the brightest images of the 10 presented here. 
Following this initial simple screening, the 5 carbonate particles were selected to carry out 
more robust screenings. Due to a technical issue the Er carbonate could not be included in 
further work.  
Two agarose phantoms containing the 4 remaining carbonate particles (Yb, Nd, Dy, Gd) at 
concentrations of 10 and 100mM were therefore made as described in section 6.2.4. 
Representative OCT images of each section of the 100mM phantom are shown in Figure 6-2. 
The images corresponding to the particle laden gels look clearly different to the agarose 
control, with a lot of large bright speckles present throughout the image which are absent in 
the control. Between each other, the different particle images look very similar, however, it 
does seem that Yb and Gd cause a reduced depth penetration of the signal (the image is dark 




Figure 6-1: Initial OCT screening of 9 different Lanthanide based nanoparticles with either a 
fluoride or carbonate structure. All particle solutions were diluted to 100 mM in distilled water 
and imaged as such in the 3D-printed phantom mould. The images show approximately half 
the content of the mould section to be air (dark) and half to be the sample solution with 





Figure 6-2: OCT imaging of an agarose phantom made with 4 different lanthanide carbonate 
nanoparticles. Each section of the phantom was made up of 1.5% agarose mixed with the 
stated particle at 100mM final concentration. One representative OCT slice for each particle 
gel and the agarose only control are shown. 
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As explained and demonstrated in previous chapters, the standard deviation (SD) of the 
mean pixel intensity within certain regions of the OCT images was used as a metric of the 
“granularity” to measure the effects of the different phantom compositions. In order to avoid 
imaging artefacts, ROIs were drawn on each of the OCT slices and the SD values for each ROI 
were processed in Matlab as described in methods section 2.4. Figure 6-3, presents the mean 
of these SD values for each section of the two “simple” phantoms laden with lanthanide-
carbonate particles (Dy, Nd, Y, Gd) at concentrations of 100mM (phantom introduced in 
Figure 6-2) and 10mM. The image analysis results of the 100mM phantom do corroborate 
the qualitative assessment of the OCT images presented previously. Indeed, each of the 
nanoparticles tested (at both 100 and 10mM) led to a significantly higher mean standard 
deviation of pixel intensity (MSD) within the OCT images compared to the agarose only 
control images. Furthermore, at 100mM the Gd particle gave a significantly higher OCT 
contrast compared to each of the 3 other lanthanide carbonates. In the case of the 10mM 
phantom, both Y and Gd particles show significantly higher MSDs than Dy and Nd with Y itself 
being significantly higher than Gd. 
 
 
Figure 6-3: Standard deviation of pixel intensity analysis of OCT images from 2 phantoms 
made with 1.5% agarose and 4 different lanthanide carbonate particles. All values normalised 
to the agarose only control. Letters show results of statistical test, when two bars share the 
same letter they are not significantly different whereas different letters indicate significant 




6.3.2 Comparison of 3 differently coated Gd-carbonate particles 
From the results presented in the previous section it was clear that all the lanthanide 
carbonate particles were able to effectively increase the OCT signal. Of the 4 particles tested, 
the Gd and Y based ones were found to have the highest effect and due to its multi-modal 
capabilities (and previous approval for use in humans)145 Gd was selected to move forward 
with the OCT study. In order to commence work with cells, the Gd-carbonate particle was 
produced with 3 different coatings: polyacrylic acid (PAA), polyethylene glycol (PEG) and 
polyethyleneimine (PEI). The three new particles, Gd-PAA, Gd-PEG and Gd-PEI were 
subsequently tested for OCT signal enhancement on their own in simple phantoms (section 
6.3.2.1). Then they were tested for biocompatibility with RAW macrophages (section 6.3.2.2) 
before being used in macrophage phantoms to determine whether they retain their OCT 
contrast properties when packaged inside cells (section 6.3.2.3). Lastly, their MRI imaging 
potential was determined (section 6.3.2.4). 
6.3.2.1 OCT testing particles alone 
Similarly to section 6.3.1, a simple phantom was made with the differently coated Gd-
carbonate particles (Gd-PAA, Gd-PEG, Gd-PEI) embedded in separate agarose sections at final 
concentrations of 1mM. This was done in order to verify that the coatings do not have a 
detrimental effect on the OCT signal enhancement and also to test the efficacy of the 
particles at a concentration more suitable for use with cells. Representative images of each 
section of the simple phantom are shown in Figure 6-4. The images corresponding to the 
particle-laden gels look very similar to the agarose only control aside from being overall 
slightly brighter and having a few bright speckles. Indeed, the Gd-PAA, Gd-PEG and Gd-PEI 
images have some bright specks whereas the control image has none. When comparing 
between the different particle images it seems that Gd-PEI has the most bright speckles 





Figure 6-4: OCT images of an agarose phantom made with 3 differently coated (PAA, PEG and 
PEI) Gd-carbonate particles. Each section of the phantom was made up of 1.5% agarose mixed 
with the stated particle at 1mM final concentration. One representative OCT slice for each 
particle gel and the agarose only control are shown.  
 
Although there seem to be little qualitative differences between the particle images and the 
control, the image analysis results (Figure 6-5) show more definitive differences. Indeed, each 
particle-laden gel has a significantly higher MSD than that of the agarose only control gel 
(p<0.001), with Gd-PEI being the highest. This indicates that all three coated Gd-carbonate 
particles are effective OCT contrast agents in agarose at 1mM. Although there was no 
significant difference between the MSDs of Gd-PAA and Gd-PEG, the third coating, Gd-PEI 
actually had a significantly higher MSD (p<0.001) than each of the other two. This suggests 
that the PEI coating significantly enhances the light scattering properties of lanthanide-doped 
particles when held homogeneously in an agarose gel. However, during experimental 
manipulation of the particles we did encounter some aggregation, particularly with the PEI 





Figure 6-5: Standard deviation analysis results of a “simple” phantom containing agarose 
with Gd-carbonate particles of 3 different coatings (PAA, PEG and PEI). All values normalised 
to agarose only control, ns=not significant, * p<0.05, ** p<0.01, *** p<0.001. Error bars=SEM. 
 
6.3.2.2 Cell viability 
In order to determine the toxicity of the 3 differently coated Gd-carbonate particles, MTT cell 
proliferation assays were performed on RAW cells after incubation with each of the particles 
at concentrations of 1mM for either 2 or 20 hours. The results in Figure 6-6 show that cells 
have over 60% viability after 2-hour exposure to each of the particles whereas they have only 
about 5% viability after 2 hour exposure to the negative control, DMSO. At the 2-hour 
incubation timepoint, Gd-PEG shows the lowest toxicity, with around 95% cell viability 
compared to 65% and 60% for Gd-PAA and Gd-PEI respectively. When the macrophages were 
incubated with the particles for 20 hours Gd-PEG was again the least toxic with around 55% 
viability compared to 25% for Gd-PAA and Gd-PEI. Clearly the 20-hour time point is more 
important in terms of clinical relevance so it should be noted that all particles had a significant 




Figure 6-6: Cell viability of mouse macrophages after incubation with differently coated Gd-
carbonate particles for 2 and 20 hours. Mouse macrophages were incubated with the 
particles at concentrations of 1mM before performing an MTT colorimetric assay to assess 
viability (shown as percentage of positive control). N= 4 and Error bars = SEM. 
 
6.3.2.3 OCT testing particle-laden macrophages 
The next step was to test the efficacy of the three coated Gd particles for OCT signal 
enhancement of macrophages. To this end, a set of “macrophage phantoms” were made as 
described in section 6.2.4. The 5 sections of each phantom contained the following: 1) 
agarose only control, 2) 20 million untreated murine macrophages, 3, 4 and 5) 20 million 
murine macrophages loaded with each of the 3 Gd coated particles: Gd-PAA, Gd-PEG and Gd-
PEI. The loading of the particles into the macrophages was performed by incubations with 
the particles at 1mM concentrations in media for 24 hours. Three repeats of this phantom 
were made and imaged with IV-OCT. Representative OCT images of each macrophage gel 
from one of the phantoms are shown in Figure 6-7. It is immediately clear that these are 
brighter and more granular than those of the simple phantom in Figure 6-4, confirming that 
once again, macrophages on their own are detectable with OCT. Moreover, the particle 
loaded macrophage gel images in Figure 6-7 are substantially brighter, with more very bright 
spots than the macrophage only gel. However, it is hard to differentiate the images of the 3 
differently coated particle treatments (Gd-PAA, Gd-PEG and Gd-PEI) from each other. This 
suggests that, regardless of coating, Gd-carbonate particles are effective at the enhancing 




Figure 6-7: OCT images of an agarose phantom made with macrophage s loaded with 3 
differently coated (PAA, PEG and PEI) Gd particles. Each section of the phantom was made up 
of 1.5% agarose with 20x106 macrophages having been incubated with the stated particle at 
1mM. One representative OCT slice for each particle gel and the cells only control are shown. 
These findings are confirmed by the quantitative image analysis results from the 3 
macrophage phantoms made, shown in Figure 6-8. Indeed, in the pooled results of the 
phantoms, all 3 Gd coated particles significantly enhanced the MSD of OCT images compared 
to the cells only control. Gd-PAA showed the largest increase compared to cells control, 
followed by Gd-PEG and then Gd-PEI. This was also the case in the individual image analysis 
results for all 3 phantoms, the only difference being that Gd-PEI did not significantly increase 
the MSD compared to the cells control in phantom 1. It is clear from this figure that all three 
Gd coated particles are effective OCT contrast agents for murine macrophages, with Gd-PEI 




Figure 6-8: Standard deviation analysis results of 3 identical phantoms containing cells loaded 
with Gadolinium particles of 3 different coatings (PAA, PEG and PEI). The bottom figure shows 
the results of these 3 phantoms pooled together. All values normalised to cells only control, 
ns= not significant, * p<0.05, ** p<0.01, *** p<0.001. Error bars = SEM. 
 
6.3.2.4 MRI contrast confirmation 
After the initial OCT screenings of a panel of 9 different lanthanide particles (section 6.3.1), 
the Gd carbonate particle was selected, in part for its good OCT contrast properties but also 
in part for its potential for multi-modal imaging. Indeed, gadolinium is widely used as an MRI 
contrast agent in humans. In view of this, it is important to verify that the coated Gd 
carbonate particles screened in this section are good MRI contrast agents as well as OCT 
ones.  
Each proton in the hydrogen atoms of the human body has a magnetic moment (it spins on 
an axis) so when exposed to a large magnetic field (from the MRI machine), the protons line 
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up and spin at a particular frequency. When the magnet is turned off, the protons relax to 
their initial positions at different frequencies depending on the tissue type. The rate at which 
the protons return to their relaxed state is what is measured by the MRI machine and 
determines the image contrast between different tissues which all have slightly different 
relaxation times. T1 refers to the relaxation time of magnetisation occurring in the same 
direction as the MRI magnetic field whereas T2 refers to the relaxation time of magnetisation 
occurring perpendicular to it. T1 and T2 weighted images confer different advantages in 
different tissue types, which we will not detail here. When considering an MRI contrast agent, 
it is of interest to determine whether the agent significantly changes the T1 or T2 relaxation 
times compared to the control by making them shorter or longer. 
MRI imaging of the simple phantom (presented in section 6.3.2.1) and the macrophage 
phantom 3 (presented in section 6.3.2.3) of the 3 differently coated Gd particles was 
performed and the results are shown in Figure 6-9. The T1 and T2 relaxation times of the gels 
containing particles or particle-laden cells were all shorter than the agarose only and cell only 
control gels. Interestingly, the particle-laden cell gels all had shorter T1 and T2 relaxation 
times than the gels with particles alone. Looking at the macrophage gels, Gd-PEI shows the 
shortest T1 relaxation time, followed by Gd-PAA and the Gd-PEG, with less than 0.3s between 
each. However, the Gd-PAA laden macrophage gel had the shortest T2 relaxation time by 
about 9ms with Gd-PEG and Gd-PEI next and only 0.1ms apart. These results clearly show 
that the three coated Gd-carbonate particles are effective MRI contrast agents, but it is 




Figure 6-9: Results of MRI imaging of two phantoms, the “simple” phantom containing solely 
agarose mixed with the differently coated Gd-carbonate particles and the cell phantom 3 
containing mouse macrophages loaded with the same particles, embedded in agarose. 
6.4 DISCUSSION 
To summarize, in this chapter the IV-OCT imaging properties of novel lanthanide-based 
nanoparticles were investigated in vitro and there were three main outcomes. The first is 
that the phantom methodology developed in Chapter 3 enabled the effective screening of 
multiple nanoparticles and the identification of the Gd-based particle as the one with highest 
IV-OCT contrast potential. Secondly, the particle selected to take into subsequent cell 
experiments (Gd(OH)CO3) was shown to still produce a high IV-OCT signal when coated for 
Agarose only Cells only Gd-PAA Gd-PEG Gd-PEI
T1 map
Simple phantom
1.93 s 1.81 s 1.87 s 1.82 s
T1 map
Cell phantom 3
2 s 2.14 s 1.32 s 1.6 s 1.17 s
T2 map
Simple phantom
70.2 ms 56.5 ms 67.8 ms 41.2 ms
T2 map
Cell phantom 3



















biocompatibility and was not found to be significantly cytotoxic. And finally, when loaded 
into cells, the Gd based particles were found to significantly increase the IV-OCT signal of 
these cells and retained their MRI contrast capabilities. Each of these three outcomes will be 
discussed in more detail subsequently. 
Firstly, section 6.3.1 presented the results of screening the 9 lanthanide-based particles with 
IV-OCT using the previously developed phantom mould (section 2.3) and analysis method 
(section 2.4) and this enabled us to select Gd-based particles as those with the highest 
potential for future OCT investigations, confirming hypothesis 1 of this chapter. The first step 
of this investigation was to IV-OCT image all the particles simply in solution and the resulting 
images made it immediately obvious that the carbonate structure particles were far superior 
contrast agents to the fluoride structure ones. Therefore, 4 carbonate particles doped with 
different lanthanides (Yb, Nd, Dy, Gd) were taken to the next screening step: imaging in 
agarose phantoms. The image analysis results of the phantoms showed that all particles, 
when held homogeneously in an agarose gel, yielded significantly higher OCT contrast than 
the control gel. In addition, the Gd-based carbonate particle showed the highest OCT signal 
of the 4. Prompting us to select it for future optimisation involving cell work. For this purpose, 
Zhigao Yi coated the Gd based nanoparticle with three different coatings: PEI, PEG and PAA. 
Subsequently, section 6.3.2 presented the results of investigations of this Gd-based particle 
having been given 3 different coatings for biocompatibility. In a first instance, these 
investigations showed that the coated particles (when held homogeneously in an agarose 
gel) still produced high OCT contrast and were not found to be cytotoxic, confirming 
hypothesis 2 of this chapter. Indeed, section 6.3.2.1 tested the IV-OCT properties of the three 
coated Gd particles held homogeneously in agarose gels with the same methods as 
previously and found them to each cause a significant increase in the OCT signal compared 
to the agarose only control. Interestingly, the PEI coated Gd particle showed significantly 
higher OCT contrast than the other two coatings suggesting the PEI coating confers additional 
light scattering properties to the particle. However, we did observe the Gd-PEI particles 
aggregating which could explain their higher OCT standard deviation: a bigger clump of 
particles will cause higher light scattering. It would be interesting to properly investigate the 
aggregation rate of all the Gd-coated particles but that was beyond the scope of this 
screening study. In section 6.3.2.2 we presented the results of cell viability assays with the 
coated particles and were able to conclude that none of the particles had high toxicity and 
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that the PEG coating conferred the least toxicity to RAW cells both at 2-hour (5% toxicity) and 
20-hour (45% toxicity) time points. These results make sense given the widely accepted 
biocompatibility that PEGylation confers in many biological systems146–148. Additionally, many 
Gadolinium based MRI contrast agents have been FDA approved and used extensively in the 
past 30 years145, giving a good precedent for the safety of our Gadolinium doped 
upconversion particle. However, these cell viability assays were simply preliminary 
experiments and should of course be further validated in the future with safety studies in 
different cell types, animals and eventually humans. 
Finally, sections 6.3.2.3 and 6.3.2.4 presented the investigation of the effects that these 
coated Gd particles have on imaging when loaded into macrophages. The phantoms created 
showed that pre-treatment with each of the coated particles significantly enhanced the OCT 
signal and MRI contrast of macrophages, confirming hypothesis 3 of this chapter. Indeed, 
thanks to the in vitro phantom framework developed in Chapter 3 we were able to test the 
OCT and MRI imaging properties of macrophages pre-loaded with Gd-based upconversion 
nanoparticles for the very first time. Interestingly cell loading with Gd-PAA yielded the 
highest OCT signal, followed by Gd-PEG and then Gd-PEI. This is in contrast to the results of 
the particle only phantoms which showed Gd-PEI to have the highest OCT signal 
enhancement properties. The observation that these particles may aggregate when in 
solution, along with the fact that they had the highest toxicity of the 3 coatings leads us to 
believe that Gd-PEI may have been less efficiently taken up by macrophages than the other 
two particles. Less efficient cell loading would therefore lead to much lower OCT contrast. 
This theory would of course need to be verified by conducting particle uptake quantification 
assays, perhaps with flow cytometry by utilising the particles’ light emitting abilities. 
Furthermore, section 6.3.2.4 presented results of MRI imaging of the gels from two 
phantoms (particles alone and particles in macrophages) in order to confirm the magnetic 
properties of these coated upconversion particles. It was indeed found that all three coated 
particles, whether alone in gels or loaded into macrophages had shorter T1 and T2 relaxation 
times than the controls. This of course was a very simple preliminary MRI experiment which 
will require more detailed investigations should dual modality OCT-MRI imaging become a 
priority of this upconversion particle study. 
There are a few limitations to this chapter, some of which have already been referred to 
briefly. In particular, we did not quantify the uptake of the coated Gd particles by the 
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macrophages. Contrarily to USPIOs (as seen in section 3.3.1) we could not see the particles 
in the macrophage endosomes under the microscope. Thanks to the significantly enhanced 
OCT signal of the macrophages when they have been treated with the particles it is pretty 
safe to assume that the particles have been internalised. It would however be very important 
for future studies to actually quantify this internalisation and perhaps investigate the 
mechanisms of uptake. We propose here that this could be done with flow cytometry by 
utilising the particles’ remarkable ability to re-emit light absorbed at a different wavelength. 
This is also how we suggest macrophage functionalisation could be implemented. Indeed, so 
far we have not made any modifications to the particle to make it macrophage specific. An 
important aim of future studies will be to turn the Gd-PEG particle into a probe which can 
target pro-inflammatory macrophages for their specific detection in vivo with IV-OCT. 
Another limitation of this chapter is the lack of comparison to other imaging agents. It would 
be interesting to see how these new particles fair in terms of IV-OCT contrast up against the 
published gold nanostructures126–129 but this was beyond the scope of this study. A quick 
comparison between Figure 3-8 and Figure 6-8 suggests that the Gd-doped particles are 
better at enhancing the IV-OCT signal of macrophages than USPIOs are but a more robust 
analysis, with more Gd-macrophage phantoms would be necessary for confirmation of this 
observation. Finally, as mentioned previously, further biocompatibility and safety 
experiments will be necessary when moving forward with this investigation. 
In conclusion, this novel in vitro study has for the first time proven the IV-OCT contrast 
enhancement abilities of lanthanide-doped upconversion nanoparticles. A bespoke phantom 
model and image analysis method were used to screen a panel of lanthanide based particles 
and identify ones with highest OCT contrast. The Gd-doped upconversion particle was then 
PEG coated for biocompatibility, shown not to be significantly cytotoxic and found to 
significantly enhance the IV-OCT detection of macrophages. This perspective study utilised 
the robust OCT phantom framework developed in this thesis and made a first step towards 
the development of a truly OCT and macrophage specific contrast agent. The ability of this 
particle to be fine-tuned for many applications is unmatched and will prove invaluable for its 
























































The work in this thesis has concentrated on advancing methodologies aimed at enhanced 
detection of macrophages with a clinical IV-OCT system. This was investigated in vitro, in a 
mouse model of atherosclerosis and finally in humans presenting with symptomatic coronary 
artery disease. In this concluding chapter we will first give a brief summary of the findings of 
each individual chapter, followed by an overview of the translational USPIO-OCT study as a 
whole (chapters 3, 4 and 5). Finally, the limitations of the work of this thesis and possible 
future directions will be described. 
7.1 SUMMARY OF THESIS CHAPTERS 
7.1.1 Chapter Three: In vitro Phantom USPIO-OCT Study 
In Chapter 3, for the first time, we presented a robust in vitro phantom model and image 
analysis methodology which is highly translatable to in-vivo clinical imaging and allows easy, 
standardised screening of imaging agents with IV-OCT. Nothing of this kind has previously 
been published in the literature. Indeed, although a few authors have investigated the OCT 
contrast properties of nanoparticles in vitro126–130, only one has done this with particles 
loaded into macrophages93. In this study we confirmed USPIO uptake by macrophages in a 
dose dependent fashion and confirmed our chapter 3 hypothesis: intra-cellular USPIOs 
enhanced the detection of macrophages on IV-OCT images. Indeed, we demonstrated that 
RAW macrophages loaded with USPIOs produced significantly higher standard deviation of 
pixel intensity on OCT images (OCT SD) compared to untreated macrophages across seven 
repeat experiments and over a thousand total images analysed. The optimal USPIO 
concentration for this enhanced OCT signal was found to be between 0.05 and 0.25 mg/ml, 
an observation that then informed the dosing in the subsequent in vivo studies. 
7.1.2 Chapter Four: Ex vivo Mouse USPIO-OCT Study 
In Chapter 4, for the first time, we imaged the aortic plaques of ApoE-/- mice with a current 
clinical IV-OCT system. Indeed the only published study83 having attempted this did so with a 
now redundant, lower quality IV-OCT system which used a catheter half the diameter of the 
one currently used in the clinic. Our study confirmed the ability of IV-OCT to clearly depict 
the miniaturised plaque structures in mice (fibrous cap and lipid pool were easily identified). 
And image analysis comparison of mice treated with USPIO and saline confirmed the main 
chapter 4 hypothesis that the plaques of USPIO treated mice will have a higher signal on 
IV-OCT images compared to untreated mice. Indeed, the local OCT SD values were 
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significantly higher in the plaque caps of USPIO treated mice compared to saline treated mice 
and compared to non-plaque areas of the aortic wall. This increased signal is expected to 
correlate with the presence of activated USPIO-laden macrophages on histology, however 
this data, whilst acquired is not yet available. Importantly, no increase in OCT signal variance 
was observed within regions of normal aorta that were free from atherosclerosis and 
activated macrophages. To get around the large size of the current clinical IV-OCT catheter, 
we had to excise the mouse aortas and cut them open for ex vivo imaging. It would be 
preferable to confirm these findings with an in vivo whole vessel imaging approach, however 
this is only possible in a larger animal model (pig or hyperlipidaemic rabbit) which we did not 
have access to. 
7.1.3 Chapter Five: In vivo Human USPIO-OCT Clinical Trial 
In Chapter 5, we translated this novel USPIO-OCT approach into humans within the context 
of a randomised clinical trial. Even though USPIOs have been approved for clinical use in over 
10 years, this is the first attempt to use them as an OCT contrast agent in vivo. In this study 
we confirmed the main Chapter 5 hypothesis that culprit plaques of USPIO treated ACS 
patients will yield higher OCT signal compared to saline treated ACS patient culprit plaques 
and compared to all non-culprit plaques. Indeed, the local OCT SD values in culprit plaque 
caps of patients who had been administered USPIO were significantly higher than in those 
who had received saline placebo treatment. And they were also significantly higher than local 
OCT SD values in the caps of all non-culprit plaques. Following myocardial infarction there is 
generalised atherosclerotic plaque inflammation, so it is reassuring that the local SD was also 
increased in the non-culprit plaques of patients administered USPIO versus similar plaques 
in patients pre-treated with saline. These findings confirm the clinical translatability of USPIO 
enhanced detection of coronary plaque inflammation with OCT. 
7.1.4 Chapter Six: Novel OCT Contrast Agents for Macrophage Detection 
As mentioned above, in chapter 3 we demonstrated the capability of USPIOs to enhance the 
IV-OCT signal associated with macrophages when loaded into the cells by using a bespoke 3D 
printed phantom artery mould. These results were subsequently confirmed in both murine 
and human in vivo settings. Despite this success, we postulated that there must be other 
agents with high scattering properties which could be made more specific to OCT and 
importantly, targeted to activated plaque macrophages. With this in mind, in Chapter 6 we 
utilised this in vitro IV-OCT screening framework to start anew, with lanthanide-doped 
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upconversion particles. The advantage being that they are tuneable in all aspects: light 
scattering (for OCT detectability), magnetism (for MRI detection) and light emission (for 
fluorescence imaging). In this novel in vitro study, we showed for the first time that 
lanthanide-doped upconversion particles significantly increase IV-OCT local SD and many of 
them would make excellent candidates for macrophage tagging. In particular we tested the 
Gd-based particle (Gd(OH)CO3) loaded into macrophages and found it to significantly 
enhance their OCT detection (even more so than USPIOs). This confirms the main Chapter 6 
hypothesis: that a novel lanthanide based particle will significantly enhance the OCT 
detection of macrophages in-vitro.  This perspective study utilised the robust OCT phantom 
framework developed in this thesis and made a first step towards the development of a truly 
OCT and macrophage specific contrast agent. The ability of this particle to be fine-tuned for 
many applications is unmatched and will prove invaluable for its development into a plaque 
macrophage OCT probe. 
7.2 OVERVIEW OF OUR TRANSLATIONAL USPIO-OCT STUDY 
Together Chapters 3, 4 and 5 present a translational molecular imaging study in which we 
have demonstrated that USPIOs enhance the visualisation and quantification of vascular 
macrophages on OCT in vitro, in mouse models of atherosclerosis and in a clinical randomised 
controlled trial of patients presenting with acute myocardial infarction. The in vitro phantom 
and murine studies confirmed that increased OCT local SD is associated with the 
accumulation of USPIO particles in vascular macrophages, whilst the clinical studies 
demonstrated increased USPIO-enhanced OCT local SD in the culprit plaques and areas of 
recent plaque rupture responsible for myocardial infarction. This novel approach holds major 
promise in providing real time assessments of inflammatory activity in individual coronary 
plaques and could soon be ready for widespread investigation in patients undergoing 
invasive coronary angiography.   
Inflammation is a key pathological process underlying the development of atherosclerosis 
and an important trigger to plaque rupture and myocardial infarction. Whilst novel anti-
inflammatory therapies have demonstrated their ability to reduce cardiovascular events59–63, 
imaging techniques capable of directly imaging inflammation in the coronary arteries are 
lacking. For the first time we have demonstrated the ability of USPIO-enhanced OCT to detect 
macrophage accumulation in atherosclerotic plaque. A major advantage of our approach is 
that it makes use of a contrast agent and invasive imaging technology that have already 
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established an excellent safety profile in humans. It is therefore ready for widespread 
investigation in humans without the need for lengthy approvals. Moreover, OCT imaging 
systems are available in most invasive catheter laboratories and are familiar to many 
interventional cardiologists, potentially facilitating rapid future adoption of this technique. 
By comparison many other intravascular contrast agents are either not yet approved for 
human application or require bespoke catheters that are themselves not clinically approved 
or are expensive to purchase and install.  
In this translational imaging study, we have demonstrated the potential of USPIO-enhanced 
OCT imaging across a range of different experimental settings. In vitro we confirmed USPIO 
uptake by macrophages in a dose dependent fashion, and that intra-cellular USPIOs 
enhanced the detection of macrophages on IV-OCT images. The optimal USPIO concentration 
was found to be 0.05 mg/ml, an observation that then informed the dosing in the subsequent 
in vivo studies. The atherosclerotic mouse model study provided confirmation that similar 
mechanisms are occurring in vivo: increased OCT signal was observed in the atherosclerotic 
plaques of mice pre-treated with USPIO as compared to those administered saline. Finally, 
we have translated this novel approach into humans within the context of a randomised 
clinical trial in Chapter 5. Here the highest OCT signal was observed in the culprit plaques of 
patients with a recent MI who had been administered USPIO. These studies therefore suggest 
that the increased OCT signal observed with USPIO administration is specific to activated 
macrophages within atherosclerotic plaque.  
Our work supports and extends the original observations by Tearney and colleagues89 that 
macrophages present within atheroma demonstrate greater OCT signal intensity and 
variance than their surroundings causing an increase in the local standard deviation of pixel 
intensity (SD). Whilst differences due to USPIO accumulation are not readily discernible on 
visual assessment of raw OCT images, the enhanced signal becomes readily apparent when 
the OCT local SD is quantified. We believe this is because the metallic properties of the USPIO 
particles scatter the OCT light and increase variance in pixel intensity.  
Building on these observations we developed a novel image analysis approach that overlays 
this SD information on top of the anatomical information provided by OCT. A colour scale is 
used to highlight hotspots where the local SD is increased above a specific threshold, 
facilitating anatomical mapping of regions of USPIO accumulation and therefore macrophage 
inflammation. Such maps allow for a rapid visual assessment of the inflammatory activity 
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highlighted by this approach and combine it with the structural information familiar to 
interventional cardiologists. The spatial distribution of macrophages within the plaque can 
therefore also be appreciated, allowing differentiation from the many other plaque 
constituents (microcalcifications, cholesterol crystals, or internal and external elastic 
membranes) that share similar visual characteristics on OCT. If real time analysis can be 
successfully developed, then this technique would hold major promise as a biomarker of 
atherosclerotic plaque inflammation that might be used to aid clinical decision making for 
patients undergoing invasive coronary angiography.  
7.3 LIMITATIONS AND FUTURE DIRECTIONS 
The work of this thesis has several important limitations which will influence and inform 
future work in this field. Firstly, the contrast agents tested are not yet explicitly specific to 
activated macrophages and could be functionalised in the future. Secondly, we lack 
histological validation of our OCT findings in mice and humans. Thirdly, our murine and 
clinical studies are small and whilst their randomized nature and the blinded image analysis 
are strengths, this data needs to be confirmed in larger studies and in different patient 
populations. A fourth important limitation is that the image analysis methods, particularly 
the SD hotspot overlay tool are not fully automated and still currently require manual ROI 
drawing. Finally, once the image analysis tools will be ready to use in the clinic, treatment 
strategies will need to be developed and tested in randomised clinical trials. These limitations 
will be discussed in more detail subsequently. 
7.3.1 Specificity to activated macrophages 
Our work in the in vitro chapters (3 and 6) did not investigate specifically targeting activated 
plaque macrophages. In these chapters we relied on the premise that macrophages readily 
take up nanoparticles and that this is enhanced when they are activated. In the case of 
USPIOs this is partly true in that these particles have been previously been found to 
accumulate in activated plaque macrophages in humans105–107 and animal models98–104, 
however the mechanism of uptake is not well studied. It would be interesting to investigate 
which macrophage profiles preferentially uptake USPIOs, if other immune cells also take 
them up and whether this affects the efficacy of their use in vivo. In the case of the 
lanthanide-doped particles studied in chapter 6, there was evidence in our studies that the 
PEI coated Gd particles were aggregating and this was affecting their cellular uptake. 
Although we didn’t notice any of these issues with the other particles, it is important to 
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investigate this in the future. How efficiently are particles being taken up? Which type of cells 
preferentially take them up? Can this mechanism be tuned for more specific and efficient 
uptake by activated plaque macrophages? Indeed, the limitations outlined here with our in 
vitro work highlight the need for a macrophage profiling and targeting study in order to 
better functionalise future OCT contrast agents. There have been many published studies of 
plaque macrophage profiling, some of which are cited here149–151 and reviewed here152. The 
methods developed in these papers could be used as a starting point for functionalising our 
OCT contrast agents. As outlined in Chapter 6, the novel lanthanide-doped upconversion 
particles have a notable advantage for conducting this kind of study: in addition to being 
excellent at scattering light (essential for good detection with OCT) they have the potential 
to emit light at almost any wavelength desired143,144,153. 
7.3.2 Histological validation of USPIO-laden macrophages 
In our mouse and human studies (Chapters 4 and 5), we lack histological validation of our 
OCT findings. However, obtaining coronary tissue from patients undergoing percutaneous 
coronary intervention (PCI) for myocardial infarction is not possible. We must therefore rely 
on histological validation provided in mouse models, so it is a shame that this investigation 
was not able to be finalised before the publication of this thesis. In this histology 
investigation, each ApoE-/- mouse aorta is being sectioned and stained for iron with Perls 
Prussian blue (shown to stain USPIOs in previous studies) and plaque macrophages with 
CD68. We expect this analysis to provide confirmation that USPIOs have accumulated in 
plaque macrophages and that their locations within the fibrous caps will correlate with the 
“SD hotspots” found on OCT imaging. Without the results of this investigation, we cannot yet 
properly confirm that the increased OCT local SD in USPIO treated mice is due specifically to 
USPIO accumulation within plaque macrophages. However, it is highly likely to be the case, 
given the clear and consistent in vitro data demonstrating increased OCT-SD to be due to 
USPIO loading of mouse macrophages.  
7.3.3 Automation of SD hotspot tool 
One of the main limitations of the thesis as a whole is the partially manual nature of the 
image analysis method. Indeed, for both the SD analysis and the SD hotspot tool overlay, 
regions of interest had to be drawn on the OCT images in order to avoid artefacts and restrict 
the analysis to the cap of plaques (in the case of the mouse and human study). This is 
necessary because many things outside the cap of plaques will cause a high SD. Indeed the 
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boundaries between different tissue structures such as the fibrous cap and the lipid pool or 
the intima and a calcium nodule will cause a high SD value due to the structures having such 
different pixel intensities. For these reasons, all studies currently published on the 
identification of macrophages with OCT have had to draw ROIs to restrict their analysis to 
the fibrous caps,  as we have 89,92,139,140. However in recent years there have been many 
studies attempting to develop automated detection and characterisation of coronary plaque 
components on IV-OCT images such as lumen and plaque contours, plaque constitution (lipid 
or calcium rich) and even the fibrous cap82,154–158. In these studies, many different 
computational techniques were tested, resulting in varying degrees of specificity and 
sensitivity. While we cannot review them all here, it is reasonable to believe that one of these 
will soon help us achieve automatic real time visualisation of plaque cap macrophage burden 
using the SD hotspot tool. 
7.3.4 USPIO-OCT treatment strategies 
Once the automated SD hotspot tool is developed, how might USPIO enhanced OCT imaging 
be used in clinical practice? The imaging of inflammation within individual coronary plaques 
holds promise in directing decision making in patients undergoing invasive angiography with 
a view to PCI. In some patients, uncertainty exists as to the true culprit lesion and therefore 
which plaque should undergo PCI. A readily available, near real-time measure of local 
inflammation may help in the identification of such plaques. In addition, controversy persists 
about whether patients with a recent MI and multi-vessel coronary artery disease should 
undergo intervention to all obstructive coronary lesions or just the culprit. Here also a 
readout of inflammation at an individual plaque level may help guide appropriate 
intervention, avoiding the need for unnecessary stents whilst directing therapy to plaques at 
highest risk of causing recurrent events. At a more general level, the precise detection of a 
high burden of inflamed “vulnerable plaques” could aid in patient stratification. This could in 
the future inform the used of targeted, more expensive anti-inflammatory therapies shown 
to work extremely well on particularly vulnerable patients59–63 but perhaps unnecessary and 
even detrimental to the health of more stable patients. USPIO-OCT holds promise as an easy-
to-use, readily accessible technique with which to test these important treatment strategies 




In this novel translational thesis, we have established methods for the enhanced detection 
and quantification of macrophages with the clinical IV-OCT system in-vitro, ex-vivo and in-
vivo. We have confirmed our overarching hypothesis that macrophages can be detected and 
quantified on IV-OCT images using the standard deviation of pixel intensity metric and that 
this detection can be enhanced and made more specific by labelling with metallic particles, 
specifically USPIOs and novel lanthanide-based nanoparticles. Administration of USPIO 
enhances the detection of activated macrophages by OCT in pre-clinical models of 
atherosclerosis and patients undergoing invasive angiography following myocardial 
infarction. This novel approach is ready for human application, with major potential to 
enhance the imaging of inflammation within individual coronary plaques and to help guide 
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Matlab code for automated quantification of ROI metrics from images of the Terumo 
LunawaveTM system (clinical trial data) 
% OCT Macrophage study: E151502_OCTMA 
% PI: Dr Nick Cruden 
% Researchers: Simon Wilson, Andrew Mitchell, and Clara Vergez 
% Software Version: 6 
% Written: 01/03/16 
% Updated: 11/05/17 
% Written by Dr Calum Gray 
% Edited by Clara Vergez 
% Clinical Research Imaging Centre (CRIC) 
% The following processing is based on the paper: Quantification of Macrophage Content in 
Atherosclerotic Plaques by Optical Coherence Tomography(Circulation 2003 Tearney.pdf) 
clear  
clc  
software_version = ('v6_terumo_RAW'); 
%------------------------------------------------------------------- 
% Define the empty arrays which will be added to during processing to give a list/table of 
results  
AllSliceNum = []; %List of slice numbers that contained an ROI 
AllROINum = []; %List of the ROI/Tag numbers (i.e. objectmap) 
AllblobNum = []; %List of the separate blobs comprising the ROI/Tag 
AllROI_min = []; %List of min of the ROI 
AllROI_max = []; %List of max of the ROI 
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AllROI_mean = []; %List of mean of the ROI 
AllROI_var = []; %List of variance of the ROI 
AllROI_stdev = []; %List of standard deviation of the ROI 
AllTotalROIPixels = []; %List of total number of pixels in the ROI  
AllROI_NSD = []; %List of Normalised standard deviation of the ROI 
AllBackgroundMean = []; %List of mean background noise level 
AllNumExcludedPixels = []; %List of the number of excluded pixels in the stats calculations  
AllWI_min = []; %List of min within the whole image 
AllWI_max = []; %List of max within the whole image 
AllWI_NSD = []; %List of Normalised standard deviation (NSD) to the whole image min and 
max values             
%------------------------------------------------------------------- 
% Load image volume & ROI's 
% Load volume image 
[volume_filename,pathname] = uigetfile('*.hdr','Select the volume file'); 
% Split into pathname, filename and file extension 
[pathname, volume_filename, volume_ext] = fileparts(strcat(pathname,volume_filename)); 
volume = analyze75read (fullfile(pathname,strcat(volume_filename,volume_ext))); 
volume=flip(volume,1); 
% Load ROI file 
[ROIfilename,ROIpathname] = uigetfile('*.*','Select the ROI file for processing'); 
% Split into pathname, filename and file extension 




% Check to see if ROI file is in SliceOmatic (.tag) or Analyze (.obj) format 
if strcmp(ROIext,'.tag')  % Check if file extension is a tag file 
% Load Tag file 
[ROI,x_pixel_size,y_pixel_size,z_pixel_size,x_dim,y_dim,z_dim]=ReadTag(fullfile(ROIpathna
me,[ROIfilename ROIext])); 
    % convert ROI to type double 
    ROI = double(ROI); 
    % impixelinfo 
else if strcmp(ROIext,'.obj')  % Check if file extension is an objectmap file  
% Load objectmap file 
        ROI = AVWObjectMap (fullfile(ROIpathname,strcat(ROIfilename,ROIext))); 
% Use only the image within the ROI structure 
        ROI=ROI.Image; 
% Analyze values range from [1 to 256] whereas we want the values in the range [0 to 255] 
so that black is '0' - therefore subtract '1' from the ROI image volume to get it in this range 
        ROI = ROI-1; 
% The Analyze objectmap format does not contain info on pixel size, however it is a 1-to-1 
mapping on the .hdr it was created on. Therefore we can use the header info in the volume 
file 
info = analyze75info(fullfile(pathname,strcat(volume_filename,volume_ext))); 
        x_pixel_size = info.PixelDimensions(1); 
        y_pixel_size = info.PixelDimensions(2); 
        z_pixel_size = info.PixelDimensions(3); 
        x_dim = info.Dimensions(1); 
        y_dim = info.Dimensions(2); 
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        z_dim = info.Dimensions(3);    
    else 
% ROI file is not a recognised file format and the program will exit 
        error('ROI file format not recognised - exiting program ...')         
    end 
end 
% Find the number of slices in the volume (i.e. in the z-axis) 
no_of_slices=size(volume,3); 
% Find the number of Sliceomatic tags 
no_of_ROIs  = max(max(max(ROI))); 
% Define the mask of the crosshair annotations to be applied to each OCT image so that they 
are excluded from calculations 
[OCTCrosshairMask, screenshot] = mask_crosshairs(volume); 
% Save screenshot of mask overlaid on image as a 'sanity check' 
screenshot_name = strcat(pathname,'\','Crosshair_Mask_Screenshot.jpg'); 
imwrite(screenshot,screenshot_name) 
for i = 1:no_of_ROIs  % for each Tag/ROI 
fprintf('Processing ROI no. %d of %d ...\n',i, no_of_ROIs); 
    for j = 1:no_of_slices  % for each slice 
fprintf('Processing slice no. %d of %d for ROI no. %d ...\n',j, no_of_slices, i); 
    ROINum = i; 
  SliceNum = j;        
        % Select an image slice and ROI 
        image = volume(:,:,j); 
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        ROI_temp = ROI(:,:,j); 
% Test if the current ROI in the loop exists on the current slice (i.e. only make measurements 
for slice if the ROI/Tag number = i. If not, then move onto the next slice and re-test 
        if ismember(i,ROI_temp)           
% If the tag/ROI is present in the current image then set the ROI_temp image to only include 
this tag so that the other tags are not included in the calculation 
          ROI_temp = (ROI_temp==i);             
%-------- Remove the effect of crosshair annotations from image 
% Invert the OCT crosshair mask image 
            OCTCrosshairMask2 = 1-OCTCrosshairMask;            
%Mask the image with the OCT crosshair mask by setting values outwith the mask to NaN to 
exclude crosshair annotations from calculations 
            image2 = im2double(image);             
            image2(OCTCrosshairMask2==0)=NaN;                   
%------------------------------------------------------------------- 
% Set the background default value to zero (in this version, background value is not being 
measured and subtracted)            BackgroundMean = 0;        
%------------------------------------------------------------------- 
% Calculate the number of 'blobs' within the slice 
            blobs_label = bwlabel(ROI_temp); 
            Numblobs = max(max(blobs_label));             
            for z = 1:Numblobs 
            blobNum = z; 
%select each blob individually to process 




% Calculate the standard deviation within the objectmap/ROI 
%change to type double so that we can use NaN's   
image3 = double(image2);  
            ROI_mask = double(blob);   
            ROI_mask(ROI_mask==0)=NaN;             
            filter_ROI = image3.*ROI_mask; 
% It is very unlikely that there will be 'true' zero values within the image. These may cause 
issues when calculating statistics therefore it is in practice a good idea to set these to NaN's 
before calculating stats. However it is also a good idea to record the number of these pixels 
which have been excluded from the calculation. 
            NumExcludedPixels = sum(filter_ROI(:)<=0); 
            filter_ROI(filter_ROI<=0)=NaN; 
            ROI_min = min(filter_ROI(~isnan(filter_ROI)));  %calculate the min of the ROI 
            ROI_max = max(filter_ROI(~isnan(filter_ROI)));  %calculate the max of the ROI 
            ROI_mean = mean(filter_ROI(~isnan(filter_ROI)));   %calculate the mean of the ROI 
            ROI_var = var(filter_ROI(~isnan(filter_ROI)));   %calculate the variance of the ROI 
            ROI_stdev = std(filter_ROI(~isnan(filter_ROI)));  %calculate the standard deviation of 
the ROI 
            TotalROIPixels = sum(ROI_mask(:)==1);  
%calculate the number of pixels in the ROI  
            ROI_NSD = ROI_stdev / (ROI_max - ROI_min); 




% Calculate the Max and Min values of the whole image - the prefix WI_ stands for 'whole 
image' 
            WI_min = min(image3(image3>0));   
%find the minimum 'non zero' value 
            WI_max = max(max(image3)); 
%Calculate the normalised standard deviation of the OCT signal 
            WI_NSD = ROI_stdev / (WI_max - WI_min); 
%------------------------------------------------------------------- 
% Concatenate the cell columns by adding newly read values to previously read values 
AllSliceNum = [AllSliceNum ; SliceNum]; 
AllROINum = [AllROINum ; ROINum]; 
AllblobNum = [AllblobNum ; blobNum]; 
AllBackgroundMean = [AllBackgroundMean ; BackgroundMean]; 
AllROI_min = [AllROI_min ; ROI_min]; 
AllROI_max = [AllROI_max ; ROI_max]; 
AllROI_mean = [AllROI_mean ; ROI_mean]; 
AllROI_var = [AllROI_var ; ROI_var]; 
AllROI_stdev = [AllROI_stdev ; ROI_stdev]; 
AllTotalROIPixels = [AllTotalROIPixels ; TotalROIPixels]; 
AllROI_NSD = [AllROI_NSD ; ROI_NSD]; 
AllNumExcludedPixels = [AllNumExcludedPixels ; NumExcludedPixels]; 
AllWI_min = [AllWI_min ; WI_min]; 
AllWI_max = [AllWI_max ; WI_max]; 
AllWI_NSD = [AllWI_NSD ; WI_NSD];         
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            end              
        end 
    end      
end  
%------------------------------------------------------------------- 
% Save the results from processing OCT data to a text file 
fid_tag_results_file = 
fopen((fullfile(pathname,strcat(volume_filename,'_',software_version,'.txt'))),'at');     
    if (fid_tag_results_file < 0) 
        error('could not open file "*_results_v6_terumo_RAW.txt"'); 
    end; 
% Write the name of the software 
fprintf(fid_tag_results_file, 'OCT Macrophage Study: Metrics for SliceOmatic or Analyze ROI 
files \n\n'); 
% Write the path and filename of the tag file 
fprintf(fid_tag_results_file, '%s \n\n',fullfile(ROIpathname,strcat(ROIfilename,ROIext))); 
% Write the software version 
fprintf(fid_tag_results_file, 'Software Version: %s \n',software_version); 
% Write the date data was processed 
fprintf(fid_tag_results_file, 'Data Processed: %s \n',date); 
% Write the volume dimensions 
fprintf(fid_tag_results_file, 'Volume Dimensions: \t'); 
fprintf(fid_tag_results_file, 'Width=%g \t',x_dim); 
fprintf(fid_tag_results_file, 'Height=%g \t',y_dim); 
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fprintf(fid_tag_results_file, 'Depth= %g \n',z_dim); 
% Write the voxel size 
fprintf(fid_tag_results_file, 'Voxel Size: \t'); 
fprintf(fid_tag_results_file, 'VoxelWidth=%g \t',x_pixel_size); 
fprintf(fid_tag_results_file, 'VoxelHeight=%g \t',y_pixel_size); 
fprintf(fid_tag_results_file, 'VoxelDepth=%g \n\n',z_pixel_size); 
% Write the column headers for the batch_results text file 
fprintf(fid_tag_results_file, 'Slice No. \t');  
fprintf(fid_tag_results_file, 'Tag No. \t');   
fprintf(fid_tag_results_file, 'Blob No. \t');   
fprintf(fid_tag_results_file, 'Mean Background Noise Level \t'); 
fprintf(fid_tag_results_file, 'ROI Min \t');   
fprintf(fid_tag_results_file, 'ROI Max \t');   
fprintf(fid_tag_results_file, 'ROI Mean \t');   
fprintf(fid_tag_results_file, 'ROI Variance \t');   
fprintf(fid_tag_results_file, 'ROI Std Dev \t');   
fprintf(fid_tag_results_file, 'ROI Total Pixels \t');  
fprintf(fid_tag_results_file, 'ROI Normalised Standard Deviation (NSD) \t');  
fprintf(fid_tag_results_file, 'No. of Excluded Pixels from ROI Calculation \t');  
fprintf(fid_tag_results_file, 'Slice Min \t');   
fprintf(fid_tag_results_file, 'Slice Max \t');   
fprintf(fid_tag_results_file, 'Slice Normalised Standard Deviation (NSD) \n');  
for k = 1:numel(AllSliceNum) 
%   Write the Image Metrics results to the text file 
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fprintf(fid_tag_results_file, '%d \t', AllSliceNum(k));  
fprintf(fid_tag_results_file, '%d \t', AllROINum(k));   
fprintf(fid_tag_results_file, '%d \t', AllblobNum(k));    
fprintf(fid_tag_results_file, '%f \t', AllBackgroundMean(k));   
fprintf(fid_tag_results_file, '%f \t', AllROI_min(k)); 
fprintf(fid_tag_results_file, '%f \t',  AllROI_max(k)); 
fprintf(fid_tag_results_file, '%f \t', AllROI_mean(k));  
fprintf(fid_tag_results_file, '%f \t', AllROI_var(k));  
fprintf(fid_tag_results_file, '%f \t', AllROI_stdev(k));  
fprintf(fid_tag_results_file, '%d \t', AllTotalROIPixels(k)); 
fprintf(fid_tag_results_file, '%f \t', AllROI_NSD(k)); 
fprintf(fid_tag_results_file, '%d \t', AllNumExcludedPixels(k));  
fprintf(fid_tag_results_file, '%f \t', AllWI_min(k)); 
fprintf(fid_tag_results_file, '%f \t',  AllWI_max(k));  










Matlab code for automated quantification of ROI metrics from images of the Ilumien 
OptisTM system (in-vitro phantoms and ex-vivo mouse data) 
% OCT Macrophage study: E151502_OCTMA 
% PI: Dr Nick Cruden 
% Researchers: Simon Wilson, Andrew Mitchell, and Clara Vergez 
% Software Version: 5 
% Written: 01/03/16 
% Updated: 10/05/17 
% Written by Dr Calum Gray 
% Edited by Clara Vergez (simplification) 
% Clinical Research Imaging Centre (CRIC) 
% The following processing is based on the paper: Quantification of Macrophage Content in 




software_version = ('v5_jude_RAW'); 
%------------------------------------------------------------------- 
% Define the empty arrays which will be added to during processing to give a list/table of 
results (to be written to Excel spreadsheet) 
AllSliceNum = []; %List of slice numbers that contained an ROI 
AllROINum = []; %List of the ROI/Tag numbers (i.e. objectmap) 
AllblobNum = []; %List of the separate blobs comprising the ROI/Tag 
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AllROI_min = []; %List of min of the ROI 
AllROI_max = []; %List of max of the ROI 
AllROI_mean = []; %List of mean of the ROI 
AllROI_var = [];   %List of variance of the ROI 
AllROI_stdev = []; %List of standard deviation of the ROI 
AllTotalROIPixels = []; %List of total number of pixels in the ROI  
AllROI_NSD = []; %List of Normalised standard deviation of the ROI 
AllBackgroundMean = []; %List of mean background noise level 
AllNumExcludedPixels = []; %List of the number of excluded pixels in the stats calculations  
AllWI_min = []; %List of min within the whole image 
AllWI_max = []; %List of max within the whole image 
AllWI_NSD = []; %List of Normalised standard deviation (NSD) to the whole image min and 
max values 
%------------------------------------------------------------------- 
% Load volume image (to remove for multiple files) 
[volume_filename,pathname] = uigetfile('*.hdr','Select the volume file'); 
% Split into pathname, filename and file extension 
[pathname, volume_filename, volume_ext] = fileparts(strcat(pathname,volume_filename)); 
volume = analyze75read (fullfile(pathname,strcat(volume_filename,volume_ext))); 
volume=flip(volume,1); 
%------------------------------------------------------------------- 
% Load ROI file 
[ROIfilename,ROIpathname] = uigetfile('*.*','Select the ROI file for processing'); 
% Split into pathname, filename and file extension 
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[ROIpathname, ROIfilename, ROIext] = fileparts(strcat(ROIpathname,ROIfilename)); 
        % Analyze objectmap file format 
        ROI = AVWObjectMap (fullfile(ROIpathname,strcat(ROIfilename,ROIext))); 
        % Use only the image within the ROI structure 
        ROI=ROI.Image; 
% Analyze values range from [1 to 256] whereas we want the values in the range [0 to 255] 
so that black is '0' - therefore subtract '1' from the ROI image volume to get it in this range 
        ROI = ROI-1; 
% The Analyze objectmap format does not contain info on pixel size, however it is a 1-to-1 
mapping on the hdr it was created on. Therefore we can use the header info in the volume 
file 
info = analyze75info(fullfile(pathname,strcat(volume_filename,volume_ext)); 
        x_pixel_size = info.PixelDimensions(1); 
        y_pixel_size = info.PixelDimensions(2); 
        z_pixel_size = info.PixelDimensions(3); 
        x_dim = info.Dimensions(1); 
        y_dim = info.Dimensions(2); 
        z_dim = info.Dimensions(3); 
% Find the number of slices in the volume (i.e. in the z-axis) 
no_of_slices=size(volume,3); 
% Find the number of tags 
no_of_ROIs  = max(max(max(ROI))); 
for i = 1:no_of_ROIs  % for each Tag/ROI 
fprintf('Processing ROI no. %d of %d ...\n',i, no_of_ROIs); 
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    for j = 1:no_of_slices  % for each slice 
fprintf('Processing slice no. %d of %d for ROI no. %d ...\n',j, no_of_slices, i); 
    ROINum = i; 
  SliceNum = j;           
        % Select an image slice and ROI 
        image = volume(:,:,j); 
        ROI_temp = ROI(:,:,j);                
% Test if the current ROI in the loop exists on the current slice (i.e. only make measurements 
for slice if the ROI/Tag number = i). If not, then move onto the next slice and re-test 
        if ismember(i,ROI_temp)   
% If the tag/ROI is present in the current image then set the ROI_temp image to only include 
this tag so that the other tags are also not included in the calculation 
          ROI_temp = (ROI_temp==i);             
            image2 = im2double(image);     
%------------------------------------------------------------------- 
% Set the background default value to zero (in this version, background value is not being 
measured and subtracted) 
            BackgroundMean = 0;             
%------------------------------------------------------------------- 
% Calculate the number of 'blobs' within the slice 
            blobs_label = bwlabel(ROI_temp); 
            Numblobs = max(max(blobs_label));             
            for z = 1:Numblobs 
            blobNum = z; 
            blob = (blobs_label==blobNum);  
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%select each blob individually to process             
%------------------------------------------------------------------- 
% Calculate the standard deviation within the objectmap/ROI            
            image3 = double(image2);  
%change to type double so that we can use NaN's 
            ROI_mask = double(blob);  
%change to type double so that we can use NaN's 
            ROI_mask(ROI_mask==0)=NaN; 
            filter_ROI = image3.*ROI_mask;          
% It is very unlikely that there will be 'true' zero values within the image. These may cause 
issues when calculating statistics therefore it is in practice a good idea to set these to NaN's 
before calculating stats. However it is also a good idea to note/record the number of these 
pixels which have been excluded from the calculation. 
            NumExcludedPixels = sum(filter_ROI(:)<=0); 
            filter_ROI(filter_ROI<=0)=NaN;                        
            ROI_min = min(filter_ROI(~isnan(filter_ROI)));  %calculate the min of the ROI 
            ROI_max = max(filter_ROI(~isnan(filter_ROI)));  %calculate the max of the ROI 
            ROI_mean = mean(filter_ROI(~isnan(filter_ROI)));   %calculate the mean of the ROI 
            ROI_var = var(filter_ROI(~isnan(filter_ROI)));   %calculate the variance of the ROI 
            ROI_stdev = std(filter_ROI(~isnan(filter_ROI)));  %calculate the standard deviation of 
the ROI 
            TotalROIPixels = sum(ROI_mask(:)==1); %calculate the number of pixels in the ROI (i.e. 
within the masked area) 
            ROI_NSD = ROI_stdev / (ROI_max - ROI_min); 




%Find the NSD value using the min & max values of the whole image (WI) rather than just 
the max & min of the ROI (WI_NSD). 
            WI_min = min(image3(image3>0));   
            WI_max = max(max(image3)); 
% Calculate the normalised standard deviation of the OCT signal 
            WI_NSD = ROI_stdev / (WI_max - WI_min); 
%------------------------------------------------------------------- 
% Concatenate the cell columns by adding newly read values to previously read values 
AllSliceNum = [AllSliceNum ; SliceNum]; 
AllROINum = [AllROINum ; ROINum]; 
AllblobNum = [AllblobNum ; blobNum]; 
AllBackgroundMean = [AllBackgroundMean ; BackgroundMean]; 
AllROI_min = [AllROI_min ; ROI_min]; 
AllROI_max = [AllROI_max ; ROI_max]; 
AllROI_mean = [AllROI_mean ; ROI_mean]; 
AllROI_var = [AllROI_var ; ROI_var]; 
AllROI_stdev = [AllROI_stdev ; ROI_stdev]; 
AllTotalROIPixels = [AllTotalROIPixels ; TotalROIPixels]; 
AllROI_NSD = [AllROI_NSD ; ROI_NSD]; 
AllNumExcludedPixels = [AllNumExcludedPixels ; NumExcludedPixels]; 
AllWI_min = [AllWI_min ; WI_min]; 
AllWI_max = [AllWI_max ; WI_max]; 
AllWI_NSD = [AllWI_NSD ; WI_NSD]; 
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            end 
        end 
    end 
end   
%------------------------------------------------------------------- 
% Save the results from processing OCT data to a text file 
fid_tag_results_file = 
fopen((fullfile(pathname,strcat(volume_filename,'_',software_version,'.txt'))),'at');     
    if (fid_tag_results_file < 0) 
        error('could not open file "*_results_v5_jude_RAW.txt"'); 
    end;   
% Write the name of the software 
fprintf(fid_tag_results_file, 'OCT Macrophage Study: Metrics for Analyze ROI files \n\n'); 
% Write the path and filename of the tag file 
fprintf(fid_tag_results_file, '%s \n\n',fullfile(ROIpathname,strcat(ROIfilename,ROIext))); 
% Write the software filename 
fprintf(fid_tag_results_file, 'Software name: %s.m \n',mfilename); 
% Write the software version 
fprintf(fid_tag_results_file, 'Software Version: %s \n',software_version); 
% Write the date data was processed 
fprintf(fid_tag_results_file, 'Data Processed: %s \n',date); 
% Write the volume dimensions 
fprintf(fid_tag_results_file, 'Volume Dimensions: \t'); 
fprintf(fid_tag_results_file, 'Width=%g \t',x_dim); 
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fprintf(fid_tag_results_file, 'Height=%g \t',y_dim); 
fprintf(fid_tag_results_file, 'Depth= %g \n',z_dim); 
% Write the voxel size 
fprintf(fid_tag_results_file, 'Voxel Size: \t'); 
fprintf(fid_tag_results_file, 'VoxelWidth=%g \t',x_pixel_size); 
fprintf(fid_tag_results_file, 'VoxelHeight=%g \t',y_pixel_size); 
fprintf(fid_tag_results_file, 'VoxelDepth=%g \n\n',z_pixel_size);  
% Write the column headers for the batch_results text file 
fprintf(fid_tag_results_file, 'Slice No. \t');      
fprintf(fid_tag_results_file, 'Tag No. \t');      
fprintf(fid_tag_results_file, 'Blob No. \t');      
fprintf(fid_tag_results_file, 'Mean Background Noise Level \t');   
fprintf(fid_tag_results_file, 'ROI Min \t');   
fprintf(fid_tag_results_file, 'ROI Max \t');   
fprintf(fid_tag_results_file, 'ROI Mean \t');   
fprintf(fid_tag_results_file, 'ROI Variance \t');   
fprintf(fid_tag_results_file, 'ROI Std Dev \t');   
fprintf(fid_tag_results_file, 'ROI Total Pixels \t');  
fprintf(fid_tag_results_file, 'ROI Normalised Standard Deviation (NSD) \t');  
fprintf(fid_tag_results_file, 'No. of Excluded Pixels from ROI Calculation \t');  
fprintf(fid_tag_results_file, 'Slice Min \t');  
fprintf(fid_tag_results_file, 'Slice Max \t');   




for k = 1:numel(AllSliceNum) 
%   Write the Image Metrics results to the text file 
fprintf(fid_tag_results_file, '%d \t', AllSliceNum(k));      
fprintf(fid_tag_results_file, '%d \t', AllROINum(k));      
fprintf(fid_tag_results_file, '%d \t', AllblobNum(k));      
fprintf(fid_tag_results_file, '%f \t', AllBackgroundMean(k));   
fprintf(fid_tag_results_file, '%f \t', AllROI_min(k));   
fprintf(fid_tag_results_file, '%f \t',  AllROI_max(k));   
fprintf(fid_tag_results_file, '%f \t', AllROI_mean(k));   
fprintf(fid_tag_results_file, '%f \t', AllROI_var(k));   
fprintf(fid_tag_results_file, '%f \t', AllROI_stdev(k));   
fprintf(fid_tag_results_file, '%d \t', AllTotalROIPixels(k));  
fprintf(fid_tag_results_file, '%f \t', AllROI_NSD(k));  
fprintf(fid_tag_results_file, '%d \t', AllNumExcludedPixels(k));  
fprintf(fid_tag_results_file, '%f \t', AllWI_min(k));  
fprintf(fid_tag_results_file, '%f \t',  AllWI_max(k)); 
fprintf(fid_tag_results_file, '%f \n', AllWI_NSD(k));  
end  








Matlab code for automated production of SD hotspot maps for images from both 
Terumo and St Jude OCT systems 
% OCT Macrophage study: E151502_OCTMA 
% PI: Dr Nick Cruden 
% Researchers: Simon Wilson, Andrew Mitchell, and Clara Vergez 
% Software Version: 2 
% Written: 05/10/16 
% Updated: 01/07/19 
% Written by Dr Calum Gray 
% Edited and repurposed by Dr Pierre Bagnaninchi and Clara Vergez 
% Edinburgh Imaging Facility QMRI  
% The following processing is based on the paper: Focal and Multi-Focal Plaque Macrophage 




close all;  
opengl hardware 
opengl info   
% Sweeping block size to adjust: use 9 for st jude images (phantoms and mice) and 5 for 
terumo images (clinical trial) 





% Add Matlab paths required to run code 
% Determine where this m-file's folder is. 
folder = fileparts(which(mfilename));  
% Add that folder plus all subfolders to the path. 
addpath(genpath(folder)); 
%-------------------------------------------------------------------  
% Load volume image 
[volume_filename,pathname] = uigetfile('*.tif','Select the volume file'); 
% Split into pathname, filename and file extension 
[pathname, volume_filename, volume_ext] = fileparts(strcat(pathname,volume_filename)); 
volume = imread (fullfile(pathname,strcat(volume_filename,volume_ext)));  
% Find the number of slices in the volume (i.e. in the z-axis) 
no_of_slices=size(volume,3); 
j = 1; %only process a single image 
fprintf('Processing Slice no. %d of %d ...\n',j, no_of_slices); 
% Select an image slice and ROI 
image = volume(:,:,j); 
%------------------------------------------------------------------- 
image2 = im2double(image); 
% Mask the image using user-drawn ROI (as Analyze .obj)    
% Load ROI file  
[ROI_filename,ROIpathname] = uigetfile('*.obj','Select the volume file'); 
% Split into pathname, filename and file extension 
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[ROIpathname, ROI_filename, ROI_ext] = fileparts(strcat(ROIpathname,ROI_filename)); 
 ROI = AVWObjectMap (fullfile(ROIpathname,strcat(ROI_filename,ROI_ext))); 
% Use only the image within the ROI structure 
 ROI=ROI.Image; 
% Analyze values range from [1 to 256] whereas we want the values in the range [0 to 255] 
so that black is '0' - therefore subtract '1' from the ROI image volume to get it in this range 
 ROI = ROI-1;  
% Make it a binary image (i.e. all pixel values > 1 == 1) 
image2(ROI==0)=NaN; 
image6 = double(image2); %change to type double so that we can use NaN's 
% Calculate the Max and Min values of the whole image (WI) rather than just the max & min 
of the ROI 
WI_min = nanmin(nanmin(image6));  %find the minimum 'non zero' value 
WI_max = nanmax(nanmax(image6)); 
% Custom filter: Standard Deviation 
% Create a 'nlfilter' - a General sliding-neighbourhood operation using a function (fun) 
% calculate the standard deviation (omitting NaN's in the calculation), divided by the 
difference between the OCT signal max and min values, multiplied by 100 
fun = @(x) (std(x(:),'omitnan')/(WI_max - WI_min))*100;  
% Apply filter to a block of neighbouring pixels (of predefined size) 
image7 = nlfilter(image6,[STD_block_zize STD_block_zize],fun); 
% Create new image comprising variance map image overlaid onto original grayscale image, 
with a colorbar on the side 
% set threshold above which the colormap pixels will be displayed on the grayscale image 




ax1 = axes; 
imagesc(image,[0 255]); 
colormap(ax1,'gray'); 
ax2 = axes; 
imagesc(ax2,image7,'alphadata',image7>ColMapThresh); 
% best colour is "hot" but flipped and restricted to 13 colours (st jude) and 20 for terumo 
colormap(ax2,flipud(hot(13)));  
caxis(ax2, [0 25]) ; % Max and min of axis: To keep axis and colour values the same across 
different images - For St Jude, set max to 25, for Terumo, 34 
ax2.Visible = 'off'; 
linkprop([ax1 ax2],'Position'); 
ax1.DataAspectRatioMode = 'manual'; 
ax2.DataAspectRatioMode = 'manual'; 
colorbar; 






% save the image as a tiff with name of original file and "_map" appended 
 mapfigname = strcat(volume_filename,'_','map'); 
 saveas(gcf,mapfigname,'tif') 
